

## References

- [1] R. A. Adams, A. M. Meade, A. Madi, D. Fisher, E. Kay, S. Kenny, R. S. Kaplan, and T. S. Maughan. Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience. *British Journal of Cancer*, 100(2):251–258, 2009.
- [2] J.-B. Ahn, K. H. Jung, Y. S. Park, Y. H. Kim, H. J. Chang, D. K. Sohn, S. B. Lim, H. S. Choi, S.-Y. Jeong, and J. G. Park. Phase II trial of irinotecan and capecitabine in patients with advanced colorectal cancer (ACRC). *ASCO Meeting Abstracts*, 23(16S):3714, 2005.
- [3] Steven R. Alberts, William L. Horvath, William C. Sternfeld, Richard M. Goldberg, Michelle R. Mahoney, Shaker R. Dakhil, Ralph Levitt, Kendrith Rowland, Suresh Nair, Daniel J. Sargent, and John H. Donohue. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A north central cancer treatment group phase II study. *Journal of Clinical Oncology*, 23(36):9243–9249, 2005.
- [4] Steven R. Alberts, Daniel J. Sargent, Suresh Nair, Michelle R. Mahoney, Margaret Mooney, Stephen N. Thibodeau, Thomas C. Smyrk, Frank A. Sinicrope, Emily Chan, Sharlene Gill, Morton S. Kahlenberg, Anthony F. Shields, James T. Quesenberry, Thomas A. Webb, Gist H. Farr, Jr., Barbara A. Pockaj, Axel Grothey, and Richard M. Goldbergo. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: A randomized trial. *JAMA*, 307(13):1383–1393, 2012.
- [5] Carmen J. Allegra, Greg Yothers, Michael J. O’Connell, Saima Sharif, Nicholas J. Petrelli, Samia H. Lopa, and Norman Wolmark. Bevacizumab in stage II-III colon cancer: 5-year update of the national surgical adjuvant breast and bowel project C-08 trial. *Journal of Clinical Oncology*, 31(3):359–364, 2013.
- [6] Ivy Altomare, Johanna C. Bendell, Karen E. Bullock, Hope E. Uronis, Michael A. Morse, S. David Hsu, S. Yousuf Zafar, Gerard C. Blobe, Herbert Pang, Wanda Honeycutt, Linda Sutton, and Herbert I. Hurwitz. A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. *The Oncologist*, 16(8):1131–1137, 2011.
- [7] Rafael G. Amado, Michael Wolf, Marc Peeters, Eric Van Cutsem, Salvatore Siena, Daniel J. Freeman, Todd Juan, Robert Sikorski, Sid Suggs, Robert Radinsky, Scott D. Patterson, and David D. Chang. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. *Journal of Clinical Oncology*, 26(10):1626–1634, 2008.
- [8] Ming-Wen An, Sumithra J. Mandrekar, Megan E. Branda, Shauna L. Hillman, Alex A. Adjei, Henry C. Pitot, Richard M. Goldberg, and Daniel J. Sargent. Comparison of continuous versus categorical tumor measurement based metrics to predict overall survival in cancer treatment trials. *Clinical Cancer Research*, 17(20):6592–6599, 2011.
- [9] T. André, H. Blons, M. Mabro, B. Chibaudel, J.-B. Bachet, C. Tournigand, M. Bennamoun, P. Artru, S. Nguyen, C. Ebenezer, N. Aissat, A. Cayre, F. Penault-Llorca, P. Laurent-Puig, and A. de Gramont. Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: A GERCOR efficacy, tolerance, and translational molecular study. *Annals of Oncology*, 24(2):412–419, 2013.

- [10] T André, C Tournigand, L Mineur, R Fellague-Chebra, M Flesch, M Mabro, M Hebbar, S Postel Vinay, FC Bidard, C Louvet, and A de Gramont. Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: A GERCOR study. *Annals of Oncology*, 18(1):77–81, 2007.
- [11] Thierry André, Corrado Boni, Lamia Mounedji-Boudiaf, Matilde Navarro, Josep Taberero, Tamas Hickish, Clare Topham, Marta Zaninelli, Philip Clingan, John Bridgewater, Isabelle Tabah-Fisch, and Aimery de Gramont. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. *New England Journal of Medicine*, 350(23):2343–2351, 2004.
- [12] Thierry André, Corrado Boni, Matilde Navarro, Josep Taberero, Tamas Hickish, Clare Topham, Andrea Bonetti, Philip Clingan, John Bridgewater, Fernando Rivera, and Aimery de Gramont. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. *Journal of Clinical Oncology*, 27(19):3109–3116, 2009.
- [13] Thierry André, Timothy Iveson, Roberto Labianca, Jeffrey A. Meyerhardt, Ioannis Souglakos, Takayuki Yoshino, James Paul, Alberto Sobrero, Julien Taieb, Anthony F. Shields, Atsushi Ohtsu, Axel Grothey, and Daniel J. Sargent. The IDEA (International duration evaluation of adjuvant chemotherapy) collaboration: Prospective combined analysis of phase III trials investigating duration of adjuvant therapy with the FOLFOX (FOLFOX4 or modified FOLFOX6) or XELOX (3 versus 6 months) regimen for patients with stage III colon cancer: Trial design and current status. *Current Colorectal Cancer Reports*, 9(3):261–269, 2013.
- [14] Thierry André, Emmanuel Quinaux, Christophe Louvet, Philippe Colin, Erik Gamelin, Olivier Bouche, Emmanuel Achille, Pascal Piedbois, Nicole Tubiana-Mathieu, Arnaud Boutan-Laroze, Michel Flesch, Grard Lledo, Yves Raoul, Isabelle Debrix, Marc Buyse, and Aimery de Gramont. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: Final results of GERCOR C96.1. *Journal of Clinical Oncology*, 25(24):3732–3738, 2007.
- [15] E. Aranda, M. Valladares, M. Martinez-Villacampa, M. Benavides, A. Gomez, B. Massutti, E. Marcuello, M. Constenla, J. C. Cámara, A. Carrato, R. Dueñas, M. Reboredo, M. Navarro, and E. Díaz-Rubio. Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: A Spanish Cooperative Group for the treatment of digestive tumors study. *Annals of Oncology*, 20(2):251–257, 2009.
- [16] Alexandros Ardavanis, Panteleimon Kountourakis, Ioannis Mantzaris, Savvoula Malliou, Dimitrios Doufexis, Despina Sykoutri, Ioannis Fragos, and Gerassimos. Rigatos. Bevacizumab added to the irinotecan and capecitabine combination for advanced colorectal cancer: A well-tolerated, active and convenient regimen. *Anticancer Research*, 28(5B):3087–3092, 2008.
- [17] D. Arnold, T. Höhler, C. Dittrich, F. Lordick, T. Seufferlein, J. Riemann, E. Wöll, T. Herrmann, A. Zube, and H.-J. Schmoll. Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: A phase Ib/II study of the AIO GI Group. *Annals of Oncology*, 19(8):1442–1449, April 2008.
- [18] T. R. Asmis, E. Powell, C. S. Karapetis, D. J. Jonker, D. Tu, M. Jeffery, N. Pavlakis, P. Gibbs, L. Zhu, D. A. Dueck, R. Whittom, C. Langer, and C. J. O’Callaghan. Comorbidity, age and overall survival in cetuximab-treated patients with advanced colorectal cancer (ACRC) results

- from NCIC CTG CO.17: A phase III trial of cetuximab versus best supportive care. *Annals of Oncology*, 22(1):118–126, 2011.
- [19] Eric Assenat, Françoise Desseigne, Simon Thezenas, Frédéric Viret, Laurent Mineur, Andrew Kramar, Emmanuelle Samalin, Fabienne Portales, Frédéric Bibeau, Evelyne Crapez-Lopez, Jean Pierre Bleuse, and Marc Ychou. Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: A phase II trial. *The Oncologist*, 16(11):1557–1564, 2011.
- [20] Nimer Assy, Walid Basher, Lika Chetver, Julia Shnaider, and Jamal. Zidan. First-line treatment with capecitabine combined with irinotecan in patients with advanced colorectal carcinoma: A phase II study. *Journal of Clinical Gastroenterology*, 46(4):27–30, 2012.
- [21] Heather-Jane Au, Christos S. Karapetis, Chris J. O’Callaghan, Dongsheng Tu, Malcolm J. Moore, John R. Zalberg, Hagen Kennecke, Jeremy D. Shapiro, Sheryl Koski, Nick Pavlakis, Danielle Charpentier, David Wyld, Michael Jefford, Gregory J. Knight, Nadine M. Magoski, Michael D. Brundage, and Derek J. Jonker. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: Overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 trial. *Journal of Clinical Oncology*, 27(11):1822–1828, 2009.
- [22] A. M. Azmy, Khalid Elhousseiny Nasr, Nagy Samy Gobran, and Mohamed Yassin. Mostafa. Infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer. *Journal of Cell Science & Therapy*, 3(4):125–129, May 2012.
- [23] Nicolas Azzopardi, Thierry Lecomte, David Ternant, Michelle Boisdron-Celle, Friedrich Piller, Alain Morel, Valérie Gouilleux-Gruart, Céline Vignault-Desvignes, Hervé Watier, Erick Gamelin, and Gilles Paintaud. Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. *Clinical Cancer Research*, 17(19):6329–6337, 2011.
- [24] Eishi Baba, Hiromitsu Fujishima, Akitaka Makiyama, Keita Uchino, Risa Tanaka, Taito Esaki, Hitoshi Kusaba, Kenji Mitsugi, Shuji Nakano, and Koichi Akashi. Phase 2 study of modified irinotecan and bolus 5-fluorouracil/l-leucovorin in Japanese metastatic colorectal cancer patients. *Advances in Therapy*, 29(3):287–296, 2012.
- [25] Nathalie Baize, Béatrice Gerard Berthier, Harry Bleiberg, François Caroli-Bosc, Frédéric Berthier, Hughes Legendre, Jean-Claude Pector, and Alain Hendlisz. Long-term survival of patients downstaged by oxaliplatin and 5-fluorouracil combination followed by rescue surgery for unresectable colorectal liver metastases. *Gastroentérologie Clinique et Biologique*, 30(12):1349–1353, 2006.
- [26] E Bajetta, M Di Bartolomeo, R Buzzoni, L Mariani, N Zilembo, E Ferrario, S Lo Vullo, E Aitini, L Isa, C Barone, S Jacobelli, E Recaldin, G Pinotti, and A. Iop. Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: Results of randomised phase II study. *British Journal of Cancer*, 96(3):439–444, January 2007.
- [27] Emilio Bajetta, Maria Di Bartolomeo, Luigi Mariani, Antonio Cassata, Salvatore Artale, Sergio Frustaci, Graziella Pinotti, Andrea Bonetti, Ignazio Carreca, Guido Biasco, Luigi Bonaglia, Giovanni Marini, Antonio Iannelli, Diego Cortinovis, Ermina Ferrario, Elena Beretta, Antonio Lambiase, Roberto Buzzoni, and for the Italian Trials in Medical Oncology (I.T.M.O.) Group.

- Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. *Cancer*, 100(2):279–287, 2004.
- [28] C Barone, G Nuzzo, A Cassano, M Basso, G Schinzari, F Giuliani, E D’Argento, N Trigila, A Astone, and C Pozzo. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. *British Journal of Cancer*, 97(8):1035–1039, September 2007.
- [29] S. A. Barroso, E. Sanches, M. Ferreira, M. Passos, A. Sa, R. Nabico, C. Sotto-Mayor, J. Espirito Santo, and R. San-Bento. Efficacy and safety of cetuximab, oxaliplatin, and capecitabine as first-line therapy for metastatic colorectal cancer (mCRC): Results of a phase II study. *ASCO Meeting Abstracts*, 27(15S):e15013, 2009.
- [30] Oliver Bathe, Scott Ernst, Francis Sutherland, Elijah Dixon, Charles Butts, David Bigam, David Holland, Geoffrey Porter, Jennifer Koppel, and Scot. Dowden. A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases. *BioMed Central Cancer*, 9(1):156, 2009.
- [31] Carlos R. Becerra, Ramon Salazar, Rocio Garcia-Carbonero, AnneL. Thomas, Federico J. Vázquez-Mazón, James Cassidy, Tim Maughan, Manuel Gallén Castillo, Tim Iveson, Donghua Yin, Stephanie Green, and Emily K. Bergsland. Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: A non randomized, open-label, phase II trial. *Cancer Chemotherapy and Pharmacology*, 73(4):695–702, 2014.
- [32] Y. Bécouarn, P. Senesse, S. Thézenas, E. Boucher, A. Adenis, L. Cany, J.H. Jacob, F. Cvitkovic, C. Montoto-Grillot, and M. Ychou. A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5FU2 + irinotecan or LV5FU2 + oxaliplatin) in first-line metastatic colorectal cancer: A study of the Digestive Group of the Fédération Nationale des Centres de Lutte Contre le Cancer. *Annals of Oncology*, 18(12):2000–2005, 2007.
- [33] Tanios S. Bekaii-Saab, Amir Mortazavi, Lee G. Hicks, Mark Zalupski, Robert J. Pelley, Kenneth K. Chan, and Eric H. Kraut. A phase II study of chloroquinoxaline sulfonamide (CQS) in patients with metastatic colorectal carcinoma (MCRC). *Investigational New Drugs*, 24(4):343–346, 2006.
- [34] Robert Benamouzig, Jacques Deyra, Antoine Martin, Bernard Girard, Eric Jullian, Benoit Piednoir, Daniel Couturier, Thierry Coste, Julian Little, and Stanislas Chaussade. Daily soluble aspirin and prevention of colorectal adenoma recurrence: One-year results of the APACC trial 1. *Gastroenterology*, 125(2):328–336, 2003.
- [35] Robert Benamouzig, Bernard Uzzan, Jacques Deyra, Antoine Martin, and Stanislas Chaussade. Prevention by aspirin of colorectal adenoma recurrence: Some advances and latest results of the APACC trial. *Current Colorectal Cancer Reports*, 7(1):33–41, 2011.
- [36] Robert Benamouzig, Bernard Uzzan, Jacques Deyra, Antoine Martin, Bernard Girard, Julian Little, Stanislas Chaussade, and for the Association pour la Prvention par l’Aspirine du Cancer Colorectal Study Group (APACC). Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial. *Gut*, 61(2):255–261, 2012.

- [37] Manuel Benavides, Carles Pericay, Manuel Valladares-Ayerbes, Silvia Gil-Calle, Bartomeu Massutí, Jorge Aparicio, Rosario Due nas, Encarna González-Flores, Alfredo Carrato, Eugenio Marcuello, Auxiliadora Gómez, Enrique Cabrera, Bernardo Queralt, Ma José Gómez, Inmaculada Guasch, Arantxa Etxeberria, Jordi Alfaro, Juan Manuel Campos, Juan José Reina, and Enrique Aranda. Oxaliplatin in combination with infusional 5-fluorouracil as first-line chemotherapy for elderly patients with metastatic colorectal cancer: A phase II study of the spanish cooperative group for the treatment of digestive tumors. *Clinical Colorectal Cancer*, 11(3):200–206, 2012.
- [38] Johanna C. Bendell, Tanios S. Bekaii-Saab, Allen L. Cohn, Herbert I. Hurwitz, Mark Kozloff, Haluk Tezcan, Nancy Roach, Yong Mun, Susan Fish, E. Dawn Flick, Darshan Dalal, and Axel Grothey. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX – bevacizumab or FOLFIRI – bevacizumab: Results from ARIES, a bevacizumab observational cohort study. *The Oncologist*, 17(12):1486–1495, 2012.
- [39] Johanna C. Bendell, Thomas J. Ervin, David Gallinson, Jaswinder Singh, James A. Wallace, Mansoor N. Saleh, Marcy Vallone, See-Chun Phan, and Stephen P. Hack. Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer. *Clinical Colorectal Cancer*, 12(3):218–222, 2013.
- [40] Johanna C. Bendell, John Nemunaitis, Sasha J. Vukelja, Christopher Hagenstad, Luis T. Campos, Robert C. Hermann, Peter Sportelli, Lesa Gardner, and Donald A. Richards. Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. *Journal of Clinical Oncology*, 29(33):4394–4400, 2011.
- [41] Johanna C. Bendell, Christophe Tournigand, Anna Swieboda-Sadlej, Carlo Barone, Zev A. Wainberg, Jong Gwang Kim, Carles Pericay, Davide Pastorelli, Jamal Tarazi, Brad Rosbrook, Joanna Bloom, Alejandro D. Ricart, Sinil Kim, and Alberto F. Sobrero. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: A randomized phase II study. *Clinical Colorectal Cancer*, 12(4):239–247, 2013.
- [42] L. Bengrine-Lefevre, B. Chibaudel, C. Tournigand, E. Carola, D. Brusquant, and A. de Gramont. Impact of age on treatment efficacy and safety in metastatic colorectal cancer: A subgroup analysis from the GERCOR Dream phase III study. *Journal of Geriatric Oncology*, 3(1S):S46, October 2012.
- [43] J. Bennouna, H. Perrier, B. Paillot, F. Priou, J. H. Jacob, M. Hebbbar, S. Bordenave, J. F. Seitz, F. Cvitkovic, E. Dorval, K. Malek, D. Tonelli, and J. Y. Douillard. A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer. *British Journal of Cancer*, 94(1):69–73, December 2005.
- [44] Jaafar Bennouna, Christophe Borg, Jean-Pierre Delord, Faress Hussein, Véronique Trillet-Lenoir, Roger Faroux, Eric François, Marc Ychou, François Goldwasser, Olivier Bouché, Helene Senellart, Sandrine Kræmer, and Jean-Yves Douillard. Bevacizumab combined with

- chemotherapy in the second-line treatment of metastatic colorectal cancer: Results from the phase II BEVACOLOR study. *Clinical Colorectal Cancer*, 11(1):38–44, 2012.
- [45] Jaafar Bennouna, Istvan Lang, Manuel Valladares-Ayerbes, Katalin Boer, Antoine Adenis, Pilar Escudero, Tae-You Kim, Gillian M. Pover, Clive D. Morris, and Jean-Yves. Douillard. A phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. *Investigational New Drugs*, 29(5):1021–1028, 2011.
- [46] Jaafar Bennouna, Javier Sastre, Dirk Arnold, Pia Österlund, Richard Greil, Eric Van Cutsem, Roger von Moos, Jose Maria Viéitez, Olivier Bouché, Christophe Borg, Claus-Christoph Steffens, Vicente Alonso-Ordu na, Christoph Schlichting, Irmarié Reyes-Rivera, Belguendouz Bendahmane, Thierry André, and Stefan Kubicka. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. *The Lancet Oncology*, 14(1):29–37, 2013.
- [47] Stéphane Benoist and Bernard Nordlinger. The role of preoperative chemotherapy in patients with resectable colorectal liver metastases. *Annals of Surgical Oncology*, 16(9):2385–2390, 2009.
- [48] Jordan Berlin, Johanna C. Bendell, Lowell L. Hart, Irfan Firdaus, Ira Gore, Robert C. Hermann, Mary F. Mulcahy, Mark M. Zalupski, Howard M. Mackey, Robert L. Yauch, Richard A. Graham, Gordon L. Bray, and Jennifer A. Low. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. *Clinical Cancer Research*, 19(1):258–267, 2013.
- [49] Jordan Berlin, James Posey, Simon Tchekmedyian, Eddie Hu, David Chan, Imtiaz Malik, Liqiang Yang, Rafael G. Amado, and J. Randolph Hecht. Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer. *Clinical Colorectal Cancer*, 8, Supplement(0):9–14, 2009.
- [50] Massimiliano Berretta, Giuseppe Aprile, Guglielmo Nasti, Martina Urbani, Alessandra Bearz, Stefania Lutrino, Luisa Foltran, Laura Ferrari, Renato Talamini, Francesco Fiorica, Arben Lleshi, Vincenzo Canzonieri, Chiara Lestuzzi, Eugenio Borsatti, Rossella Fisichella, and Umberto Tirelli. Oxaliplatin and capecitabine (XELOX) based chemotherapy in the treatment of metastatic colorectal cancer: The right choice in elderly patients. *Anti-Cancer Agents in Medicinal Chemistry*, 13(9):1344–1353, 2013.
- [51] F.-C. Bidard, C. Tournigand, T. André, M. Mabro, A. Figer, A. Cervantes, G. Lledo, L. Bengrine-Lefevre, F. Maindrault-Göbel, C. Louvet, and A. de Gramont. Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. *Annals of Oncology*, 20(6):1042–1047, 2009.
- [52] Arvinder Bir, Wei Tan, Gregory E Wilding, Jeffery Lombardo, and Marwan G Fakih. 5-fluorouracil, leucovorin and oxaliplatin plus bevacizumab in the first-line treatment of metastatic colorectal cancer: A single-institute study. *Oncology*, 72(1-2):4–9, 2007.

- [53] Ralph V. Boccia, Thomas M. Cosgriff, David L. Headley, Suprith Badarinath, and Shaker R. Dakhil. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer. *Clinical Colorectal Cancer*, 9(2):102–107, 2010.
- [54] Valérie Boige, Jean Mendiboure, Jean-Pierre Pignon, Marie-Anne Lorient, Marine Castaing, Michel Barrois, David Malka, David-Alexandre Trégouët, Olivier Bouché, Delphine Le Corre, Isabelle Miran, Claire Mulot, Michel Ducreux, Philippe Beaune, and Pierre Laurent-Puig. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFC2000-05. *Journal of Clinical Oncology*, 28(15):2556–2564, 2010.
- [55] M. K. Boisen, J. S. Johansen, C. Dehlendorff, J. S. Larsen, K. Østerlind, J. Hansen, S. E. Nielsen, P. Pfeiffer, L. S. Tarpgaard, N. H. Holländer, N. Keldsen, T. F. Hansen, B. B. Jensen, and B. V. Jensen. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. *Annals of Oncology*, 24(10):2554–2559, 2013.
- [56] C. Bokemeyer, I. Bondarenko, J. T. Hartmann, F. de Braud, G. Schuch, A. Zubel, I. Celik, M. Schlichting, and P. Koralewski. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study. *Annals of Oncology*, 22(7):1535–1546, 2011.
- [57] Carsten Bokemeyer, Igor Bondarenko, Anatoly Makhson, Joerg T. Hartmann, Jorge Aparicio, Filippo de Braud, Serban Donea, Heinz Ludwig, Gunter Schuch, Christopher Stroh, Anja H. Loos, Angela Zubel, and Piotr Koralewski. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. *Journal of Clinical Oncology*, 27(5):663–671, 2009.
- [58] M. Borner, D. Koeberle, R. Von Moos, P. Saletti, D. Rauch, V. Hess, A. Trojan, D. Helbling, B. Pestalozzi, C. Caspar, T. Ruhstaller, A. Roth, A. Kappeler, D. Dietrich, D. Lanz, and W. Mingrone. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: A randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. *Annals of Oncology*, 19(7):1288–1292, 2008.
- [59] M. M. Borner, J. Bernhard, D. Dietrich, R. Popescu, M. Wernli, P. Saletti, D. Rauch, R. Herrmann, D. Koeberle, H. Honegger, P. Brauchli, D. Lanz, and A. D. Roth. A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: Efficacy, quality-of-life and toxicity. *Annals of Oncology*, 16(2):282–288, 2005.
- [60] Markus M. Borner, Daniel Dietrich, Roger Stupp, Rudolf Morant, Hanspeter Honegger, Martin Wernli, Richard Herrmann, Bernhard C. Pestalozzi, Piercarlo Saletti, Silvia Hanselmann, Samuel Müller, Peter Brauchli, Monica Castiglione-Gertsch, Aron Goldhirsch, Arnaud D. Roth, and for the Swiss Group for Clinical Cancer Research. Phase II study of capecitabine and oxaliplatin in first - and second-line treatment of advanced or metastatic colorectal cancer. *Journal of Clinical Oncology*, 20(7):1759–1766, 2002.
- [61] M.M. Borner, P. Schöffski, R. de Wit, F. Caponigro, G. Comella, A. Sulkes, G. Greim, G. A. J. Peters, K. van der Born, J. Wanders, R.F. de Boer, C. Martin, and P. Fumoleau. Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: A randomised crossover trial in advanced colorectal cancer. *European Journal of Cancer*, 38(3):349–358, 2002.

- [62] M. Bouchahda, T. Macarulla, G. Lledo, F. Lévi, M.E. Elez, B. Paule, A. Karaboué, P. Artru, J. Tabernero, D. Machover, P. Innominato, E. Goldschmidt, D. Bonnet, M. Ducreux, V. Castagne, and R. Guimbaud. Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: A multicenter, retrospective analysis. *Medical Oncology*, 28(1):253–258, 2011.
- [63] M. Bouchahda, T. Macarulla, J.P. Spano, J.B. Bachet, G. Lledo, T. Andre, B. Landi, J. Tabernero, A. Karaboué, J. Domont, F. Levi, and P. Rougier. Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer. *Critical Reviews in Oncology/Hematology*, 67(3):255–262, 2008.
- [64] O. Bouché, F. Maindrault, G., M. Ducreux, G. Lledo, T. André, P. Stopfer, N. Amellal, M. Merger, and A. De Gramont. Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer. *Anticancer Research*, 31(6):2271–2281, 2011.
- [65] Michael S. Braun, Susan D. Richman, Philip Quirke, Catherine Daly, Julian W. Adlard, Faye Elliott, Jennifer H. Barrett, Peter Selby, Angela M. Meade, Richard J. Stephens, Mahesh K.B. Parmar, and Matthew T. Seymour. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial. *Journal of Clinical Oncology*, 26(16):2690–2698, 2008.
- [66] Michael S. Braun, Susan D. Richman, Lindsay Thompson, Catherine L. Daly, Angela M. Meade, Julian W. Adlard, James M. Allan, Mahesh K.B. Parmar, Philip Quirke, and Matthew T. Seymour. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: The FOCUS trial. *Journal of Clinical Oncology*, 27(33):5519–5528, 2009.
- [67] T. Brodowicz, T. E. Ciuleanu, D. Radosavljevic, E. Shacham-Shmueli, D. Vrbanec, S. Plate, Z. Mrcic-Krmpotic, M. Dank, G. Purkalne, D. Messinger, and C. C. Zielinski. FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: A randomized phase II CECOG study. *Annals of Oncology*, 24(7):1769–1777, 2013.
- [68] Gemma Bruera, Katia Cannita, Aldo Victor Giordano, Roberto Vicentini, Corrado Ficorella, and Enrico Ricevuto. Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer patients. *BioMed Research International*, 2013(2013):1–9, 2013. Article ID 143273.
- [69] Gemma Bruera and Enrico Ricevuto. Intensive chemotherapy of metastatic colorectal cancer: Weighing between safety and clinical efficacy. *Expert Opinion on Biological Therapy*, 11(6):821–824, 2011.
- [70] Gemma Bruera, Alessandra Santomaggio, Katia Cannita, Paola Baldi, Marianna Tadini, Federica De Galitiis, Maria Mancini, Paolo Marchetti, Adelmo Antonucci, Corrado Ficorella, and Enrico Ricevuto. "Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: A phase II study. *BioMed Central Cancer*, 10(1):567, 2010.
- [71] Emiliano Calvo, Javier Cortés, Javier Rodríguez, Óscar Fernández-Hidalgo, Joseba Rebollo, Salvador Martín-Algarra, Jesús García-Foncillas, Rafael Martínez-Monge, Jokin de Irala, and Antonio Brugarolas. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination



- chemotherapy in advanced colorectal carcinoma: A phase {II} study. *Clinical Colorectal Cancer*, 2(2):104–110, 2002.
- [72] Weiguo Cao, Weiping Yang, Guying Lou, Jinsong Jiang, Mei Geng, Wenqi Xi, Hao Li, Tao Ma, and Yening Jin. Phase II study of oxaliplatin, capecitabine and endostar as first line treatment for patients with advanced colorectal cancer. *Chinese Journal of Lymphology and Oncology*, 8(1):55–57, March 2009.
- [73] Leslie E. Carlini, Neal J. Meropol, John Bever, Michael L. Andria, Todd Hill, Philip Gold, Andre Rogatko, Hao Wang, and Rebecca L. Blanchard. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. *Clinical Cancer Research*, 11(3):1226–1236, 2005.
- [74] Benedito A. Carneiro, Ramesh K. Ramanathan, Marwan G. Fakih, Smitha S. Krishnamurthi, Barry C. Lembersky, Ronald G. Stoller, Stewart L. Lancaster, Richard A. Pinkerton, Theodore L. Crandall, Amy R. Schmotzer, Douglas M. Potter, and Nathan Bahary. Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer. *Clinical Colorectal Cancer*, 11(1):53–59, 2012.
- [75] A. Carrato, A. Gómez, P. Escudero, M. Chaves, F. Rivera, E. Marcuello, E. González, C. Grávalos, M. Constenla, J. Luis Manzano, F. Losa, J. Maurel, R. Dueñas, B. Massuti, J. Gallego, J. Aparicio, A. Antón, and Aranda E. Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer. *Clinical and Translational Oncology*, 15(9):705–711, September 2013.
- [76] Alfredo Carrato, Anna Swieboda-Sadlej, Marzanna Staszewska-Skurczynska, Robert Lim, Laslo Roman, Yaroslav Shparyk, Igor Bondarenko, Derek J. Jonker, Yan Sun, Jhony A. De la Cruz, J. Andrew Williams, Beata Korytowsky, James G. Christensen, Xun Lin, Jennifer M. Tursi, Maria J. Lechuga, and Eric. Van Cutsem. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: A randomized, phase III trial. *Journal of Clinical Oncology*, 31(10):1341–1347, 2013.
- [77] Thomas Cartwright, Timothy Lopez, Svetislava J. Vukelja, Carlos Encarnacion, Kristi A. Boehm, and Lina Asmar. Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. *Clinical Colorectal Cancer*, 5(1):50–56, 2005.
- [78] S Cascinu, R Berardi, S Salvagni, G D Beretta, V Catalano, F Pucci, A Sobrero, P Tagliaferri, R Labianca, M Scartozzi, F Crocicchio, E Mari, and A Ardizzoni. A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. *British Journal of Cancer*, 98(1):71–76, December 2007.
- [79] S. Cascinu, F. Graziano, F. Ferraú, V. Catalano, C. Massacesi, D. Santini, R. R. Silva, S. Barni, A. Zaniboni, N. Battelli, S. Siena, P. Giordani, D. Mari, A. M. Baldelli, S. Antognoli, R. Maisano, D. Priolo, M. A. Pessi, G. Tonini, S. Rota, and R. Labianca. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the italian group for the study of gastrointestinal tract carcinomas (GISCAD). *Annals of Oncology*, 13(5):716–720, 2002.

- [80] J Cassidy, S Clarke, E Diaz-Rubio, W Scheithauer, A Figer, R Wong, S Koski, K Rittweger, F Gilberg, and L Saltz. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. *British Journal of Cancer*, 105(1):58–64, June 2011.
- [81] J. Cassidy, L. Saltz, C. Twelves, E. Van Cutsem, P. Hoff, Y. Kang, J. P. Saini, F. Gilberg, and D. Cunningham. Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: A meta-analysis of individual data from 6171 patients. *Annals of Oncology*, 22(12):2604–2609, 2011.
- [82] J. Cassidy, C. Twelves, E. Van Cutsem, P. Hoff, E. Bajetta, M. Boyer, R. Bugat, U. Burger, A. Garin, U. Graeven, J. McKendrick, J. Maroun, J. Marshall, B. Osterwalder, G. Pérez-Manga, R. Rosso, P. Rougier, and R. L. Schilsky. First-line oral capecitabine therapy in metastatic colorectal cancer: A favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. *Annals of Oncology*, 13(4):566–575, 2002.
- [83] James Cassidy, Leonard B. Saltz, Bruce J. Giantonio, Fairouz F. Kabbinavar, Herbert I. Hurwitz, and Ulrich-Peter Rohr. Effect of bevacizumab in older patients with metastatic colorectal cancer: Pooled analysis of four randomized studies. *Journal of Cancer Research and Clinical Oncology*, 136(5):737–743, 2010.
- [84] Jim Cassidy, Stephen Clarke, Eduardo Díaz-Rubio, Werner Scheithauer, Arie Figer, Ralph Wong, Sheryl Koski, Mikhail Lichinitser, Tsai-Shen Yang, Fernando Rivera, Felix Couture, Florin Sirzén, and Leonard. Saltz. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. *Journal of Clinical Oncology*, 26(12):2006–2012, 2008.
- [85] Jim Cassidy, Josep Tabernero, Chris Twelves, René Brunet, Charles Butts, Thierry Conroy, Filippo Debraud, Arie Figer, Johannes Grossmann, Noriaki Sawada, Patrick Schöffski, Alberto Sobrero, Eric Van Cutsem, and Eduardo. Díaz-Rubio. XELOX (capecitabine plus oxaliplatin): Active first-line therapy for patients with metastatic colorectal cancer. *Journal of Clinical Oncology*, 22(11):2084–2091, 2004.
- [86] Richard Cathomas, Dieter Köberle, Thomas Ruhstaller, Gisela Mayer, Andrea Räss, Ulrich Mey, and Roger von Moos. Heated (37C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: Can it reduce neuropathy? *Supportive Care in Cancer*, 18(10):1263–1270, 2010.
- [87] B. H. Chao, N. K. LoConte, W. R. Schelman, D. Mulkerin, M. S. Huie, J. C. Eickhoff, and K. D. Holen. A phase II study of neoadjuvant FOLFOX4 and cetuximab (C) in patients with locally advanced rectal adenocarcinoma (RA). *Journal of Clinical Oncology (Meeting Abstracts)*, 28(15S):e14122, 2010.
- [88] Helen X. Chen, Margaret Mooney, Matthew Boron, Don Vena, Kimberly Mosby, Louise Grochow, Carl Jaffe, Lawrence Rubinstein, James Zwiebel, and Richard S. Kaplan. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: An NCI treatment referral center trial TRC-0301. *Journal of Clinical Oncology*, 24(21):3354–3360, 2006.
- [89] Ann-Lii Cheng, Gerardo H. Cornelio, Lin Shen, Timothy Jay Price, Tsai-Shen Yang, Ik-Joo Chung, Guanghai Dai, Jen-Kou Lin, Atul Sharma, Kun-Huei Yeh, Brigitte Ma, Adel Zaatar, Zhongzhen Guan, Nehal Masood, Vichien Srimuninnimit, Thomas Cheung Yau, Barbara

- Sarholz, and Robert S.C. Lim. Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC). *Journal of Clinical Oncology (Meeting Abstracts)*, 31(15S):e14501, 2013.
- [90] B. Chibaudel, C. Tournigand, P. Artru, T. André, A. Cervantes, A. Figer, G. Lledo, M. Flesch, M. Buyse, L. Mineur, E. Carola, F. Rivera, N. Perez-Staub, C. Louvet, and A. de Gramont. FOLFOX in patients with metastatic colorectal cancer and high alkaline phosphatase level: An exploratory cohort of the GERCOR OPTIMOX1 study. *Annals of Oncology*, 20(8):1383–1386, 2009.
- [91] Benoist Chibaudel, Frédérique Maindrault-Göebel, Gérard Lledo, Laurent Mineur, Thierry André, Mostepha Bennamoun, May Mabro, Pascal Artru, Elisabeth Carola, Michel Flesch, Olivier Dupuis, Philippe Colin, Annette K. Larsen, Pauline Afchain, Christophe Tournigand, Christophe Louvet, and Aimery de Gramont. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 study. *Journal of Clinical Oncology*, 27(34):5727–5733, 2009.
- [92] G Chong, J L B Dickson, D Cunningham, A R Norman, S Rao, M E Hill, T J Price, J Oates, and N Tebbutt. Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. *British Journal of Cancer*, 93(5):510–514, August 2005.
- [93] G. Chong, N. Starling, A. R. Norman, G. Brown, J. Thomas, P. J. Ross, and D. C. Cunningham. Phase II study of fixed dose rate gemcitabine in patients with pretreated advanced colorectal cancer. *ASCO Meeting Abstracts*, 24(18S):13558, 2006.
- [94] Quincy Siu-Chung Chu. Aflibercept (AVE0005): An alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. *Expert Opinion on Biological Therapy*, 9(2):263–271, 2009.
- [95] Ki Young Chung, Jinru Shia, Nancy E. Kemeny, Manish Shah, Gary K. Schwartz, Archie Tse, Audrey Hamilton, Dorothy Pan, Deborah Schrag, Lawrence Schwartz, David S. Klimstra, Daniel Fridman, David P. Kelsen, and Leonard B. Saltz. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. *Journal of Clinical Oncology*, 23(9):1803–1810, 2005.
- [96] Stephen Clarke, Matt Burge, Cassandra Cordwell, Peter Gibbs, William Reece, and Niall Tebbutt. An australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab (Avastin™) ASCENT. *BioMed Central Cancer*, 13(1):120, 2013.
- [97] A. L. Cohn, J. Tabernero, J. Maurel, E. Nowara, J. Sastre, B. Y. S. Chuah, M. V. Kopp, D. D. Sakaeva, E. P. Mitchell, S. Dubey, S. Suzuki, Y.-J. Hei, F. Galimi, I. Mc Caffery, Y. Pan, R. Loberg, S. Cottrell, and S.-P. Choo. A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. *Annals of Oncology*, 24(7):1777–1785, 2013.
- [98] Allen L. Cohn, Grace C. Shumaker, Pankaj Khandelwal, David A. Smith, Marcus A. Neubauer, Nilesh Mehta, Donald Richards, David L. Watkins, Kathy Zhang, and Mohamed R. Yassine. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer. *Clinical Colorectal Cancer*, 10(3):171–177, 2011.

- [99] Giuseppe Colucci, Vittorio Gebbia, Giancarlo Paoletti, Francesco Giuliani, Michele Caruso, Nicola Gebbia, Giacomo Cartení, Biagio Agostara, Giuseppe Pezzella, Luigi Manzione, Nicola Borsellino, Andrea Misino, Sante Romito, Ernesto Durini, Stefano Cordio, Marisa Di Seri, Massimo Lopez, and Evaristo Maiello. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the gruppo oncologico dell'Italia meridionale. *Journal of Clinical Oncology*, 23(22):4866–4875, 2005.
- [100] Giuseppe Colucci, Francesco Giuliani, Carlo Garufi, Rodolfo Mattioli, Luigi Manzione, Antonio Russo, Massimo Lopez, Paola Parrella, Stefania Tommasi, Massimiliano Copetti, et al. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: A gruppo oncologico de l'Italia meridionale multicenter phase II study. *Oncology*, 79(5-6):415–422, April 2011.
- [101] P Comella, R Casaretti, E Crucitta, F De Vita, S Palmeri, A Avallone, M Orditura, L De Lucia, S Del Prete, G Catalano, V Lorusso, and G Comella. Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: A salvage regimen for colorectal cancer patients. *British Journal of Cancer*, 86(12):1871–1875, 2002.
- [102] Pasquale Comella, Bruno Massidda, Gianfranco Filippelli, Antonio Farris, Donato Natale, Giuseppe Barberis, Luigi Maiorino, Sergio Palmeri, Michele Cannone, and Giovanni Condemi. Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: Results of the southern Italy cooperative oncology study 0401. *Journal of Cancer Research and Clinical Oncology*, 135(2):217–226, 2009.
- [103] Pasquale Comella, Donato Natale, Antonio Farris, Antonio Gambardella, Luigi Maiorino, Bruno Massidda, Rossana Casaretti, Salvatore Tafuto, Vito Lorusso, Silvana Leo, and Michele Cannone. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma. *Cancer*, 104(2):282–289, 2005.
- [104] Pierpaolo Correale, Maria Grazia Cusi, Kwong Yok Tsang, Maria Teresa Del Vecchio, Stefania Marsili, Marco La Placa, Chiara Intrivici, Angelo Aquino, Lucia Micheli, Cristina Nencini, Francesco Ferrari, Giorgio Giorgi, Enzo Bonmassar, and Guido Francini. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. *Journal of Clinical Oncology*, 23(35):8950–8958, 2005.
- [105] Jean-François Côté, Sylvain Kirzin, Andrew Kramar, Jean-François Mosnier, Marie-Danièle Diebold, Isabelle Soubeyran, Anne-Sophie Thirouard, Janick Selves, Pierre Laurent-Puig, and Marc Ychou. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. *Clinical Cancer Research*, 13(11):3269–3275, 2007.
- [106] Antonio Cubillo, Jesús Rodríguez-Pascual, Fernando López-Ríos, Carlos Plaza, Elena García, Rafael Álvarez, Emilio de Vicente, Yolanda Quijano, Ovidio Hernando, Carmen Rubio, Soffia Perea, Gema Sanchez, and Manuel Hidalgo. Phase II trial of target-guided personalized chemotherapy in first-line metastatic colorectal cancer. *American Journal of Clinical Oncology*, 2014.
- [107] D Cunningham, R P W Wong, G D'Haens, J-Y Douillard, J Robertson, A M Stone, and Ecu. Van Cutsem. Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously

- treated metastatic colorectal cancer. *British Journal of Cancer*, 108(3):493–502, February 2013.
- [108] David Cunningham, Yves Humblet, Salvatore Siena, David Khayat, Harry Bleiberg, Armando Santoro, Danny Bets, Matthias Mueser, Andreas Harstrick, Chris Verslype, Ian Chau, and Eric Van Cutsem. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *New England Journal of Medicine*, 351(4):337–345, 2004.
- [109] David Cunningham, Istvan Lang, Eugenio Marcuello, Vito Lorusso, Janja Ocvirk, Dong Bok Shin, Derek Jonker, Stuart Osborne, Niko Andre, Daniel Waterkamp, and Mark P Saunders. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): An open-label, randomised phase 3 trial. *The Lancet Oncology*, 14(11):1077–1085, 2013.
- [110] E Van Cutsem, P M Hoff, P Harper, R M Bukowski, D Cunningham, P Dufour, U Graeven, J Lokich, S Madajewicz, J A Maroun, J L Marshall, E P Mitchell, G Perez-Manga, P Rougier, W Schmiegel, J Schoelmerich, A Sobrero, and R L Schilsky. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomised, phase III trials. *British Journal of Cancer*, 90(6):1190–1197, February 2004.
- [111] Z. Daher Abdi, S. Lavau-Denes, A. Prémaud, S. Urien, F.L. Sauvage, J. Martin, S. Leobon, P. Marquet, N. Tubiana-Mathieu, and A. Rousseau. Pharmacokinetics and exposure-effect relationships of capecitabine in elderly patients with breast or colorectal cancer. *Cancer Chemotherapy and Pharmacology*, 73(6):1285–1293, 2014.
- [112] Lissandra Dal Lago, Marc F. Richter, AnnaI. Cancela, Sabrina A. Fernandes, Keylla T. Jung, Ana C. Rodrigues, Teresa Dalla Costa, Luciane P. Di Leone, and Gilberto. Schwartzmann. Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer. *Investigational New Drugs*, 21(3):359–366, 2003.
- [113] Menno T. De Bruijn, Daniëlle A.E. Raats, Jolien Tol, John Hinrichs, Steven Teerenstra, Cornelis J.A. Punt, Inne H.M. Borel Rinkes, and Onno Kranenburg. Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer. *Anticancer Research*, 31(4):1379–1385, 2011.
- [114] A. De Gramont, A. Figer, M. Seymour, M. Homerin, A. Hmissi, J. Cassidy, C. Boni, H. Cortes-Funes, A. Cervantes, G. Freyer, D. Papamichael, N. Le Bail, C. Louvet, D. Hendler, F. de Braud, C. Wilson, F. Morvan, and A. Bonetti. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. *Journal of Clinical Oncology*, 18(16):2938–2947, 2000.
- [115] Aimery De Gramont, Marc Buyse, Jose Cortinas Abrahantes, Tomasz Burzykowski, Emmanuel Quinaux, Andres Cervantes, Arie Figer, Grard Lledo, Michel Flesch, Laurent Mineur, Elisabeth Carola, Pierre-Luc Etienne, Fernando Rivera, Isabel Chirivella, Nathalie Perez-Staub, Christophe Louvet, Thierry André, Isabelle Tabah-Fisch, and Christophe Tournigand. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. *Journal of Clinical Oncology*, 25(22):3224–3229, 2007.
- [116] T. Delaunoy, S. R. Alberts, D. J. Sargent, E. Green, R. M. Goldberg, J. Krook, C. Fuchs, R. K. Ramanathan, S. K. Williamson, R. F. Morton, and B. P. Findlay. Chemotherapy permits resection of metastatic colorectal cancer: Experience from intergroup N9741. *Annals of Oncology*, 16(3):425–429, 2005.

- [117] Thierry Delaunoy, Richard M. Goldberg, Daniel J. Sargent, Roscoe F. Morton, Charles S. Fuchs, Brian P. Findlay, Sachdev P. Thomas, Muhammad Salim, Paul L. Schaefer, Philip J. Stella, Erin Green, and James A. Mailliard. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin. *Cancer*, 101(10):2170–2176, 2004.
- [118] Maria L. Delioukina, Diane Prager, Mandy Parson, J. Randolph Hecht, Peter Rosen, and Lee S. Rosen. Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma. *Cancer*, 94(8):2174–2179, 2002.
- [119] J-P Delord, J Bennouna, P Artru, H Perrier, F Husseini, F Desseigne, E François, R Faroux, D Smith, P Piedbois, H Naman, J Y Douillard, and R Bugat. Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): First-line therapy for metastatic colorectal cancer. *British Journal of Cancer*, 97(3):297–301, 2007.
- [120] Jean-Pierre Delord, Josep Tabernero, Rocío García-Carbonero, Andres Cervantes, Carlos Gomez-Roca, Yann Bergé, Jaume Capdevila, Luis Paz-Ares, Desamparados Roda, Paul Delmar, David Oppenheim, Sophia Soehrman Brossard, Farzin Farzaneh, Luigi Manenti, Alexandre Passiukov, Marion Gabriele Ott, and Jean-Charles Soria. Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. *European Journal of Cancer*, 50(3):496–505, 2014.
- [121] Ting Deng, Le Zhang, Xiao-jian Liu, Jian-ming Xu, Yu-xian Bai, Yan Wang, Yu Han, Yu-hong Li, and Yi Ba. Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as the second-line therapy for patients with metastatic colorectal cancer, a multicenter study. *Medical Oncology*, 30(4):752, December 2013.
- [122] Apurva A. Desai, Hedy L. Kindler, David Taber, Edem Agamah, Sridhar Mani, Kurombi Wade-Oliver, Mark J. Ratain, and Everett E. Vokes. Modulation of irinotecan with cyclosporine: A phase II trial in advanced colorectal cancer. *Cancer Chemotherapy and Pharmacology*, 56(4):421–426, 2005.
- [123] A Dewdney, D Cunningham, Y Barbachano, and I Chau. Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection. *British Journal of Cancer*, 106(11):1718–1721, May 2012.
- [124] F. Di Fiore, F. Blanchard, F. Charbonnier, F. Le Pessot, A. Lamy, M. P. Galais, L. Bastit, A. Killian, R. Sesboue, J. J. Tuech, A. M. Queumiet, B. Paillot, J. C. Sabourin, F. Michot, P. Michel, and T. Frebourg. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. *British Journal of Cancer*, 96(8):1166–1169, March 2007.
- [125] Luis A. Diaz Jr, Richard T. Williams, Jian Wu, Isaac Kinde, J. Randolph Hecht, Jordan Berlin, Benjamin Allen, Ivana Bozic, Johannes G. Reiter, Martin A. Nowak, Kenneth W. Kinzler, Kelly S. Oliner, and Bert Vogelstein. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. *Nature*, 486(7404):537–540, June 2012.
- [126] Eduardo Díaz-Rubio, Auxiliadora Gómez-España, Bartomeu Massutí, Javier Sastre, Albert Abad, Manuel Valladares, Fernando Rivera, Maria J. Safont, Purificación Martínez de

- Prado, Manuel Gallén, Encarnación González, Eugenio Marcuello, Manuel Benavides, Carlos Fernández-Martos, Ferrán Losa, Pilar Escudero, Antonio Arrivi, Andrés Cervantes, Rosario Dueñas, Amelia López-Ladrón, Adelaida Lacasta, Marta Llanos, Jose M. Tabernero, Antonio Antón, and Enrique Aranda. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The Phase III MACRO TTD study. *The Oncologist*, 17(1):15–25, 2012.
- [127] Eduardo Díaz-Rubio, Auxiliadora Gonzalez, Gómez-España, Bartomeu Massutí, Javier Sastre, Margarita Reboredo, José Luis Manzano, Fernando Rivera, M. José Safont, Clara Montagut, Encarnación González, Manuel Benavides, Eugenio Marcuello, Andrés Cervantes, Purificación Martínez de Prado, Carlos Fernando Fernández-Martos, Antonio Arrivi, Inmaculada Bando, Enrique Aranda, and Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Role of KRAS status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: A TTD group cooperative study. *Plos ONE*, 7(10):e47345, 10 2012.
- [128] Eduardo Díaz-Rubio, Filippo Pietrantonio, and Filippo. de Braud. Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer. *The Oncologist*, 17(11):1426–1428, 2012.
- [129] Eduardo Díaz-Rubio, Jose Tabernero, Auxiliadora Gómez-España, Bartomeu Massutí, Javier Sastre, Manuel Chaves, Alberto Abad, Alfredo Carrato, Bernardo Queralt, Juan José Reina, Joan Maurel, Encarnación González-Flores, Jorge Aparicio, Fernando Rivera, Ferrán Losa, and Enrique Aranda. Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: Final report of the spanish cooperative group for the treatment of digestive tumors trial. *Journal of Clinical Oncology*, 25(27):4224–4230, 2007.
- [130] James J. Dignam, Blase N. Polite, Greg Yothers, Peter Raich, Linda Colangelo, Michael J. O’Connell, and Norman Wolmark. Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer. *Journal of the National Cancer Institute*, 98(22):1647–1654, 2006.
- [131] Efrat Dotan, Neal J. Meropol, Barbara Burtness, Crystal S. Denlinger, James Lee, David Mintzer, Fang Zhu, Karen Ruth, Holly Tuttle, Judi Sylvester, et al. A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase Extramural Research Study. *Journal of gastrointestinal cancer*, 43(4):562–569, 2012.
- [132] J. Y. Douillard, D. Cunningham, A. D. Roth, M. Navarro, R. D. James, P. Karasek, P. Jandik, T. Iveson, J. Carmichael, M. Alakl, G. Gruia, L. Awad, and P. Rougier. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. *The Lancet*, 355(9209):1041–1047, 2000.
- [133] Jean-Yves Douillard, Paulo M. Hoff, Jamey R. Skillings, Peter Eisenberg, Neville Davidson, Peter Harper, Mark D. Vincent, Barry C. Lembersky, Seth Thompson, Antonella Maniero, and Steven E. Benner. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. *Journal of Clinical Oncology*, 20(17):3605–3616, 2002.

- [134] Jean-Yves Douillard, Kelly S. Oliner, Salvatore Siena, Josep Taberbero, Ronald Burkes, Mario Barugel, Yves Humblet, Gyorgy Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocákova, Paul Ruff, Maria Blasinska Morawiec, Martin Šmakal, Jean Luc Canon, Mark Rother, Richard Williams, Alan Rong, Jeffrey Wiezorek, Roger Sidhu, and Scott D. Patterson. Panitumumab - FOLFOX4 treatment and RAS mutations in colorectal cancer. *New England Journal of Medicine*, 369(11):1023–1034, 2013.
- [135] Jean-Yves Douillard, Salvatore Siena, James Cassidy, Josep Taberbero, Ronald Burkes, Mario Barugel, Yves Humblet, György Bodoky, David Cunningham, Jacek Jassem, Fernando Rivera, Ilona Kocákova, Paul Ruff, Maria Blasinska-Morawiec, Martin Šmakal, Jean-Luc Canon, Mark Rother, Kelly S. Oliner, Michael Wolf, and Jennifer Gansert. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME Study. *Journal of Clinical Oncology*, 28(31):4697–4705, 2010.
- [136] Jean-Yves Douillard, Tomasz Zemelka, George Fountzilias, Carlo Barone, Michael Schlichting, Jim Heighway, S. Peter Eggleton, and Vichien Srimuninnimit. FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study. *Clinical Colorectal Cancer*, 13(1):14–26, 2014.
- [137] Tomislav Dragovich, David Mendelson, Sandra Kurtin, Kelly Richardson, Daniel Von Hoff, and Axel Hoos. A phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. *Cancer Chemotherapy and Pharmacology*, 58(6):759–764, 2006.
- [138] M. Ducreux, A. Adenis, J.-P. Pignon, E. François, B. Chauffert, J.L. Ichanté, E. Boucher, M. Ychou, J.-Y. Pierga, C. Montoto-Grillot, and T. Conroy. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study). *European Journal of Cancer*, 49(6):1236–1245, 2013.
- [139] M. Ducreux, J. Bennouna, M. Hebbar, M. Ychou, G. Lledo, T. Conroy, A. Adenis, R. Faroux, C. Rebuschung, and J. Douillard. Efficacy and safety findings from a randomized phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs. infusional 5-FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC). *Journal of Clinical Oncology (Meeting Abstracts)*, 25(18S):4029, 2007.
- [140] Michel Ducreux, Jaafar Bennouna, Mohamed Hebbar, Marc Ychou, Gérard Lledo, Thierry Conroy, Antoine Adenis, Roger Faroux, Christine Rebuschung, Loic Bergougnoux, Leila Kockler, and Jean-Yves Douillard. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer. *International Journal of Cancer*, 128(3):682–690, 2011.
- [141] Michel Ducreux, David Malka, Jean Mendiboure, Pierre-Luc Etienne, Patrick Texereau, Dominique Auby, Philippe Rougier, Mohamed Gasmi, Marine Castaing, Moncef Abbas, Pierre Michel, Dany Gargot, Ahmed Azzedine, Catherine Lombard-Bohas, Patrick Geoffroy, Bernard Denis, Jean-Pierre Pignon, Laurent Bedenne, and Olivier Bouché. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-2005): An open-label, randomised, phase 3 trial. *The Lancet Oncology*, 12(11):1032–1044, 2011.



- [142] Michel Ducreux, J-L Raoul, Pierre Marti, Yacine Merrouche, J-M Tigaud, Christine Reischung, and Valérie Boige. High-dose irinotecan plus LV5FU2 or simplified LV5FU (HD-FOLFIRI) for patients with untreated metastatic colorectal cancer: A new way to allow resection of liver metastases? *Oncology*, 74(1-2):17–24, 2008.
- [143] Grace K. Dy, James E. Krook, Erin M. Green, Daniel J. Sargent, Thierry Delaunoy, Roscoe F. Morton, Charles S. Fuchs, Ramesh K. Ramanathan, Stephen K. Williamson, Brian P. Findlay, Barbara A. Pockaj, Robert P. Sticca, Steven R. Alberts, Henry C. Pitot, and Richard M. Goldberg. Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: Results from Intergroup N9741. *Journal of Clinical Oncology*, 25(23):3469–3474, 2007.
- [144] M. Echarri, C. Gravalos, J. Camara, A. Ruiz, L. Garcia-Garcia, M. Hernandez, E. Holgado, C. Gomez, G. Garcia, H. Cortes-Funes, and ONCOSUR Group. Bevacizumab in combination with continuous administration of capecitabine plus biweekly oxaliplatin: Preliminary results from the XELOX-AV trial. *Journal of Clinical Oncology (Meeting Abstracts)*, 26(15S):15074, 2008.
- [145] Fabio Efficace, Pasquale F. Innominato, Georg Bjarnason, Corneel Coens, Yves Humblet, Salvatore Tumolo, Dominique Genet, Marco Tampellini, Andrew Bottomley, Carlo Garufi, Christian Focan, Sylvie Giacchetti, and Francis Lévi. Validation of patient’s self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: Results of an international study by the chronotherapy group of the european organisation for research and treatment of cancer. *Journal of Clinical Oncology*, 26(12):2020–2026, 2008.
- [146] A. B. El-Khoueiry, S. Iqbal, D. A. Singh, S. D’Andre, R. K. Ramanathan, S. Shibata, D. Y. Yang, H. J. Lenz, T. Synold, and D. R. Gandara. A randomized phase II non-comparative study of ispinesib given weekly or every three weeks in metastatic colorectal cancer. A California Cancer Consortium Study (CCC-P). *ASCO Meeting Abstracts*, 24(18S):3595, 2006.
- [147] Bassel F. El-Rayes, Mark M. Zalupski, Stephanie G. Manza, Barbara Rusin, AnnMarie Ferris, Ulka Vaishampayan, Lance K. Heilbrun, Raghu Venkatramanamoorthy, Anthony F. Shields, and A. Philip. Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. *Cancer Chemotherapy and Pharmacology*, 61(2):283–289, 2008.
- [148] C. Emmanouilides, M. Pegram, R. Robinson, R. Hecht, F. Kabbinavar, and W. Isacoff. Anti-VEGF antibody bevacizumab (Avastin) with 5FU/LV as third line treatment for colorectal cancer. *Techniques in Coloproctology*, 8(1):50–52, 2004.
- [149] C. Eng, H. L. Kindler, S. Nattam, R. H. Ansari, K. Kasza, K. Wade-Oliver, and E. Vokes. A phase II trial of the epothilone B analog, BMS-247550, in patients with previously treated advanced colorectal cancer. *Annals of Oncology*, 15(6):928–932, 2004.
- [150] Cathy Eng, Lowell L. Hart, Aleksey Severtsev, Oleg Gladkov, Lothar Mueller, Mikhail V. Kopp, Vladimir Ivanovich Vladimirov, Robert M. Langdon, Bogdan Kotiv, Sandro Barni, Ching Hsu, Ellen Bolotin, Reinhard Von Roemeling, Brian E. Schwartz, and Johanna C. Bendell. A randomized, placebo-controlled, phase II study of tivantinib (ARQ 197) in combination with cetuximab and irinotecan as second-line therapy in patients (pts) with KRAS wild-type (WT) metastatic colorectal cancer (MCRC) . *ASCO Meeting Abstracts*, 31(15S):3508, 2013.

- [151] Marie-Christine Etienne-Grimaldi, Jean-Louis Formento, Mireille Francoual, Eric François, Patricia Formento, Nicole Renée, Pierre Laurent-Puig, Maurice Chazal, Daniel Benchimol, Jean-Robert Delpero, Christian Letoublon, Denis Pezet, Jean-François Seitz, and Gérard Milano. K-RAS mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. *Clinical Cancer Research*, 14(15):4830–4835, 2008.
- [152] Marie-Christine Etienne-Grimaldi, Gérard Milano, Frédérique Maindrault-Göebel, Benoist Chibaudel, Jean-Louis Formento, Mireille Francoual, Gérard Lledo, Thierry André, May Mabro, Laurent Mineur, Michel Flesch, Elisabeth Carola, and Aimery. De Gramont. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients. *British Journal of Clinical Pharmacology*, 69(1):58–66, 2010.
- [153] M.G. Fakih, C. Andrews, J. McMahon, and J.R. Muindi. A prospective clinical trial of cholecalciferol 2000 IU/day in colorectal cancer patients: Evidence of a chemotherapy-response interaction. *Anticancer Research*, 32(4):1333–1338, 2012.
- [154] M.G. Fakih, A. Groman, J. McMahon, G. Wilding, and J.R. Muindi. A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. *Cancer Chemotherapy and Pharmacology*, 69(3):743–751, 2012.
- [155] Alfredo Falcone, Chiara Cremolini, Gianluca Masi, Sara Lonardi, Vittorina Zagonel, Lisa Salvatore, Patrizia Trenta, Gianluca Tomasello, Monica Ronzoni, Libero Ciuffreda, Alberto Zaniboni, Giuseppe Tonini, Angela Buonadonna, Chiara Valsuani, Silvana Chiara, Chiara Carlomagno, Corrado Boni, Lorenzo Marcucci, Luca Boni, and Fotios. Loupakis. FOLFOXIRI/bevacizumab (Bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group. *ASCO Meeting Abstracts*, 31(15S):3505, 2013.
- [156] Alfredo Falcone, Sergio Ricci, Isa Brunetti, Elisabetta Pfanner, Giacomo Allegrini, Cecilia Barbara, Lucio Crinó, Giovanni Benedetti, Walter Evangelista, Laura Fanchini, Enrico Cortesi, Vincenzo Picone, Stefano Vitello, Silvana Chiara, Cristina Granetto, Gianfranco Porcile, Luisa Fioretto, Cinzia Orlandini, Michele Andreuccetti, and Gianluca Masi. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The gruppo oncologico nord ovest. *Journal of Clinical Oncology*, 25(13):1670–1676, 2007.
- [157] J. Feliu, M. J. Safont, A. Salud, F. Losa, C. Garcia-Giron, C. Bosch, P. Escudero, R. Lopez, C. Madronal, M. Bolanos, M. Gil, A. Llombart, J. Castro-Carpeno, and M. Gonzalez-Baron. Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. *British Journal of Cancer*, 102(10):1468–1473, May 2010.
- [158] J. Feliu, A. Salud, P. Escudero, L. Lopez-Gomez, M. Bolanos, A. Galan, J.-M. Vicent, A. Yubero, F. Losa, J. De Castro, M. A. de Mon, E. Casado, and M. Gonzalez-Baron. XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. *British Journal of Cancer*, 94(7):969–975, March 2006.
- [159] Jaime Feliu, Pilar Escudero, Ferrán Llosa, Matilde Bolaños, Jose-Manuel Vicent, Alfonso Yubero, Jose-Javier Sanz-Lacalle, Rafael Lopez, Luis Lopez-Gómez, Enrique Casado, María-José Gómez-Reina, and Manuel González-Baron. Capecitabine as first-line treatment for

- patients older than 70 years with metastatic colorectal cancer: An Oncopaz Cooperative Group Study. *Journal of Clinical Oncology*, 23(13):3104–3111, 2005.
- [160] A. L. A. Fields, D. A. Rinaldi, C. A. Henderson, C. J. Germond, L. Chu, K. J. Brill, L. H. Leopold, and M. S. Berger. An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer. *ASCO Meeting Abstracts*, 23(16S):3583, 2005.
- [161] Arié Figer, Nathalie Perez-Staub, Elisabeth Carola, Christophe Tournigand, Gerard Lledo, Michel Flesch, Ramon Barcelo, Andre Cervantes, Thierry André, Philippe Colin, Christophe Louvet, and Aimery de Gramont. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer. *Cancer*, 110(12):2666–2671, 2007.
- [162] George A. Fisher, Timothy Kuo, Meghan Ramsey, Erich Schwartz, Robert V. Rouse, Cheryl D. Cho, Joanne Halsey, and Branimir I. Sikic. A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. *Clinical Cancer Research*, 14(21):7074–7079, 2008.
- [163] G. Folprecht, D. Cunningham, P. Ross, B. Glimelius, F. Di Costanzo, J. Wils, W. Scheithauer, P. Rougier, E. Aranda, H. Hecker, and C.-H. Köhne. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: A pooled analysis of clinical trials. *Annals of Oncology*, 15(9):1330–1338, 2004.
- [164] G. Folprecht, T. Gruenberger, W. Bechstein, H.-R. Raab, J. Weitz, F. Lordick, J. T. Hartmann, J. Stoehmacher-Williams, H. Lang, T. Trarbach, T. Liersch, D. Ockert, D. Jaeger, U. Steger, T. Suedhoff, A. Rentsch, and C.-H. Köhne. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). *Annals of Oncology*, 25(5):1018–1025, 2014.
- [165] Gunnar Folprecht, Thomas Gruenberger, Wolf O Bechstein, Hans-Rudolf Raab, Florian Lordick, Jörg T Hartmann, Hauke Lang, Andrea Frilling, Jan Stoehmacher, Jürgen Weitz, Ralf Konopke, Christian Stroszczyński, Torsten Liersch, Detlev Ockert, Thomas Herrmann, Eray Goekkurt, Fabio Parisi, and Claus-Henning Köhne. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial. *The Lancet Oncology*, 11(1):38–47, 2010.
- [166] Gunnar Folprecht, Matthew T. Seymour, Leonard Saltz, Jean-Yves Douillard, Hartmut Hecker, Richard J. Stephens, Timothy S. Maughan, Eric Van Cutsem, Philippe Rougier, Emmanuel Mitry, Ute Schubert, and Claus-Henning Köhne. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: Combined analysis of 2,691 patients in randomized controlled trials. *Journal of Clinical Oncology*, 26(9):1443–1451, 2008.
- [167] A.A. Fora, J.A. McMahon, G. Wilding, A. Groman, W.W. Ma, K.S. Romano, and M.G. Fakih. A phase II study of high-dose cetuximab plus irinotecan in colorectal cancer patients with KRAS wild-type tumors who progressed after standard dose of cetuximab plus irinotecan. *Oncology*, 84(4):210–213, 2013.
- [168] L. Fornaro, S. Lonardi, G. Masi, F. Loupakis, F. Bergamo, L. Salvatore, C. Cremolini, M. Schirripa, C. Vivaldi, G. Aprile, A. Zaniboni, S. Bracarda, G. Fontanini, E. Sensi, C. Lupi, M. Morvillo, V. Zagonel, and A. Falcone. FOLFOXIRI in combination with panitumumab

- as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: A phase II trial by the Gruppo Oncologico Nord Ovest (GONO). *Annals of Oncology*, 24(8):2062–2067, 2013.
- [169] Lorenzo Fornaro, Giacomo Giulio Baldi, Gianluca Masi, Giacomo Allegrini, Fotios Loupakis, Enrico Vasile, Samanta Cupini, Irene Stasi, Lisa Salvatore, Chiara Cremolini, Bruno Vincenzi, Daniele Santini, Giuseppe Tonini, Francesco Graziano, Annamaria Ruzzo, Emanuele Canestrari, Mauro Magnani, and Alfredo Falcone. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: Clinical outcome according to KRAS and BRAF mutational status. *Critical Reviews in Oncology/Hematology*, 78(3):243–251, 2011.
- [170] Lorenzo Fornaro, Enrico Vasile, Gianluca Masi, Fotios Loupakis, Giacomo Giulio Baldi, Giacomo Allegrini, Lisa Salvatore, Chiara Cremolini, Samanta Cupini, Enrico Cortesi, Alessandro Tuzi, Cristina Granetto, Isa Maura Brunetti, Sergio Ricci, and Alfredo Falcone. Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen. *Clinical Colorectal Cancer*, 11(1):71–76, 2012.
- [171] Annie Fourrier-Réglat, Denis Smith, Magali Rouyer, Jacques Bénichou, Rosine Guimbaud, Yves Bécouarn, Olivier Bernard, Pernelle Noize, Nicholas Moore, and Alain Ravaud. Survival outcomes of bevacizumab in first-line metastatic colorectal cancer in a real-life setting: Results of the ETNA cohort. *Targeted Oncology*, 9(4):311–319, 2014.
- [172] Eric Francois, Denis Smith, Laetitia Dahan, Cecile Michel, Hervé Perrier, Véronique Mari, Jean-François Seitz, Philippe Follana, Ludovic Evesque, and Emmanuel Chamorey. Uracil-tegafur/leucovorin and mitomycin C salvage therapy in patients with advanced colorectal cancer: A phase II study. *Journal of Chemotherapy*, 24(4):207–211, 2012.
- [173] Daniel Frank, Alcee Jumonville, Noelle K LoConte, William R Schelman, Daniel Mulkerin, Sam Lubner, Katie Richter, Natalie Winterle, Mary Beth Wims, Leah Dietrich, J Mitchell Winkler, Michael Volk, KyungMann Kim, and Kyle D Hoen. A phase II study of capecitabine and lapatinib in advanced refractory colorectal adenocarcinoma: A Wisconsin Oncology Network study. *Journal of Gastrointestinal Oncology*, 3(2):90–96, October 2011.
- [174] Jan Franko, Qian Shi, Charles D. Goldman, Barbara A. Pockaj, Garth D. Nelson, Richard M. Goldberg, Henry C. Pitot, Axel Grothey, Steven R. Alberts, and Daniel J. Sargent. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of north central cancer treatment group phase III Trials N9741 and N9841. *Journal of Clinical Oncology*, 30(3):263–267, 2012.
- [175] G. Freyer, A. Duret, G. Milano, E. Chatelut, C. Rebischung, J.-P. Delord, Y. Merrouche, G. Lledo, M.-C. Etienne, and C. Falandry. Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: Results of a pilot study. *Anticancer Research*, 31(1):359–366, 2011.
- [176] Charles S. Fuchs, Richard M. Goldberg, Daniel J. Sargent, Jeffrey A. Meyerhardt, Brian M. Wolpin, Erin M. Green, Henry C. Pitot, and Michael. Pollak. Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: Results from Intergroup Trial N9741. *Clinical Cancer Research*, 14(24):8263–8269, 2008.
- [177] Charles S. Fuchs, John Marshall, Edith Mitchell, Rafal Wierzbicki, Vinod Ganju, Mark Jeffery, Joseph Schulz, Donald Richards, Raoudha Soufi-Mahjoubi, Benjamin Wang, and

- José. Barrueco. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results From the BICC-C Study. *Journal of Clinical Oncology*, 25(30):4779–4786, 2007.
- [178] P Garcia-Alfonso, A Munoz-Martin, M Mendez-Urena, R Quiben-Pereira, E Gonzalez-Flores, and G Perez-Manga. Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: A phase II study of the Spanish GOTI group. *British Journal of Cancer*, 101(7):1039–1043, September 2009.
- [179] P Garcia-Alfonso, A J Munoz-Martin, S Alvarez-Suarez, Y Jerez-Gilarranz, M Riesco-Martinez, P Khosravi, and M Martin. Bevacizumab in combination with biweekly capecitabine and irinotecan, as first-line treatment for patients with metastatic colorectal cancer. *British Journal of Cancer*, 103(10):1524–1528, November 2010.
- [180] Christopher R. Garrett, Tanios S. Bekaii-Saab, Theresa Ryan, George A. Fisher, Sally Clive, Petr Kavan, Einat Shacham-Shmueli, Aby Buchbinder, and Richard M. Goldberg. Randomized phase 2 study of pegylated SN-38 (EZN-2208) or irinotecan plus cetuximab in patients with advanced colorectal cancer. *Cancer*, 119(24):4223–4230, 2013.
- [181] Elaina M. Gartner, Kent A. Griffith, Quintin Pan, George J. Brewer, Gwen F. Henja, Sofia D. Merajver, and Mark M. Zalupski. A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-fluorouracil, and leucovorin for metastatic colorectal cancer. *Investigational New Drugs*, 27(2):159–165, 2009.
- [182] C. Garufi, E. Bria, B. Vanni, A. M. R. Zappala, I. Sperduti, and E. Terzoli. A phase II study of irinotecan plus chronomodulated oxaliplatin, 5-fluorouracil and folinic acid in advanced colorectal cancer patients. *British Journal of Cancer*, 89(10):1870–1875, 2003.
- [183] C. Garufi, S. Brienza, P. Pugliese, A. M. Aschelter, M. A. Bensmaine, F. Bertheault-Cvitkovic, C. Nisticó, S. Giunta, M. Caterino, D. Giannarelli, M. Cosimelli, F. Lévi, and E. Terzoli. Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients. *Anti-Cancer Drugs*, 11(6):495–501, 2000.
- [184] Alain J. Gelibter, Teresa Gamucci, Camillo F. Pollera, Francesco Di Costanzo, Carmen Nuzzo, Angela Gabriele, Carlo Signorelli, Silvia Gasperoni, Virginia Ferraresi, Diana Giannarelli, Francesco Cognetti, and Massimo Zeuli. A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer. *Current Medical Research and Opinion*, 23(9):2117–2123, 2007.
- [185] Thomas J. George, Alison Marguerite Ivey, Long H. Dang, Karen Colleen Daily, Wei Hou, Dana Lynn Viviano, Scott Watson, Renee Granicz, Margaret A. McEwan, Hui Yan, and Carmen Joseph Allegra. Phase II study of sorafenib and capecitabine (SorCape) in previously treated metastatic colorectal cancer (mCRC): NCT01471353. *ASCO Meeting Abstracts*, 31(4S):489, 2013.
- [186] Vassilis Georgoulas, Charalambos Kouroussis, John Souglakos, Dimitris Mavroudis, Savvakis Papadouris, Stylianos Kakolyris, Sophia Agelaki, Kostas Kalbakis, Christos Panopoulos, Nikos Vardakis, and Evanthia Sarra. Oxaliplatin with high-dose leucovorin and infusional 5-fluorouracil in irinotecan-pretreated patients with advanced colorectal cancer (ACC). *American Journal of Clinical Oncology*, 25(6):627–631, 2002.

- [187] Pascal Gervaz, Laura Rubbia-Brandt, Axel Andres, Pietro Majno, Arnaud Roth, Philippe Morel, and Gilles Mentha. Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: A comparison of histological response in liver metastases, primary tumors, and regional lymph nodes. *Annals of Surgical Oncology*, 17(10):2714–2719, 2010.
- [188] François Ghiringhelli, Julie Vincent, Boris Guiu, Bruno Chauffert, and Sylvain Ladoire. Bevacizumab plus FOLFIRI-3 in chemotherapy-refractory patients with metastatic colorectal cancer in the era of biotherapies. *Investigational New Drugs*, 30(2):758–764, 2012.
- [189] S. Giacchetti, B. Perpoint, R. Zidani, N. Le Bail, R. Faggiuolo, C. Focan, P. Chollet, J.F. Llory, Y. Letourneau, B. Coudert, F. Bertheaut-Cvitkovic, D. Larregain-Fournier, A. Le Rol, S. Walter, R. Adam, J.L. Misset, and F. Lévi. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. *Journal of Clinical Oncology*, 18(1):136, 2000.
- [190] Sylvie Giacchetti, Georg Bjarnason, Carlo Garufi, Dominique Genet, Stefano Iacobelli, Marco Tampellini, Rune Smaaland, Christian Focan, Bruno Coudert, Yves Humblet, Jean Luc Canon, Antoine Adenis, Giovanni Lo Re, Carlos Carvalho, Johannes Schueller, Nicole Anciaux, Marie-Ange Lentz, Benoît Baron, Thierry Gorlia, and Francis Lévi. Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group. *Journal of Clinical Oncology*, 24(22):3562–3569, 2006.
- [191] B. J. Giantonio, D. E. Levy, P. J. O’Dwyer, N. J. Meropol, P. J. Catalano, and A. B. Benson. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: Results from the eastern cooperative oncology group study E2200. *Annals of Oncology*, 17(9):1399–1403, 2006.
- [192] Bruce J. Giantonio, Paul J. Catalano, Neal J. Meropol, Peter J. O’Dwyer, Edith P. Mitchell, Steven R. Alberts, Michael A. Schwartz, and Al B. Benson. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the eastern cooperative oncology group study E3200. *Journal of Clinical Oncology*, 25(12):1539–1544, 2007.
- [193] Peter Gibbs, Philip R. Clingan, Vinod Ganju, Andrew H. Strickland, Shirley S. Wong, Niall C. Tebbutt, Craig R. Underhill, Richard M. Fox, Steven P. Clavant, Jenny Leung, Minh Pho, and Tracey J. Brown. Hyaluronan-irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: A randomized phase II trial. *Cancer Chemotherapy and Pharmacology*, 67(1):153–163, 2011.
- [194] Clemens Giessen, Ludwig von Weikersthal, Axel Hinke, Sebastian Stintzing, Frank Kullmann, Ursula Vehling-Kaiser, Julia Mayerle, Markus Bangerter, Claudio Denzlinger, Markus Sieber, Christian Teschendorf, Jens Freiberg-Richter, Christoph Schulz, Dominik Modest, Nicolas Moosmann, Philipp Aubele, and Volker Heinemann. A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial. *BioMed Central Cancer*, 11(1):367, 2011.
- [195] B. Glimelius, M. Lahn, S. Gawande, A. Cleverly, C. Darstein, L. Musib, Y. Liu, K. L. Spindler, J.-E. Frödin, Å. Berglund, P. Byström, C. Qvortrup, A. Jakobsen, and P. Pfeiffer. A window

- of opportunity phase II study of enzastaurin in chemo-naïve patients with asymptomatic metastatic colorectal cancer. *Annals of Oncology*, 21(5):1020–1026, 2009.
- [196] B. Glimelius, H. Sørbye, L. Balteskard, P. Byström, P. Pfeiffer, K. Tveit, R. Heikkilä, N. Keldsen, M. Albertsson, H. Starkhammar, H. Garmo, and Å. Berglund. A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (LV5FU2) in patients with metastatic colorectal cancer. *Annals of Oncology*, 19(5):909–914, 2008.
- [197] Gabriel Glockzin, Justine Rochon, Dirk Arnold, Sven Lang, Frank Klebl, Florian Zeman, Michael Koller, Hans Schlitt, and Pompiliu Piso. A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: The COMBATAC trial. *BioMed Central Cancer*, 13(1):67, 2013.
- [198] Sanjay Goel, Scott Wadler, Anthony Hoffman, Fabio Volterra, Cheryl Baker, Elliot Nazario, Percy Ivy, Alyson Silverman, and Sridhar Mani. A phase II study of rebeccamycin analog NSC 655649 in patients with metastatic colorectal cancer. *Investigational New Drugs*, 21(1):103–107, 2003.
- [199] Richard M Goldberg, Daniel J Sargent, and Howard McLeod. Leveraging learning from a phase III colorectal cancer clinical trial: Outcomes, methodology, meta-analysis and pharmacogenetics. *Transactions of the American Clinical and Climatological Association*, 121:21–33, 2010.
- [200] Richard M. Goldberg, Daniel J. Sargent, Roscoe F. Morton, Charles S. Fuchs, Ramesh K. Ramanathan, Stephen K. Williamson, Brian P. Findlay, Henry C. Pitot, and Steven Alberts. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: A north american intergroup trial. *Journal of Clinical Oncology*, 24(21):3347–3353, 2006.
- [201] Richard M. Goldberg, Daniel J. Sargent, Roscoe F. Morton, Charles S. Fuchs, Ramesh K. Ramanathan, Stephen K. Williamson, Brian P. Findlay, Henry C. Pitot, and Steven R. Alberts. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. *Journal of Clinical Oncology*, 22(1):23–30, 2004.
- [202] Richard M. Goldberg, Daniel J. Sargent, Roscoe F. Morton, Erin Green, Hanna K. Sanoff, Howard McLeod, and Jan Buckner. NCCTG study N9741: Leveraging learning from an NCI cooperative group phase III trial. *The Oncologist*, 14(10):970–978, 2009.
- [203] Michael S. Gordon, Christopher J. Sweeney, David S. Mendelson, S. Gail Eckhardt, Abraham Anderson, Darrin M. Beaupre, Daniel Branstetter, Teresa L. Burgess, Angela Coxon, Hongjie Deng, Paula Kaplan-Lefko, Ian M. Leitch, Kelly S. Oliner, Lucy Yan, Min Zhu, and Lia Gore. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors. *Clinical Cancer Research*, 16(2):699–710, 2010.
- [204] Aimery De Gramont, Eric Van Cutsem, Hans-Joachim Schmoll, Josep Tabernero, Stephen Clarke, Malcolm J Moore, David Cunningham, Thomas H Cartwright, J Randolph Hecht,

- Fernando Rivera, Seock-Ah Im, György Bodoky, Ramon Salazar, Frédérique Maindrault-Goebel, Einat Shacham-Shmueli, Emilio Bajetta, Martina Makrutzki, Aijing Shang, Thierry André, and Paulo M Hoff. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): A phase 3 randomised controlled trial. *The Lancet Oncology*, 13(12):1225–1233, 2012.
- [205] Cristina Gravalos, Antonieta Salut, Carlos García-Girón, Rocío García-Carbonero, AnaIsabel León, Isabel Sevilla, Joan Maurel, Beatriz Esteban, Eduardo García-Rico, Adolfo Murias, and Hernán Cortés-Funes. A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer. *Clinical and Translational Oncology*, 14(8):606–612, 2012.
- [206] Francesco Graziano, Annamaria Ruzzo, Fotios Loupakis, Emanuele Canestrari, Daniele Santini, Vincenzo Catalano, Renato Bissoni, Umberto Torresi, Irene Floriani, Gaia Schiavon, Francesca Andreoni, Paolo Maltese, Eliana Rulli, Bostjan Humar, Alfredo Falcone, Lucio Giustini, Giuseppe Tonini, Andrea Fontana, Gianluca Masi, and Mauro Magnani. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. *Journal of Clinical Oncology*, 26(9):1427–1434, 2008.
- [207] A. Grothey, J. M. Lafky, B. W. Morlan, P. J. Stella, S. R. Dakhil, P. D. Steen, W. S. Loui, B. M. Bot, S. R. Alberts, and J. T. Reynolds. Dual VEGF inhibition with sorafenib and bevacizumab (BEV) as salvage therapy in metastatic colorectal cancer (mCRC): Results of the phase II north central cancer treatment group study N054C. *ASCO Meeting Abstracts*, 28(15S):3549, 2010.
- [208] Axel Grothey, Eric Van Cutsem, Alberto Sobrero, Salvatore Siena, Alfredo Falcone, Marc Ychou, Yves Humblet, Olivier Bouché, Laurent Mineur, Carlo Barone, Antoine Adenis, Josep Tabernero, Takayuki Yoshino, Heinz-Josef Lenz, Richard M Goldberg, Daniel J Sargent, Frank Cihon, Lisa Cupit, Andrea Wagner, and Dirk Laurent. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. *The Lancet*, 381(9863):303–312, 2013.
- [209] Axel Grothey, Eric E. Hedrick, Robert D. Mass, Somnath Sarkar, Sam Suzuki, Ramesh K. Ramanathan, Herbert I. Hurwitz, Richard M. Goldberg, and Daniel J. Sargent. Response-independent survival benefit in metastatic colorectal cancer: A comparative analysis of N9741 and AVF2107. *Journal of Clinical Oncology*, 26(2):183–189, 2008.
- [210] Axel Grothey, Daniel A. Nikcevich, Jeff A. Sloan, John W. Kugler, Peter T. Silberstein, Todor Dentchev, Donald B. Wender, Paul J. Novotny, Umesh Chitale, Steven R. Alberts, and Charles L. Loprinzi. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. *Journal of Clinical Oncology*, 29(4):421–427, 2011.
- [211] Axel Grothey, Mary M. Sugrue, David M. Purdie, Wei Dong, Daniel Sargent, Eric Hedrick, and Mark Kozloff. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRITE). *Journal of Clinical Oncology*, 26(33):5326–5334, 2008.
- [212] QUASAR Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. *The Lancet*, 370(9604):2020–2029, 2007.



- [213] Brigit Gruenberger, Dietmar Tamandl, Johannes Schueller, Werner Scheithauer, Christoph Zielinski, Friedrich Herbst, and Thomas Gruenberger. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. *Journal of Clinical Oncology*, 26(11):1830–1835, 2008.
- [214] Thomas Gruenberger, John A. Bridgewater, Ian Chau, Pilar Garcia Alfonso, Michel Rivoire, Susan Lasserre, Daniel Waterkamp, and Rene Adam. Randomized, phase II study of bevacizumab with mFOLFOX6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: Resectability and safety in OLIVIA. *ASCO Meeting Abstracts*, 31(15S):3619, 2013.
- [215] Zhong-Zhen Guan, Jian-Ming Xu, Rong-Cheng Luo, Feng-Yi Feng, Li-Wei Wang, Lin Shen, Shi-Ying Yu, Yi Ba, Jun Liang, Dong Wang, Shu-Kui Qin, Jie-Jun Wang, Jing He, Chuan Qi, and Rui-Hua Xu. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: A randomized phase III ARTIST trial. *Chinese journal of cancer*, 30(10):682–689, October 2011.
- [216] Daniel G. Haller, Jim Cassidy, Stephen J. Clarke, David Cunningham, Eric Van Cutsem, Paulo M. Hoff, Mace L. Rothenberg, Leonard B. Saltz, Hans-Joachim Schmoll, Carmen Allegra, Joseph R. Bertino, Jean-Yves Douillard, Bengt G. Gustavsson, Gerard Milano, Michael O’Connell, Youcef Rustum, Josep Taberner, Frank Gilberg, Florin Sirzn, and Chris Twelves. Potential regional differences for the tolerability profiles of fluoropyrimidines. *Journal of Clinical Oncology*, 26(13):2118–2123, 2008.
- [217] Daniel G. Haller, Paul J. Catalano, John S. Macdonald, Mark A. O’Rourke, Michael S. Frontiera, Don V. Jackson, and Robert J. Mayer. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: Final report of intergroup 0089. *Journal of Clinical Oncology*, 23(34):8671–8678, 2005.
- [218] Daniel G. Haller, Mace L. Rothenberg, Alfred O. Wong, Piotr M. Koralewski, Wilson H. Miller, Gyorgy Bodoky, Nassir Habboubi, Carlos Garay, and Luis O. Olivatto. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. *Journal of Clinical Oncology*, 26(28):4544–4550, 2008.
- [219] Tetsuya Hamaguchi, Kuniaki Shirao, Yoshihiro Moriya, Shigeaki Yoshida, Susumu Kodaira, and Yasuo Ohashi. Final results of randomized trials by the national surgical adjuvant study of colorectal cancer (NSAS-CC). *Cancer Chemotherapy and Pharmacology*, 67(3):587–596, 2011.
- [220] T F Hansen, R dP Christensen, R F Andersen, F B Sorensen, A Johnsson, and A Jakobsen. MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the nordic ACT trial. *British Journal of Cancer*, 109(5):1243–1251, September 2013.
- [221] Torben Frøstrup Hansen, Rikke Fredslund Andersen, Niels Pallisgaard, Karen-Lise Garm Spindler, John Pløen, Nina Keldsen, Jan Lindebjerg, Flemming Brandt Sørensen, and Anders Jakobsen. A 3-weekly schedule of irinotecan and panitumumab for wild-type KRAS metastatic colorectal cancer. *Colorectal Cancer*, 3(2):135–145, April 2014.

- [222] Sigurdís Haraldsdóttir, Jeffrey S. Rose, Christina Wu, Lai Wei, Richard M. Goldberg, and Tanios Bekaii-Saab. A single institutional experience with panitumumab in metastatic colorectal cancer. *Journal of Cancer Therapy*, 3(6A):948–955, November 2012.
- [223] Mohamed Hebbar, Benoist Chibaudel, Thierry André, Christophe Louvet, Denis Smith, Laurent Mineur, Mostepha Bennamoun, May Mabro, David Brusquant, Franck Bonnetain, François-René Pruvot, and Aimery de Gramont. Randomized trial of simplified LV5FU2 versus FOLFOX7 followed by FOLFIRI (MIROX) in patients with initially resectable metastatic colorectal cancer: A GERCOR study. *Journal of Chemotherapy*, 25(2):104–111, 2013.
- [224] Mohamed Hebbar, Frédéric Di Fioré, Thierry Conroy, Claire Giraud, Laurent Gasnault, Charles Fournier, Renata Péreira, Olivier Bouché, Peggy Fournier, Nathalie Deligny, et al. Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer. *Oncology*, 73(3-4):185–191, 2008.
- [225] Mohamed Hebbar, Christophe Tournigand, Gérard Lledo, May Mabro, Thierry André, Christophe Louvet, Thomas Aparicio, Michel Flesch, Charles Varette, Aimery de Gramont, and Oncology Multidisciplinary Research Group (GERCOR). Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study). *Cancer Investigation*, 24(2):154–159, 2006.
- [226] J. Randolph Hecht, Edith Mitchell, Tarek Chidiac, Carroll Scroggin, Christopher Hagenstad, David Spigel, John Marshall, Allen Cohn, David McCollum, Philip Stella, Robert Deeter, Seta Shahin, and Rafael G. Amado. A randomized phase IIIb trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. *Journal of Clinical Oncology*, 27(5):672–680, 2009.
- [227] J. Randolph Hecht, Edith Mitchell, Marcus A. Neubauer, Howard A. Burris, Paul Swanson, Timothy Lopez, Glenn Buchanan, Maureen Reiner, Jennifer Gansert, and Jordan Berlin. Lack of correlation between epidermal growth factor receptor status and response to panitumumab monotherapy in metastatic colorectal cancer. *Clinical Cancer Research*, 16(7):2205–2213, 2010.
- [228] J. Randolph Hecht, Amita Patnaik, Jordan Berlin, Alan Venook, Imtiaz Malik, Simon Tchekmedyian, Lynn Navale, Rafael G. Amado, and Neal J. Meropol. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. *Cancer*, 110(5):980–988, 2007.
- [229] J. Randolph Hecht, Madhavan Pillai, Russell Gollard, William Heim, Forrest Swan, Ravi Patel, Lyndah Dreiling, May Mo, and Imtiaz Malik. A randomized, placebo-controlled phase {II} study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. *Clinical Colorectal Cancer*, 9(2):95–101, 2010.
- [230] J. Randolph Hecht, Tanja Trarbach, John D. Hainsworth, Pierre Major, Elke Jäger, Robert A. Wolff, Katherine Lloyd-Salvant, György Bodoky, Kelly Pendergrass, William Berg, Bee-Lian Chen, Tarja Jalava, Gerold Meinhardt, Dirk Laurent, David Lebwohl, and David Kerr. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. *Journal of Clinical Oncology*, 29(15):1997–2003, 2011.

- [231] E Hedrick, M Kozloff, J Hainsworth, S Badarinath, A Cohn, P Flynn, W Dong, S Suzuki, S Sarkar, M Sugrue, et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE). *Journal of Clinical Oncology*, 24(3536):155s, 2006.
- [232] Martin J. Heslin, Jieming Yan, Heidi Weiss, Lingning Shao, Jill Owens, V. Sol Lucas, and Robert B. Diasio. Dihydropyrimidine dehydrogenase (DPD) rapidly regenerates after inactivation by eniluracil (GW776C85) in primary and metastatic colorectal cancer. *Cancer Chemotherapy and Pharmacology*, 52(5):399–404, 2003.
- [233] James M. Heun, Axel Grothey, Megan E. Branda, Richard M. Goldberg, and Daniel J. Sargent. Tumor status at 12 weeks predicts survival in advanced colorectal cancer: Findings from NCCTG N9741. *The Oncologist*, 16(6):859–867, 2011.
- [234] Timothy J. Hobday, John W. Kugler, Michelle R. Mahoney, Daniel J. Sargent, Jeff A. Sloan, Tom R. Fitch, James E. Krook, Michael J. O'Connell, James A. Mailliard, Maria Tria Tirona, Loren K. Tschetter, Charles D. Cobau, and Richard M. Goldberg. Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma. *Journal of Clinical Oncology*, 20(23):4574–4580, 2002.
- [235] Daniel Hochhauser, Rob Glynne-Jones, Vanessa Potter, Cristina Grávalos, Thomas J. Doyle, Kumudu Pathiraja, Qing Zhang, Ling Zhang, and Edward A. Sausville. A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter. *Molecular Cancer Therapeutics*, 12(5):809–818, 2013.
- [236] Howard Hochster, Abraham Chachoua, James Speyer, Juliette Escalon, Anne Zeleniuch-Jacquotte, and Franco Muggia. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. *Journal of Clinical Oncology*, 21(14):2703–2707, 2003.
- [237] Howard S. Hochster, Lowell L. Hart, Ramesh K. Ramanathan, Barrett H. Childs, John D. Hainsworth, Allen L. Cohn, Lucas Wong, Louis Fehrenbacher, Yousif Abubakr, M. Wasif Saif, Lee Schwartzberg, and Eric Hedrick. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE Study. *Journal of Clinical Oncology*, 26(21):3523–3529, 2008.
- [238] Howard S. Hochster, Weixiu Luo, Elizabeth C. Popa, Bruce T. Lyman, Mary Mulcahy, Peter A. Beatty, and Al Bowen Benson. Phase II study of uracil-tegafur with leucovorin in elderly ( $\geq 75$  years old) patients with colorectal cancer: ECOG 1299. *Journal of Clinical Oncology*, 25(34):5397–5402, 2007.
- [239] T Hoehler, G von Wichert, C Schimanski, S Kanzler, M H Moehler, A Hinke, T Seufferlein, J Siebler, A Hochhaus, D Arnold, M Hallek, R Hofheinz, and U T Hacker. Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205. *British Journal of Cancer*, 109(6):1408–1413, September 2013.
- [240] Paulo M. Hoff, Rafat Ansari, Gerald Batist, John Cox, Walter Kocha, Mario Kuperminc, Jean Maroun, David Walde, Charles Weaver, Evelyn Harrison, Hans U. Burger, Bruno Osterwalder, Alfred O. Wong, and Ralf Wong. Comparison of oral capecitabine versus

- intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. *Journal of Clinical Oncology*, 19(8):2282–2292, 2001.
- [241] Paulo M. Hoff, John A. Ellerton, S. R. Dakhil, Rodger J. Winn, James L. Abbruzzese, and Richard Pazdur. Phase II study of intravenous CI-958 in metastatic colorectal adenocarcinoma. *American Journal of Clinical Oncology*, 23(6):602–604, 2000.
- [242] Paulo M. Hoff, Andreas Hochhaus, Bernhard C. Pestalozzi, Niall C. Tebbutt, Jin Li, Tae Won Kim, Krassimir D. Koynov, Galina Kurteva, Tamás Pintér, Ying Cheng, Brigitte van Eyll, Laura Pike, Anitra Fielding, Jane D. Robertson, and Mark P. Saunders. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: A randomized, double-blind, phase III study (HORIZON II). *Journal of Clinical Oncology*, 30(29):3596–3603, 2012.
- [243] K. Homayounfar, A. Bleckmann, L.C. Conradi, T. Sprenger, T. Lorf, M. Niessner, C.O. Sahlmann, J. Meller, T. Liersch, and B.M. Ghadimi. Metastatic recurrence after complete resection of colorectal liver metastases: Impact of surgery and chemotherapy on survival. *International Journal of Colorectal Disease*, 28(7):1009–1017, 2013.
- [244] Yong Sang Hong, Hwa Jung Kim, Seong Joon Park, Kyu-Pyo Kim, Jae-Lyun Lee, Jin Hong Park, Jong Hoon Kim, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim, Ji Yeon Baek, Sun Young Kim, and Tae Won Kim. Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS. *Cancer Science*, 104(4):473–480, 2013.
- [245] Yong Sang Hong, Sung Sook Lee, Kyu-pyo Kim, Jae-Lyun Lee, Yoon-Koo Kang, Sang Joon Shin, Joong Bae Ahn, Kyung Hae Jung, Seock-Ah Im, Tae-You Kim, Jee Hyun Kim, Young Suk Park, and Tae Won Kim. A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: A prospective, multicenter trial of the Korean cancer study group. *American Journal of Clinical Oncology*, 37(1):19–23, 2014.
- [246] Yong Sang Hong, Young Suk Park, Ho Yeong Lim, Jeeyun Lee, Tae Won Kim, Kyu pyo Kim, Sun Young Kim, Ji Yeon Baek, Jee Hyun Kim, Keun-Wook Lee, Ik-Joo Chung, Sang-Hee Cho, Kyung Hee Lee, Sang Joon Shin, Hye Jin Kang, Dong Bok Shin, Sook Jung Jo, and Jae Won Lee. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: A randomised, non-inferiority phase 3 trial. *The Lancet Oncology*, 13(11):1125–1132, 2012.
- [247] YongSang Hong, Jeeyun Lee, Kyu-pyo Kim, Jae-Lyun Lee, YoungSuk Park, JoonOh Park, SeHoon Park, SunYoung Kim, JiYeon Baek, JeeHyun Kim, Keun-Wook Lee, Tae-You Kim, and TaeWon Kim. Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy. *Investigational New Drugs*, 31(1):183–191, 2013.
- [248] Yosuke Horita, Yasuhide Yamada, Ken Kato, Yoshinori Hirashima, Kouhei Akiyoshi, Kengo Nagashima, Takako Nakajima, Tetsuya Hamaguchi, and Yasuhiro Shimada. Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial. *International Journal of Clinical Oncology*, 17(6):604–609, 2012.

- [249] Herbert Hurwitz, Louis Fehrenbacher, William Novotny, Thomas Cartwright, John Hainsworth, William Heim, Jordan Berlin, Ari Baron, Susan Griffing, Eric Holmgren, Napoleone Ferrara, Gwen Fyfe, Beth Rogers, Robert Ross, and Fairouz Kabbinavar. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *New England Journal of Medicine*, 350(23):2335–2342, 2004.
- [250] Herbert Hurwitz, Edith P. Mitchell, Thomas Cartwright, Ambrose Kwok, Sylvia Hu, Edward McKenna, and Yehuda Z. Patt. A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (Dense Versus Standard). *The Oncologist*, 17(7):937–946, 2012.
- [251] Herbert I. Hurwitz, Louis Fehrenbacher, John D. Hainsworth, William Heim, Jordan Berlin, Eric Holmgren, Julie Hambleton, William F. Novotny, and Fairouz Kabbinavar. Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. *Journal of Clinical Oncology*, 23(15):3502–3508, 2005.
- [252] Herbert I. Hurwitz, Niall C. Tebbutt, Fairouz Kabbinavar, Bruce J. Giantonio, Zhong-Zhen Guan, Lada Mitchell, Daniel Waterkamp, and Josep Tabernero. Efficacy and safety of bevacizumab in metastatic colorectal cancer: Pooled analysis from seven randomized controlled trials. *The Oncologist*, 18(9):1004–1012, 2013.
- [253] Herbert I. Hurwitz, Jing Yi, William Ince, William F. Novotny, and Oliver Rosen. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of KRAS mutation status: Analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. *The Oncologist*, 14(1):22–28, 2009.
- [254] Ichinosuke Hyodo, Kuniaki Shirao, Toshihiko Doi, Kiyohiko Hatake, Yasuaki Arai, Kensei Yamaguchi, Takao Tamura, Shoji Takemiya, Hiroya Takiuchi, Kazuhiko Nakagawa, and Hideyuki Mishima. A phase II study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer. *Japanese Journal of Clinical Oncology*, 36(7):410–417, 2006.
- [255] Jeffrey R. Infante, Tony R. Reid, Allen L. Cohn, William J. Edenfield, Terrence P. Cescon, John T. Hamm, Imtiaz A. Malik, Thomas A. Rado, Philip J. McGee, Donald A. Richards, Jamal Tarazi, Brad Rosbrook, Sinil Kim, and Thomas H. Cartwright. Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: A randomized phase 2 study. *Cancer*, 119(14):2555–2563, 2013.
- [256] Pasquale F. Innominato, Sylvie Giacchetti, Thierry Moreau, Rune Smaaland, Christian Focan, Georg A. Bjarnason, Carlo Garufi, Stefano Iacobelli, Marco Tampellini, Salvatore Tumolo, Carlos Carvalho, Abdoulaye Karaboué, and Francis Lévi. Prediction of survival by neutropenia according to delivery schedule of oxaliplatin5-fluorouracil leucovorin for metastatic colorectal cancer in a randomized international trial (EORTC 05963). *Chronobiology International*, 28(7):586–600, 2011.
- [257] Megumi Ishiguro, Toshiaki Watanabe, Kensei Yamaguchi, Taroh Satoh, Hideyuki Ito, Taku Seriu, Yuh Sakata, and Kenichi Sugihara. A Japanese post-marketing surveillance of cetuximab (Erbix) in patients with metastatic colorectal cancer. *Japanese Journal of Clinical Oncology*, 42(4):287–294, 2012.

- [258] S. Iwasa, Y. Yamada, K. Kato, A. Goto, Y. Honma, T. Hamaguchi, and Y. Shimada. Long-term results of a phase II study of S-1 plus irinotecan in metastatic colorectal cancer. *Anticancer Research*, 32(9):4157–4161, 2012.
- [259] H-C Jeung, S Y Rha, B C Cho, N C Yoo, J K Roh, W J Roh, H C Chung, and J B Ahn. A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. *British Journal of Cancer*, 95(12):1637–1641, November 2006.
- [260] JunHo Ji, SeHoon Park, Jeeyun Lee, TaeWon Kim, YongSang Hong, Kyu-pyo Kim, SunYoung Kim, JiYeon Baek, HyeJin Kang, SangJoon Shin, ByoungYong Shim, and YoungSuk Park. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis. *Cancer Chemotherapy and Pharmacology*, 72(1):223–230, 2013.
- [261] Sang Hoon Ji, Young Suk Park, Jeeyun Lee, Do Hyoung Lim, Byeong-Bae Park, Keun Woo Park, Jung Hun Kang, Se-Hoon Lee, Joon Oh Park, Kihyun Kim, Won Seog Kim, Chul Won Jung, Young-Hyuck Im, Won Ki Kang, and Keunchil Park. Phase II study of irinotecan, 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer. *Japanese Journal of Clinical Oncology*, 35(4):214–217, 2005.
- [262] A. Jimeno, I. Sevilla, C. Gravalos, M. E. Vega, P. Escudero, E. Torre, F. Rivera, M. L. Garcia de Paredes, R. Colomer, and H. Cortes-Funes. Phase I/II trial of capecitabine and gefitinib in patients with advanced colorectal cancer after failure of first-line therapy. *ASCO Meeting Abstracts*, 23(16S):3176, 2005.
- [263] Antonio Jimeno, Cristina Grávalos, Pilar Escudero, Isabel Sevilla, M.Eugenia Vega-Villegas, Vicente Alonso, Ignacio Juez, Rocío García-Carbonero, Humberto Bovio, Ramón Colomer, and Hernán Cortés-Funes. Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer. *Clinical and Translational Oncology*, 10(1):52–57, 2008.
- [264] William John, Joel Picus, Charles D. Blanke, Jeffery W. Clark, Lawrence N. Schulman, Eric K. Rowinsky, Donald E. Thornton, and Patrick J. Loehrer. Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma. *Cancer*, 88(8):1807–1813, 2000.
- [265] A. Johnsson, H. Hagman, J.-E. Frödin, A. Berglund, N. Keldsen, E. Fernebro, J. Sundberg, R. De Pont Christensen, K.-L. Garm Spindler, D. Bergström, and A. Jakobsen. A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: The Nordic ACT trial. *Annals of Oncology*, 24(9):2335–2341, 2013.
- [266] Derek J. Jonker, Chris J. O’Callaghan, Christos S. Karapetis, John R. Zalberg, Dongsheng Tu, Heather-Jane Au, Scott R. Berry, Marianne Krahn, Timothy Price, R. John Simes, Niall C. Tebbutt, Guy van Hazel, Rafal Wierzbicki, Christiane Langer, and Malcolm J. Moore. Cetuximab for the treatment of colorectal cancer. *New England Journal of Medicine*, 357(20):2040–2048, 2007.
- [267] F Joulain, I Proskorovsky, C Allegra, J Tabernero, M Hoyle, S U Iqbal, and E Van Cutsem. Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer. *British Journal of Cancer*, 109(7):1735–1743, October 2013.

- [268] J M Jurgensmeier, H-J Schmoll, J D Robertson, L Brooks, M Taboada, S R Morgan, D Wilson, and P M Hoff. Prognostic and predictive value of VEGF, sVEGFR-2 and CEA in mCRC studies comparing cediranib, bevacizumab and chemotherapy. *British Journal of Cancer*, 108(6):1316–1323, April 2013.
- [269] Fairooz Kabbinavar, Herbert I. Hurwitz, Louis Fehrenbacher, Neal J. Meropol, William F. Novotny, Grazyna Lieberman, Susan Griffing, and Emily Bergsland. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. *Journal of Clinical Oncology*, 21(1):60–65, 2003.
- [270] Fairooz F. Kabbinavar, Patrick J. Flynn, Mark Kozloff, Mark A. Ashby, Amy Sing, Charles E. Barr, and Axel Grothey. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: Results from a large treatment observational cohort study. *European Journal of Cancer*, 48(8):1126–1132, 2012.
- [271] Fairooz F. Kabbinavar, Herbert I. Hurwitz, Jing Yi, Somnath Sarkar, and Oliver Rosen. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: Pooled analysis of cohorts of older patients from two randomized clinical trials. *Journal of Clinical Oncology*, 27(2):199–205, 2009.
- [272] Fairooz F. Kabbinavar, Joseph Schulz, Michael McCleod, Taral Patel, John T. Hamm, J. Randolph Hecht, Robert Mass, Brent Perrou, Betty Nelson, and William F. Novotny. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. *Journal of Clinical Oncology*, 23(16):3697–3705, 2005.
- [273] Fairooz F. Kabbinavar, Joel F. Wallace, Eric Holmgren, Jing Yi, David Cella, Kathleen J. Yost, and Herbert I. Hurwitz. Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. *The Oncologist*, 13(9):1021–1029, 2008.
- [274] S Kakolyris, J Souglakos, A Polyzos, A Ardavanis, N Ziras, A Athanasiadis, I Varthalitis, K Amarantidis, S Tsousis, L Vamvakas, et al. Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy. *Oncology*, 74(1-2):31–36, 2008.
- [275] Rajesh R. Kaldate, Abebe Haregewoin, Charles E. Grier, Stephanie A. Hamilton, and Howard L. McLeod. Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. *The Oncologist*, 17(3):296–302, 2012.
- [276] H.P. Kalofonos, P. Papakostas, T. Makatsoris, D. Papamichael, G. Vourli, I. Xanthakis, G. Aravantinos, C. Papadimitriou, G. Pentheroudakis, I. Varthalitis, G. Samelis, K.N. Syrigos, N Xiros, M Stavropoulos, P Kosmidis, C Christodoulou, H Linardou, M Skondra, D. Pectasides, T. Economopoulos, and G. Fountzilas. Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer. *Anticancer Research*, 30(10):4325–4333, 2010.
- [277] ByungWoog Kang, TaeWon Kim, Jae-Lyun Lee, Min-Hee Ryu, HeungMoon Chang, ChangSik Yu, JinCheon Kim, JongHoon Kim, Yoon-Koo Kang, and JungShin Lee. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal

- cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: A retrospective analysis. *Medical Oncology*, 26(1):32–37, 2009.
- [278] MyoungJoo Kang, YongSang Hong, Kyu-pyo Kim, SunYoung Kim, JiYeon Baek, Min-Hee Ryu, Jae-Lyun Lee, HeungMoon Chang, Mi-Jung Kim, HeeJin Chang, Yoon-Koo Kang, and TaeWon Kim. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status. *Investigational New Drugs*, 30(4):1607–1613, 2012.
- [279] Christos S. Karapetis, Shirin Khambata-Ford, Derek J. Jonker, Chris J. O’Callaghan, Dongsheng Tu, Niall C. Tebbutt, R. John Simes, Haji Chalchal, Jeremy D. Shapiro, Sonia Robitaille, Timothy J. Price, Lois Shepherd, Heather-Jane Au, Christiane Langer, Malcolm J. Moore, and John R. Zalcberg. K-RAS mutations and benefit from cetuximab in advanced colorectal cancer. *New England Journal of Medicine*, 359(17):1757–1765, 2008.
- [280] T. Kato, K. Muro, K. Yamaguchi, H. Bando, S. Hazama, K. Amagai, H. Baba, T. Denda, X. Shi, K. Fukase, J. Sakamoto, and H. Mishima. Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: Results from the randomised phase II part of a phase I/II study. *Annals of Oncology*, 23(4):933–941, 2011.
- [281] David J. Kerr, Janet A. Dunn, Michael J. Langman, Justine L. Smith, Rachel S.J. Midgley, Andrew Stanley, Joanne C. Stokes, Patrick Julier, Claire Iveson, Ravi Duvvuri, and Christopher C. McConkey. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. *New England Journal of Medicine*, 357(4):360–369, 2007.
- [282] Kelley M. Kidwell, Greg Yothers, Patricia A. Ganz, Stephanie R. Land, Clifford Y. Ko, Reena S. Cecchini, Jacek A. Kopec, and Norman Wolmark. Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: Results from national surgical adjuvant breast and bowel project trials C-07 and LTS-01. *Cancer*, 118(22):5614–5622, 2012.
- [283] George P. Kim, Linda H. Colangelo, H. Samuel Wieand, Soonmyung Paik, Ilan R. Kirsch, Norman Wolmark, and Carmen J. Allegra. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: A national cancer institutenational surgical adjuvant breast and bowel project collaborative study. *Journal of Clinical Oncology*, 25(7):767–772, 2007.
- [284] George P. Kim, Daniel J. Sargent, Michelle R. Mahoney, Kendrith M. Rowland, Philip A. Philip, Edith Mitchell, Abraham P. Mathews, Tom R. Fitch, Richard M. Goldberg, Steven R. Alberts, and Henry C. Pitot. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. *Journal of Clinical Oncology*, 27(17):2848–2854, 2009.
- [285] Jee Hyun Kim, Do-Youn Oh, Yu Jung Kim, Sae Won Han, In-Sil Choi, Dong-Wan Kim, Seock-Ah Im, Tae-You Kim, Jong-Seok Lee, Dae-Seog Heo, et al. Reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer. *Journal of Korean medical science*, 20(5):806–810, 2005.
- [286] Ji Yeon Kim, Jin Soo Kim, Moo Jun Baek, Chang Nam Kim, Won Jun Choi, Dong Kook Park, Hwan Namgung, Sang Chul Lee, and Sang-Jeon Lee. Prospective multicenter phase II



- clinical trial of FOLFIRI chemotherapy as a neoadjuvant treatment for colorectal cancer with multiple liver metastases. *Journal of the Korean Surgical Society*, 85(4):154–160, 2013.
- [287] Ji-Yeon Kim, Yu Jung Kim, Keun-Wook Lee, Jong Seok Lee, Duck-Woo Kim, Sung-Bum Kang, Hye Seung Lee, Na Young Jang, Jae-Sung Kim, and Jee Hyun Kim. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: Single-center study in Korea. *Japanese Journal of Clinical Oncology*, 43(2):132–138, 2012.
- [288] Jung Han Kim, Hyeong Su Kim, Dae Ro Choi, Geundoo Jang, Jung Hye Kwon, Ho Young Kim, Joo Young Jung, Hyo Jung Kim, Hun Ho Song, Yun Ho Shin, et al. A phase II study of mitomycin-C and S-1 as third-line chemotherapy in patients with advanced colorectal cancer. *Oncology letters*, 2(6):1253–1256, 2011.
- [289] S Y Kim, Y S Hong, E K Shim, S-Y Kong, A Shin, J Y Baek, and K H Jung. S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: A prospective phase II study and pharmacogenetic analysis. *British Journal of Cancer*, 109(6):1420–1427, September 2013.
- [290] SeHyun Kim, SangJoon Shin, SunYoung Kim, SeHoon Lee, YoungSuk Park, SeHoon Park, KyungHee Lee, TaeWon Kim, YongSang Hong, and JoongBae Ahn. Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: A multicenter phase I/II trial. *Cancer Chemotherapy and Pharmacology*, 69(1):91–97, 2012.
- [291] Stefano Kim, Erion Dobi, Marine Jary, Franck Monnien, Elsa Curtit, Thierry NGuyen, Zaher Lakkis, Bruno Heyd, Serge Fratte, Denis Cléau, et al. Bifractionated CPT-11 with LV5FU2 infusion (FOLFIRI-3) in combination with bevacizumab: Clinical outcomes in first-line metastatic colorectal cancers according to plasma angiopoietin-2 levels. *BioMed Central Cancer*, 13(1):611, 2013.
- [292] SunYoung Kim, YongSang Hong, ByungChang Kim, JiWon Park, HyoSeong Choi, Seung-Yong Jeong, DaeYong Kim, ChangWon Hong, DaeKyung Sohn, and KyungHae Jung. A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer. *Investigational New Drugs*, 27(3):269–274, 2009.
- [293] Tae Won Kim, Won Ki Kang, Heung Moon Chang, Joon Oh Park, Baek Yeol Ryoo, Jin Seok Ahn, Dae Young Zang, Kyung Hee Lee, Yoon Koo Kang, Sung Rok Kim, and Hoon-Kyo Kim. Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: A Korean cancer study group trial. *Acta Oncologica*, 44(3):230–235, 2005.
- [294] Hedy Lee Kindler, Gregory Friberg, Linda Skoog, Kurombi Wade-Oliver, and Everett E. Vokes. Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer. *American Journal of Clinical Oncology*, 28(4):340–344, 2005.
- [295] Anatole Klyosov, Eliezer Zomer, and David Platt. *DAVANAT (GM-CT-01) and Colon Cancer: Preclinical and Clinical (Phase I and II) Studies*, volume 1102, chapter 4, pages 89–130. American Chemical Society, 2012.
- [296] Dieter Koeberle, Daniel C. Betticher, Roger Von Moos, Daniel Dietrich, Peter Brauchli, Daniela Baertschi, Klazien Matter-Walstra, Ralph C. Winterhalder, Markus M. Borner,

- Sandro Anchisi, Peter Moosmann, Attila Kollar, Piercarlo Saletti, Arnaud Roth, Martin Frueh, Marc Kueng, Razvan A. Popescu, Sabina Schacher, Viviane Hess, and Richard Herrmann. Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: A randomized phase 3 non-inferiority trial (SAKK 41/06). *Journal of Clinical Oncology*, 31(3503):104–104, 2013.
- [297] C.-H. Köhne, J. De Greve, J. T. Hartmann, I. Lang, P. Vergauwe, K. Becker, D. Braumann, E. Joosens, L. Müller, J. Janssens, C. Bokemeyer, P. Reimer, H. Link, E. Späth-Schwalbe, H.-J. Wilke, H. Bleiberg, J. Van Den Brande, M. Debois, U. Bethe, and E. Van Cutsem. Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. *Annals of Oncology*, 19(5):920–926, 2008.
- [298] C.-H. Köhne, E. van Cutsem, J. Wils, C. Bokemeyer, M. El-Serafi, M.P. Lutz, M. Lorenz, P. Reichardt, H. Rückle-Lanz, N. Frickhofen, R. Fuchs, H.-G. Mergenthaler, T. Langenbuch, U. Vanhoefer, P. Rougier, R. Voigtmann, L. Müller, B. Genicot, Ö. Anak, and B. Nordlinger. Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European organisation for research and treatment of cancer gastrointestinal group study 40986. *Journal of Clinical Oncology*, 23(22):4856–4865, 2005.
- [299] Claus-Henning Köhne, Laurent Bedenne, Alfredo Carrato, Olivier Bouché, Ivan Popov, Losa Gaspà, Manuel Valladares, Phillipe Rougier, Christiane Gog, Peter Reichardt, Jacques Wils, Francesco Pignatti, and Frank Biertz. A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: The pan-european trial in adjuvant colon cancer 2 study. *European Journal of Cancer*, 49(8):1868–1875, 2013.
- [300] Claus-Henning Köhne, Ralf Hofheinz, Laurent Mineur, Henry Letocha, Richard Greil, Josef Thaler, Eva Fernebro, Erick Gamelin, Lucy DeCosta, and Meinolf Karthaus. First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer. *Journal of Cancer Research and Clinical Oncology*, 138(1):65–72, 2012.
- [301] W. Koizumi, N. Boku, K. Yamaguchi, Y. Miyata, A. Sawaki, T. Kato, Y. Toh, I. Hyodo, T. Nishina, T. Furuhashi, K. Miyashita, and Y. Okada. Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer. *Annals of Oncology*, 21(4):766–771, 2009.
- [302] Y. Komatsu, S. Yuki, S. Sogabe, H. Fukushima, I. Iwanaga, M. Kudo, M. Tateyama, T. Meguro, M. Uebayashi, A. Saga, Y. Sakata, and M. Asaka. Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). *Oncology*, 80(1-2):70–75, 2011.
- [303] Yoshito Komatsu, Satoshi Yuki, Susumu Sogabe, Hiraku Fukushima, Hiroshi Nakatsumi, Yoshimitsu Kobayashi, Ichiro Iwanaga, Michio Nakamura, Kazuteru Hatanaka, Takuto Miyagishima, Mineo Kudo, Masaki Munakata, Takashi Meguro, Miki Tateyama, and Yuh Sakata. Phase II study of combined chemotherapy with irinotecan and S-1 (IRIS) plus bevacizumab in patients with inoperable recurrent or advanced colorectal cancer. *Acta Oncologica*, 51(7):867–872, 2012.

- [304] Yoshito Komatsu, Satoshi Yuuki, Nozomu Fuse, Masaaki Takei, Takashi Kato, Takuto Miyagishima, Mineo Kudo, Yasuyuki Kunieda, Miki Tateyama, Osamu Wakahama, Takashi Meguro, Hiroko Ohizumi, Maso Watanabe, Hirotohi Akita, Yu Sakata, and Masahiro Asaka. Phase II study of oral S-1 plus irinotecan in patients with advanced colorectal cancer: Hokkaido gastrointestinal cancer study group HGCSG0302. *Japanese Journal of Clinical Oncology*, 35(2):88–89, 2005.
- [305] M Koopman, NF Antonini, J Douma, J Wals, AH Honkoop, FLG Erdkamp, RS de Jong, CJ Rodenburg, G Vreugdenhil, JM Akkermans-Vogelaar, and CJA Punt. Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch colorectal cancer group (DCCG) phase III study. *Annals of Oncology*, 17(10):1523–1528, 2006.
- [306] Miriam Koopman, Ninja F Antonini, Joep Douma, Jaap Wals, Aafke H Honkoop, Frans LG Erdkamp, Robert S de Jong, Cees J Rodenburg, Gerard Vreugdenhil, Olaf JL Loosveld, Aart van Bochove, Harm AM Sinnige, Geert-Jan M Creemers, Margot ET Tesselaar, Peter H Th J Slee, Marjon JBP Werter, Linda Mol, Otilia Dalesio, and Cornelis JA Punt. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): A phase III randomised controlled trial. *The Lancet*, 370(9582):135–142, 2007.
- [307] Miriam Koopman, Lieke HJ Simkens, Albert J. Ten Tije, Geert-Jan Creemers, Olaf JL Loosveld, Felix E. de Jongh, Frans Erdkamp, Zoran Erjavec, Adelheid ME van der Torren, Jacobus JM Van der Hoeven, Peter Nieboer, J. J. Braun, Rob L. Jansen, Janny G. Haasjes, Annemieke Cats, Jacob J. Wals, Linda Mol, Otilia Dalesio, Harm van Tinteren, and Cornelis J. A. Punt. Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). *ASCO Meeting Abstracts*, 31(15S):3502, 2013.
- [308] Jacek A. Kopec, Greg Yothers, Patricia A. Ganz, Stephanie R. Land, Reena S. Cecchini, H. Samuel Wieand, Barry C. Lembersky, and Norman Wolmark. Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: Results from national surgical adjuvant breast and bowel project trial C-06. *Journal of Clinical Oncology*, 25(4):424–430, 2007.
- [309] Scott Kopetz, Paulo M. Hoff, Jeffrey S. Morris, Robert A. Wolff, Cathy Eng, Katrina Y. Glover, Rosie Adinin, Michael J. Overman, Vincete Valero, Sijin Wen, Christopher Lieu, Shaoyu Yan, Hai T. Tran, Lee M. Ellis, James L. Abbruzzese, and John V. Heymach. Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: Efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. *Journal of Clinical Oncology*, 28(3):453–459, 2010.
- [310] Marko Kornmann, Holger Hebart, Kathleen Danenberg, Roland Goeb, Ludger Staib, Martina Kron, Doris Henne-Bruns, Peter Danenberg, and Karl-Heinrich Link. Response prediction in metastasised colorectal cancer using intratumoural thymidylate synthase: Results of a randomised multicentre trial. *European Journal of Cancer*, 48(10):1443–1451, 2012.
- [311] C Kouroussis, J Souglakos, S Kakolyris, D Mavroudis, N Malamos, K Kalbakis, N Androulakis, A Agelaki, N Vardakis, G Samonis, and V Georgoulis. Oxaliplatin in combination with

- infusional 5-fluorouracil and leucovorin every 2 weeks as first-line treatment in patients with advanced colorectal cancer: A phase II study. *Oncology*, 61(1):36–41, 2001.
- [312] Mark Kozloff, Marianne Ulcickas Yood, Jordan Berlin, Patrick J. Flynn, Fairouz F. Kabbinavar, David M. Purdie, Mark A. Ashby, Wei Dong, Mary M. Sugrue, Axel Grothey, and for the investigators of the BRiTE study. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: The BRiTE observational cohort study. *The Oncologist*, 14(9):862–870, 2009.
- [313] Mark F Kozloff, Jordan Berlin, Patrick J Flynn, Fairouz Kabbinavar, Mark Ashby, Wei Dong, Amy P Sing, and Axel Grothey. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: Results from the BRiTE observational cohort study. *Oncology*, 78(5-6):329–339, 2010.
- [314] Peter Kozuch, Steve Malamud, Carrie Wasserman, Peter Homel, Takhir Mirzoyev, and Michael Grossbard. Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer. *Clinical Colorectal Cancer*, 8(1):38–42, 2009.
- [315] Peter S. Kozuch, Caio Max Rocha-Lima, Tomislav Dragovich, Howard Hochster, Bert H. O’Neil, Omar T. Atiq, J. Marc Pipas, David P. Ryan, and Heinz-Josef Lenz. Bortezomib with or without irinotecan in relapsed or refractory colorectal cancer: Results from a randomized phase II study. *Journal of Clinical Oncology*, 26(14):2320–2326, 2008.
- [316] S. Kubicka, R. Greil, T. André, J. Bennouna, J. Sastre, E. Van Cutsem, R. von Moos, P. Österlund, I. Reyes-Rivera, T. Müller, M. Makrutzki, D. Arnold, and On behalf of the ML18147 study investigators including AIO, GERCOR, FFCD, UNICANCER GI, TTD, BGDO, GEMCAD, and AGMT groups. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. *Annals of Oncology*, 24(9):2342–2349, 2013.
- [317] J. Philip Kuebler, H. Samuel Wieand, Michael J. O’Connell, Roy E. Smith, Linda H. Colangelo, Greg Yothers, Nicholas J. Petrelli, Michael P. Findlay, Thomas E. Seay, James N. Atkins, John L. Zapas, J. Wendall Goodwin, Louis Fehrenbacher, Ramesh K. Ramanathan, Barbara A. Conley, Patrick J. Flynn, Gamini Soori, Lauren K. Colman, Edward A. Levine, Keith S. Lanier, and Norman Wolmark. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. *Journal of Clinical Oncology*, 25(16):2198–2204, 2007.
- [318] Timothy Kuo, Cheryl D. Cho, Joanne Halsey, Heather A. Wakelee, Ranjana H. Advani, James M. Ford, George A. Fisher, and Branimir I. Sikic. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. *Journal of Clinical Oncology*, 23(24):5613–5619, 2005.
- [319] Hitoshi Kusaba, Taito Esaki, Kitaro Futami, Sinnosuke Tanaka, Hiromitsu Fujishima, Kenji Mitsugi, Kenji Sakai, Hiroshi Ariyama, Risa Tanaka, Naoko Kinugawa, Takashi Ueki, Rhuichi Mibu, Eishi Baba, Shuji Nakano, and Koichi Akashi. Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer. *Cancer Science*, 101(12):2591–2595, 2010.

- [320] Hyuk-Chan Kwon, Kyoung Tae Kim, Shin Lee, Jong-Sung Park, Sung-Hyun Kim, Jae-Seok Kim, and Hyo Jin Kim. Oxaliplatin with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (Modified FOLFOX 4) as first-line therapy for patients with metastatic colorectal cancer. *Cancer Research and Treatment*, 36(2):115–120, 2004.
- [321] Hyuk-Chan Kwon, Sung Yong Oh, Suae Lee, Sung-Hyun Kim, and Hyo-Jin Kim. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: A pilot study. *World Journal of Gastroenterology*, 13(46):6231–6235, December 2007.
- [322] Mario E. Lacouture, Edith P. Mitchell, Bilal Piperdi, Madhavan V. Pillai, Heather Shearer, Nicholas Iannotti, Feng Xu, and Mohamed Yassine. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. *Journal of Clinical Oncology*, 28(8):1351–1357, 2010.
- [323] Ka On Lam, Victor Ho Fun Lee, Rico Kin Yin Liu, To Wai Leung, and Dora Lai Wan Kwong. Bevacizumab-containing regimens after cetuximab failure in KRAS wild-type metastatic colorectal carcinoma. *Oncology Letters*, 5(2):637–640, 2013.
- [324] István Láng, Claus-Henning Köhne, Gunnar Folprecht, Philippe Rougier, Desmond Curran, Erika Hitre, Ute Sartorius, Ingolf Griebisch, and Eric Van Cutsem. Quality of life analysis in patients with {KRAS} wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin. *European Journal of Cancer*, 49(2):439–448, 2013.
- [325] Duk-Joo Lee, Ho-Suk Oh, Jung-Hye Choi, Young-Yeul Lee, In-Soon Kim, and Myung-Ju Ahn. Phase II study of oxaliplatin, 5-fluorouracil, and leucovorin in relapsed or metastatic colorectal cancer as second line therapy. *Cancer Research and Treatment*, 38(4):201–205, 2006.
- [326] Jeeyun Lee, YongSang Hong, JungYong Hong, SeWon Han, TaeWon Kim, HyeJin Kang, TaeYou Kim, Kyu-pyo Kim, SukHyung Kim, In-Gu Do, Kyoung-Mee Kim, Insuk Sohn, SeHoon Park, JoonOh Park, HoYeong Lim, YongBeom Cho, WooYong Lee, SeongHyeon Yun, HeeCheol Kim, YoungSuk Park, and WonKi Kang. Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab. *Investigational New Drugs*, 32(3):535–541, 2014.
- [327] Jeeyun Lee, Kyung Hae Jung, Young Suk Park, Joong Bae Ahn, Sang Jun Shin, Seock-Ah Im, Do Youn Oh, Dong Bok Shin, Tae Won Kim, Namsu Lee, Jae Ho Byun, Yong Sang Hong, Joon Oh Park, Se Hoon Park, Ho Yeong Lim, and Won Ki Kang. Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: A multicenter phase II study. *Cancer Chemotherapy and Pharmacology*, 64(4):657–663, 2009.
- [328] Myung-Ah Lee, Jae-Ho Byun, Byoung-Young Shim, In-Sook Woo, Jin-Hyung Kang, Young Seon Hong, Kyung Shik Lee, Myung Gyu Choi, Suk Kyun Chang, Seong Taek Oh, Sung Il Choi, and Doo Suk Lee. Irinotecan, continuous 5-fluorouracil, and low dose of leucovorin (modified FOLFIRI) as first line of therapy in recurrent or metastatic colorectal cancer. *The Korean Journal of Internal Medicine*, 20(3):205–209, 2005.
- [329] Po-Huang Lee, Young-Suk Park, Jia-Fu Ji, Yiu-Tung Fu, and Vorachai Ratanatharathorn. Safety and tolerability of FOLFOX4 in the adjuvant treatment of colon cancer in Asian patients: The MASCOT study. *Asia-Pacific Journal of Clinical Oncology*, 5(2):101–110, 2009.

- [330] Cynthia G. Leichman, Kari Chansky, John S. Macdonald, Michael A. Doukas, G. Thomas Budd, Jeffrey K. Giguere, and James L. Abbruzzese. Biochemical modulation of 5-fluorouracil through dihydropyrimidine dehydrogenase inhibition: A southwest oncology group phase II trial of eniluracil and 5-fluorouracil in advanced resistant colorectal cancer. *Investigational New Drugs*, 20(4):419–424, 2002.
- [331] N B Leighl, J Bennouna, J Yi, N Moore, J Hambleton, and H Hurwitz. Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. *British Journal of Cancer*, 104(3):413–418, February 2011.
- [332] B. C. Lembersky, R. Sehgal, K. K. Rajasenan, T. L. Crandall, E. P. Balaban, R. A. Pinkerton, P. Kane, D. M. Potter, C. Kinney, and R. K. Ramanathan. Phase II study of bevacizumab (BEV), weekly (wkly) intermittent capecitabine (Cap), and oxaliplatin (Ox) on an every-2-week schedule for patients (Pts) with untreated advanced colorectal cancer (CRC). *ASCO Meeting Abstracts*, 26(15S):4061, 2008.
- [333] Heinz-Josef Lenz, Eric Van Cutsem, Shirin Khambata-Ford, Robert J. Mayer, Philip Gold, Philip Stella, Barry Mirtsching, Allen L. Cohn, Andrew W. Pippas, Nozar Azarnia, Zenta Tsuchihashi, David J. Mauro, and Eric K. Rowinsky. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. *Journal of Clinical Oncology*, 24(30):4914–4921, 2006.
- [334] P Leonard, M T Seymour, R James, D Hochhauser, and J A Ledermann. Phase II study of irinotecan with bolus and high dose infusional 5-FU and folinic acid (modified de Gramont) for first or second line treatment of advanced or metastatic colorectal cancer. *British Journal of Cancer*, 87(11):1216–1220, 2002.
- [335] Yan Li, Jing Li, Ming Lu, Xi-cheng Wang, and Lin Shen. Capecitabine maintenance therapy after first-line chemotherapy in patients with metastatic colorectal cancer. *Chinese Journal of Cancer Research*, 22(3):181–185, 2010.
- [336] YuHong Li, HuiYan Luo, FengHua Wang, ZhiQiang Wang, MiaoZhen Qiu, YanXia Shi, XiaoJuan Xiang, XiaoQing Chen, YouJian He, and RuiHua Xu. Phase II study of capecitabine plus oxaliplatin (XELOX) as first-line treatment and followed by maintenance of capecitabine in patients with metastatic colorectal cancer. *Journal of Cancer Research and Clinical Oncology*, 136(4):503–510, 2010.
- [337] Hong-Liang Liang, Ai-Ping Hu, Sen-Lin Li, and Ji-Yong Liu. Combining bevacizumab and panitumumab with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as second-line treatment in patients with metastatic colorectal cancer. *Medical Oncology*, 31:976, 2014.
- [338] Lisa Licitra, Stephan Störkel, Keith M. Kerr, Eric Van Cutsem, Robert Pirker, Fred R. Hirsch, Jan B. Vermorken, Anja von Heydebreck, Regina Esser, Ilhan Celik, and Fortunato Ciardiello. Predictive value of epidermal growth factor receptor expression for first-line chemotherapy plus cetuximab in patients with head and neck and colorectal cancer: Analysis of data from the EXTREME and CRYSTAL studies. *European Journal of Cancer*, 49(6):1161–1168, 2013.
- [339] Astrid Lièvre, Jean-Baptiste Bachet, Valérie Boige, Anne Cayre, Delphine Le Corre, Emmanuel Buc, Marc Ychou, Olivier Bouché, Bruno Landi, Christophe Louvet, Thierry André, Frédéric Bibeau, Marie-Danièle Diebold, Philippe Rougier, Michel Ducreux, Gorana Tomasic, Jean-François Emile, Frédérique Penault-Llorca, and Pierre Laurent-Puig. KRAS mutations as

an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. *Journal of Clinical Oncology*, 26(3):374–379, 2008.

- [340] Astrid Lièvre, Emmanuelle Samalin, Emmanuel Mitry, Eric Assenat, Christine Boyer-Gestin, Céline Lepère, Jean-Baptiste Bachet, Fabienne Portales, Jean-Nicolas Vaillant, Marc Ychou, et al. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: A retrospective study. *BioMed Central Cancer*, 9(1):347, 2009.
- [341] DoHyoung Lim, YoungSuk Park, Byeong-Bae Park, SangHoon Ji, Jeeyun Lee, KeonWoo Park, JungHoon Kang, Se-Hoon Lee, JoonOh Park, Kihyun Kim, WonSeog Kim, ChulWon Jung, Young-Hyuck Im, WonKi Kang, and Keunchil Park. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: A phase II study. *Cancer Chemotherapy and Pharmacology*, 56(1):10–14, 2005.
- [342] Edward Lin, Jeffrey S Morris, and Gregory D Ayers. Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity. *Oncology (Williston Park, N.Y.)*, 16(14):31–37, December 2002.
- [343] Yingmiao Liu, Mark D. Starr, Anuradha Bulusu, Herbert Pang, Nan Soon Wong, Wanda Honeycutt, Anthony Amara, Herbert I. Hurwitz, and Andrew B. Nixon. Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. *Cancer Medicine*, 2(2):234–242, 2013.
- [344] Gilberto Lopes, Jose Quesada, Eugene Ahn, Aurea Flores, Afonso Ribeiro, and Caio Max Rocha-Lima. Oxaliplatin and fixed-rate infusional gemcitabine in the second-line treatment of patients with metastatic colon cancer: Final results of a phase II trial prematurely closed as a result of poor accrual. *Clinical Colorectal Cancer*, 6(9):641–645, 2007.
- [345] S G Louie, B Ely, H-J Lenz, K S Albain, C Gotay, D Coleman, D Raghavan, A F Shields, P J Gold, and C D Blanke. Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030). *British Journal of Cancer*, 109(7):1744–1749, October 2013.
- [346] F Loupakis, C Cremolini, A Fioravanti, P Orlandi, L Salvatore, G Masi, T Di Desidero, B Canu, M Schirripa, P Frumento, A Di Paolo, R Danesi, A Falcone, and G Bocci. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer. *British Journal of Cancer*, 104(8):1262–1269, April 2011.
- [347] F. Loupakis, C. Cremolini, L. Salvatore, G. Masi, E. Sensi, M. Schirripa, A. Michelucci, E. Pfanner, I. Brunetti, C. Lupi, C. Antoniotti, F. Bergamo, S. Lonardi, V. Zagonel, P. Simi, G. Fontanini, and A. Falcone. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. *European Journal of Cancer*, 50(1):57–63, 2014.
- [348] Fotios Loupakis, Luca Pollina, Irene Stasi, Annamaria Ruzzo, Mario Scartozzi, Daniele Santini, Gianluca Masi, Francesco Graziano, Chiara Cremolini, Eliana Rulli, Emanuele Canestrari, Niccola Funel, Gaia Schiavon, Iacopo Petrini, Mauro Magnani, Giuseppe Tonini, Daniela Campani, Irene Floriani, Stefano Cascinu, and Alfredo Falcone. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. *Journal of Clinical Oncology*, 27(16):2622–2629, 2009.

- [349] C. Louvet, T. André, E. Gamelin, M. Hebbbar, M. Mabro, M. Bennamoun, H. Rassam, and A. de Gramont. Phase II study of biweekly pemetrexed plus irinotecan as second-line therapy for metastatic colorectal cancer. *Journal of Oncology*, 2010(2010):1–7, 2010. Article ID 785934.
- [350] Chien-Yu Lu, Ching-Wen Huang, Huang-Ming Hu, Hsiang-Lin Tsai, Chun-Ming Huang, Fang-Jung Yu, Ming-Yii Huang, Se-Fen Chang, Meng-Lin Huang, and Jaw-Yuan Wang. Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting. *Translational Research*, 164(2):169–176, 2014.
- [351] Sam J. Lubner, Noelle K. LoConte, Kyle D. Holen, William Schelman, James P. Thomas, Alcee Jumonville, Jens C. Eickhoff, Songwon Seo, and Daniel L. Mulkerin. A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer. *Clinical Colorectal Cancer*, 9(3):157–161, 2010.
- [352] Georg Lurje, Fumio Nagashima, Wu Zhang, Dongyun Yang, Heung M. Chang, Michael A. Gordon, Anthony El-Khoueiry, Hatim Husain, Peter M. Wilson, Robert D. Ladner, David J. Mauro, Christiane Langer, Eric K. Rowinsky, and Heinz-Josef Lenz. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of KRAS in metastatic colorectal cancer patients treated with single-agent cetuximab. *Clinical Cancer Research*, 14(23):7884–7895, 2008.
- [353] Jing Lv, Ning Liu, Ke-wei Liu, Ai-ping Ding, Hao Wang, and W.S. Qiu. A randomised controlled phase II trial of the combination of XELOX with thalidomide for the first-line treatment of metastatic colorectal cancer. *Cancer Biology & Medicine*, 9(2):111–114, January 2012.
- [354] Brigitte B. Y. Ma, Stephen L. Chan, Wing M. Ho, Wilson Lau, Frankie Mo, Edwin P. Hui, Charles Chan, Annette Poon, Rasalkar D. Dattatray, S. C. Cesar Wong, Ka F. To, Ann D. King, Anil Ahuja, and Anthony T. C. Chan. Intermittent versus continuous erlotinib with concomitant modified XELOX (q3W) in first-line treatment of metastatic colorectal cancer. *Cancer*, 119(23):4145–4153, 2013.
- [355] M Mabro, P Artru, T Andre, M Flesch, F Maindrault-Goebel, B Landi, G Lledo, A Plantade, C Louvet, and A de Gramont. A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients. *British Journal of Cancer*, 94(9):1287–1292, April 2006.
- [356] May Mabro, Christophe Louvet, Thierry André, Elisabeth Carola, Véronique Gilles-Amar, Pascal Artru, Marcel Krulik, Aimery de Gramont, and on behalf of GERCOR. Bimonthly leucovorin, infusion 5-fluorouracil, hydroxyurea, and irinotecan (FOLFIRI-2) for pretreated metastatic colorectal cancer. *American Journal of Clinical Oncology*, 26(3):254–258, 2003.
- [357] Nozomu Machida, Kouji Yoshizaki, Narikazu Boku, Kentaro Yamazaki, Yusuke Onozawa, Akira Fukutomi, Hirofumi Yasui, and Keisei Taku. Feasibility of mFOLFOX6 as the adjuvant treatment after curative resection of metastases from colorectal cancer in Japanese patients. *International Journal of Clinical Oncology*, 18(2):279–284, 2013.
- [358] Helen Mackay, David Hedley, Pierre Major, Carol Townsley, Mary Mackenzie, Mark Vincent, Pam Degendorfer, Ming-Sound Tsao, Trudey Nicklee, Diana Birle, John Wright, Lillian Siu,



- Malcolm Moore, and Amit Oza. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. *Clinical Cancer Research*, 11(15):5526–5533, 2005.
- [359] Stefan Madajewicz, David M. Waterhouse, Paul S. Ritch, M. Qaseem Khan, Donald J. Higby, Cynthia G. Leichman, Sandeep K. Malik, Patricia Hentschel, John F. Gill, Luping Zhao, and Steven J. Nicol. Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer. *Investigational New Drugs*, 30(2):772–778, 2010.
- [360] A Madi, D Fisher, R H Wilson, R A Adams, A M Meade, S L Kenny, L L Nichols, M T Seymour, H Wasan, R Kaplan, and T S Maughan. Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: The MRC COIN trial. *British Journal of Cancer*, 107(7):1037–1043, September 2013.
- [361] F. Maindrault-Gæbel, A. de Gramont, C. Louvet, T. André, E. Carola, V. Gilles, J.-P. Lotz, C. Tournigand, M. Mabro, J.-L. Molitor, P. Artru, V. Izrael, M. Krulik, and for the Oncology Multidisciplinary Research Group (GERCOR). Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. *Annals of Oncology*, 11(11):1477–1483, 2000.
- [362] F. Maindrault-Gæbel, A. de Gramont, C. Louvet, T. André, E. Carola, M. Mabro, P. Artru, V. Gilles, J.-P. Lotz, V. Izrael, and M. Krulik. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7). *European Journal of Cancer*, 37(8):1000–1005, 2001.
- [363] F. Maindrault-Gæbel, C. Tournigand, T. André, E. Carola, M. Mabro, P. Artru, C. Louvet, and A. de Gramont. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. *Annals of Oncology*, 15(8):1210–1214, 2004.
- [364] U Malapelle, C Carlomagno, M Salatiello, A De Stefano, C De Luca, R Bianco, R Marciano, C Cimminiello, C Bellevisine, S De Placido, and G Troncone. KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer. *British Journal of Cancer*, 107(4):626–631, August 2012.
- [365] D. Malka, V. Boige, N. Jacques, N. Vimond, A. Adenis, E. Boucher, J. Y. Pierga, T. Conroy, B. Chauffert, E. François, P. Guichard, M. P. Galais, F. Cvitkovic, M. Ducreux, and F. Farace. Clinical value of circulating endothelial cell levels in metastatic colorectal cancer patients treated with first-line chemotherapy and bevacizumab. *Annals of Oncology*, 23(4):919–927, 2012.
- [366] S. Mammoliti, V. Andretta, E. Bennicelli, F. Caprioni, D. Comandini, G. Fornarini, A. Guglielmi, A. Pessino, S. Sciallero, A. F. Sobrero, G. Mazzola, A. Lambiase, and C. Bordinon. Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies. *Annals of Oncology*, 22(4):973–978, 2010.
- [367] Jean Alfred Maroun, Derek J. Jonker, M. Christine Cripps, Rakesh Goel, Timothy R. Asmis, Rachel Anne Goodwin, Nirit Yarom, and Horia Marginean. IXOA regimen, irinotecan (I),

- capecitabine (X), oxaliplatin (O), and bevacizumab (A), as first-line therapy for advanced unresectable colorectal cancer (aCRC): Preliminary results. *ASCO Meeting Abstracts*, 30(4S):604, 2012.
- [368] Inês Marques, António Araújo, and Ramon Andrade de Mello. Anti-angiogenic therapies for metastatic colorectal cancer: Current and future perspectives. *World Journal of Gastroenterology*, 19(44):7955–7971, 2013.
- [369] John L. Marshall, Steven G. Eisenberg, Michael D. Johnson, John Hanfelt, F. Andrew Dorr, Dorraya El-Ashry, Michael Oberst, Yair Fuxman, Jon Holmlund, and Shakun Malik. A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer. *Clinical Colorectal Cancer*, 4(4):268–274, 2004.
- [370] Andrea Angelo Martoni, Carmine Pinto, Francesca Di Fabio, Giorgio Lelli, Fabiola Lorena Rojas Llimpe, Anna Lisa Gentile, Vita Mutri, PierLuigi Ballardini, Stefania Giaquinta, and Edera Piana. Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: A GOAM phase II randomised study (FOCA trial). *European Journal of Cancer*, 42(18):3161–3168, 2006.
- [371] G. Masi, G. Allegrini, S. Cupini, L. Marcucci, E. Cerri, I. Brunetti, E. Fontana, S. Ricci, M. Andreuccetti, and A. Falcone. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): Results of a phase II study with a simplified biweekly schedule. *Annals of Oncology*, 15(12):1766–1772, 2004.
- [372] G. Masi, L. Marcucci, F. Loupakis, E. Cerri, C. Barbara, S. Bursi, G. Allegrini, I. M. Brunetti, R. Murr, S. Ricci, S. Cupini, M. Andreuccetti, and A. Falcone. First-line 5-fluorouracil/folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) does not impair the feasibility and the activity of second line treatments in metastatic colorectal cancer. *Annals of Oncology*, 17(8):1249–1254, 2006.
- [373] Gianluca Masi, Fotios Loupakis, Luca Pollina, Enrico Vasile, Samanta Cupini, Sergio Ricci, Isa Maura Brunetti, Roberta Ferraldeschi, Giuseppe Naso, Franco Filipponi, Andrea Pietrabissa, Orlando Goletti, Giacomo Baldi, Lorenzo Fornaro, Michele Andreuccetti, and Alfredo Falcone. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. *Annals of Surgery*, 249(3):420–425, 2009.
- [374] Gianluca Masi, Fotios Loupakis, Lisa Salvatore, Lorenzo Fornaro, Chiara Cremolini, Samanta Cupini, Andrea Ciarlo, Francesca Del Monte, Enrico Cortesi, Domenico Amoroso, Cristina Granetto, Gabriella Fontanini, Elisa Sensi, Cristiana Lupi, Michele Andreuccetti, and Alfredo Falcone. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: A phase II trial. *The Lancet Oncology*, 11(9):845–852, 2010.
- [375] Gianluca Masi, Enrico Vasile, Fotios Loupakis, Simona Bursi, Sergio Ricci, Iacopo Petrini, Andrea Fontana, Giacomo Allegrini, and Alfredo Falcone. Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer. *Clinical Colorectal Cancer*, 7(1):7–14, 2008.
- [376] Gianluca Masi, Enrico Vasile, Fotios Loupakis, Samanta Cupini, Lorenzo Fornaro, Giacomo Baldi, Lisa Salvatore, Chiara Cremolini, Irene Stasi, Isa Brunetti, Maria Agnese Fabbri,

- Martina Puglisi, Patrizia Trenta, Cristina Granetto, Silvana Chiara, Luisa Fioretto, Giacomo Allegrini, Lucio Crinó, Michele Andreuccetti, and Alfredo Falcone. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: An updated analysis. *Journal of the National Cancer Institute*, 103(1):21–30, 2010.
- [377] Timothy S Maughan, Richard A Adams, Christopher G Smith, Angela M Meade, Matthew T Seymour, Richard H Wilson, Shelley Idziaszczyk, Rebecca Harris, David Fisher, Sarah L Kenny, Edward Kay, Jenna K Mitchell, Ayman Madi, Bharat Jasani, Michelle D James, John Bridgewater, M John Kennedy, Bart Claes, Diether Lambrechts, Richard Kaplan, and Jeremy P Cheadle. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. *The Lancet*, 377(9783):2103–2114, 2011.
- [378] TS Maughan, RD James, DJ Kerr, JA Ledermann, C McArdle, MT Seymour, D Cohen, P Hopwood, C Johnston, and RJ Stephens. Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: A multicentre randomised trial. *The Lancet*, 359(9317):1555–1563, 2002.
- [379] Laurence E. McCahill, Greg Yothers, Saima Sharif, Nicholas J. Petrelli, Lily Lau Lai, Naftali Bechar, Jeffrey K. Giguere, Shaker R. Dakhil, Louis Fehrenbacher, Samia H. Lopa, Lawrence D. Wagman, Michael J. O’Connell, and Norman Wolmark. Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: Definitive analysis of NSABP trial C-10. *Journal of Clinical Oncology*, 30(26):3223–3228, 2012.
- [380] A David McCollum, Bingyan Wu, Jeffrey W Clark, Matthew H Kulke, Peter C Enzinger, David P Ryan, Craig C Earle, Ann Michelini, and Charles S Fuchs. The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer. *American Journal of Clinical Oncology*, 29(1):40–44, 2006.
- [381] Howard L. McLeod, Daniel J. Sargent, Sharon Marsh, Erin M. Green, Cristi R. King, Charles S. Fuchs, Ramesh K. Ramanathan, Stephen K. Williamson, Brian P. Findlay, Stephen N. Thibodeau, Axel Grothey, Roscoe F. Morton, and Richard M. Goldberg. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: Results from north american gastrointestinal intergroup trial N9741. *Journal of Clinical Oncology*, 28(20):3227–3233, 2010.
- [382] Robert R. McWilliams, Matthew P. Goetz, Bruce W. Morlan, Muhammad Salim, Kendrith M. Rowland, James E. Krook, Matthew M. Ames, and Charles Erlichman. Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer. *Clinical Colorectal Cancer*, 6(7):516–521, 2007.
- [383] G. Mentha, P. E. Majno, A. Andres, L. Rubbia-Brandt, P. Morel, and A. D. Roth. Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary. *British Journal of Surgery*, 93(7):872–878, 2006.
- [384] Neal J. Meropol, Philip J. Gold, Robert B. Diasio, Michael Andria, Mandeep Dhama, Thomas Godfrey, Albert J. Kovatich, Kirk A. Lund, Edith Mitchell, and Roland Schwarting. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. *Journal of Clinical Oncology*, 24(25):4069–4077, 2006.

- [385] J. A. Meyerhardt, N. Jackson McCleary, D. Niedzwiecki, D. Hollis, A. Venook, R. Mayer, and R. Goldberg. Impact of age and comorbidities on treatment effect, tolerance, and toxicity in metastatic colorectal cancer (mCRC) patients treated on CALGB 80203. *ASCO Meeting Abstracts*, 27(15S):4038, 2009.
- [386] J.A. Meyerhardt, K. Stuart, C.S. Fuchs, A.X. Zhu, C.C. Earle, P. Bhargava, L. Blaszukowsky, P. Enzinger, R.J. Mayer, S. Battu, C. Lawrence, and D.P. Ryan. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. *Annals of Oncology*, 18(7):1185–1189, 2007.
- [387] Jeffrey A. Meyerhardt, Andrew X. Zhu, Peter C. Enzinger, David P. Ryan, Jeffrey W. Clark, Matthew H. Kulke, Craig C. Earle, Michele Vincitore, Ann Micheleni, Susan Sheehan, and Charles S. Fuchs. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastatic colorectal cancer. *Journal of Clinical Oncology*, 24(12):1892–1897, 2006.
- [388] Gary Middleton, Sarah Brown, Catherine Lowe, Timothy Maughan, Stephen Gwyther, Alfred Oliver, Susan Richman, Denise Blake, Vicky Napp, Helen Marshall, Jonathan Wadsley, Nick Maisey, Ian Chau, Mark Hill, Simon Gollins, Sun Myint, Sarah Slater, John Wagstaff, John Bridgewater, and Matthew Seymour. A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: Results of the panitumumab, irinotecan & ciclosporin in Colorectal cancer therapy trial (PICCOLO). *European Journal of Cancer*, 49(16):3507–3516, 2013.
- [389] Rachel S. Midgley, Christopher C. McConkey, Elaine C. Johnstone, Janet A. Dunn, Justine L. Smith, Simon A. Grumett, Patrick Julier, Claire Iveson, Yoko Yanagisawa, Bryan Warren, Michael J. Langman, and David J. Kerr. Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: Final results of the VICTOR trial. *Journal of Clinical Oncology*, 28(30):4575–4580, 2010.
- [390] B.S. Min, N.K. Kim, J.B. Ahn, J.K. Roh, K.S. Kim, J.S. Choi, S.H. Cha, and H.K. Kim. Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases. *Oncology Research and Treatment*, 30(12):637–643, 2007.
- [391] Edith P. Mitchell, Bilal Piperdi, Mario E. Lacouture, Heather Shearer, Nicholas Iannotti, Madhavan V. Pillai, Feng Xu, and Mohamed Yassine. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or irinotecan in second-line therapy for metastatic colorectal cancer: The secondary analysis from STEPP (skin toxicity evaluation protocol with panitumumab) by KRAS status. *Clinical Colorectal Cancer*, 10(4):333–339, 2011.
- [392] I Mochizuki, H Takiuchi, K Ikejiri, Y Nakamoto, Y Kinugasa, A Takagane, T Endo, H Shinozaki, Y Takii, Y Takahashi, H Mochizuki, K Kotake, S Kameoka, K Takahashi, T Watanabe, M Watanabe, N Boku, N Tomita, Y Matsubara, and K Sugihara. Safety of UFT/LV and S-1 as adjuvant therapy for stage III colon cancer in phase III trial: ACTS-CC trial. *British Journal of Cancer*, 106(7):1268–1273, March 2012.
- [393] Dominik P Modest, Ruediger P Laubender, Sebastian Stintzing, Clemens Giessen, Christoph Schulz, Michael Haas, Ulrich Mansmann, and Volker Heinemann. Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab

- combined with either CAPIRI or CAPOX: An analysis of the German AIO KRK 0104 trial. *Acta Oncologica*, 52(5):956–962, 2013.
- [394] Dominik Paul Modest, Anke Reinacher-Schick, Sebastian Stintzing, Clemens Giessen, Andrea Tannapfel, Ruediger Paul Laubender, Thomas Brodowicz, Regina Knittelfelder, Damir Vrbanc, Wolff Schmiegel, Volker Heinemann, and Christoph C. Zielinski. Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: A pooled analysis. *Anti-Cancer Drugs*, 23(6):666–673, 2012.
- [395] D.P. Modest, A. Jung, N. Moosmann, R.P. Laubender, C. Giessen, C. Schulz, M. Haas, J. Neumann, S. Boeck, T. Kirchner, V. Heinemann, and S. Stintzing. The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: An analysis of the AIO KRK-0104-trial. *International Journal of Cancer*, 131(4):980–986, 2012.
- [396] Markus Moehler, Martin F Sprinzl, Murad Abdelfattah, Carl C Schimanski, Bernd Adami, Werner Godderz, Klaus Majer, Dimitri Flieger, Andreas Teufel, Juergen Siebler, Thomas Hoehler, Peter R Galle, and Stephan Kanzler. Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. *World Journal of Gastroenterology*, 15(4):449–456, December 2008.
- [397] Joon Ho Moon, Jong Gwang Kim, Sang Kyun Sohn, Jin Ho Baek, Yoon Young Cho, Yee Soo Chae, Byung Min Ahn, Shi Nae Kim, Soo Jung Lee, In Taek Lee, Gyu Seog Choi, and Soo Han Jun. Outpatient-basis chemotherapy of oxaliplatin, 5-fluorouracil, and leucovorin as first-line treatment for patients with metastatic or recurrent colorectal cancer. *Journal of Korean Medical Science*, 22(3):400–404, June 2007.
- [398] Nicolas Moosmann, Ludwig Fischer von Weikersthal, Ursula Vehling-Kaiser, Martina Stauch, Holger G. Hass, Herrmann Dietzfelbinger, Daniel Oruzio, Stefan Klein, Klaus Zellmann, Thomas Decker, Mathias Schulze, Wolfgang Abenhardt, Gerhard Puchtler, Herbert Kappauf, Johann Mittermüller, Christopher Haberl, Andreas Schalhorn, Andreas Jung, Sebastian Stintzing, and Volker Heinemann. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104 - A randomized trial of the German AIO CRC Study Group. *Journal of Clinical Oncology*, 29(8):1050–1058, 2011.
- [399] Toshikazu Moriwaki, Hideaki Bando, Atsuo Takashima, Kentaro Yamazaki, Taito Esaki, Keishi Yamashita, Mutsumi Fukunaga, Yasuhiro Miyake, Kenji Katsumata, Satoshi Kato, Taroh Satoh, Mitsuharu Ozeki, Eishi Baba, Shigemasa Yoshida, Narikazu Boku, and Ichinosuke Hyodo. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: A multicenter observational cohort study (TCTG 2nd-BV study). *Medical Oncology*, 29(4):2842–2848, 2012.
- [400] K Mross, M Büchert, U Fasol, U Jaehde, F Kanefendt, D Strumberg, J Arends, J Hense, B Moritz, R Fischer, et al. A preliminary report of a phase II study of folinic acid, 5-fluorouracil, irinotecan (FOLFIRI) plus sunitinib with toxicity, efficacy, pharmacokinetics, biomarker, imaging data in patients with colorectal cancer with liver metastases as 1st line treatment. *International Journal of Clinical Pharmacology and Therapeutics*, 49(1):96, 2011.

- [401] Alberto Muñoz, Carles Pericay, Carlos García-Giròn, Vicente Alonso, Rosario Dueñas, Luis Cirera, Fernando Rivera, Esther Falcò, Iñaki Alvarez Bustos, and Antonieta Salud. Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer. *Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics*, 21(4):181–191, 2014.
- [402] Kei Muro, Narikazu Boku, Yasuhiro Shimada, Akihito Tsuji, Shinichi Sameshima, Hideo Baba, Taroh Satoh, Tadamichi Denda, Kenji Ina, Tomohiro Nishina, Kensei Yamaguchi, Hiroya Takiuchi, Taito Esaki, Shinya Tokunaga, Hiroyuki Kuwano, Yoshito Komatsu, Masahiko Watanabe, Ichinosuke Hyodo, Satoshi Morita, and Kenichi Sugihara. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: A randomised phase 2/3 non-inferiority study (FIRIS study). *The Lancet Oncology*, 11(9):853–860, 2010.
- [403] Kei Muro, Takayuki Yoshino, Toshihiko Doi, Kuniaki Shirao, Hiroya Takiuchi, Yasuo Hamamoto, Hiroyuki Watanabe, Bing-Bing Yang, and Daisuke Asahi. A phase 2 clinical trial of panitumumab monotherapy in Japanese patients with metastatic colorectal cancer. *Japanese Journal of Clinical Oncology*, 39(5):321–326, 2009.
- [404] Arash Naeim, Peter R. Ward, Hei-Jing Wang, Richard Dichmann, Andre K.D. Liem, David Chan, Ravi Patel, Edward H.L. Hu, Neres S. Tchekmedyian, Zev A. Wainberg, and J. Randolph Hecht. A phase {II} trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer. *Journal of Geriatric Oncology*, 4(4):302–309, 2013.
- [405] Goro Nakayama, Keisuke Uehara, Kiyoshi Ishigure, Hiroyuki Yokoyama, Akiharu Ishiyama, Takehiko Eguchi, Kenji Tsuboi, Norifumi Ohashi, Tsutomu Fujii, Hiroyuki Sugimoto, Masahiko Koike, Michitaka Fujiwara, Yuich Ando, and Yasuhiro Kodera. The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: A multicenter, single-arm, phase II trial (CCOG-0801). *Cancer Chemotherapy and Pharmacology*, 70(4):575–581, 2012.
- [406] G. Nasti, M. C. Piccirillo, F. Izzo, A. Ottaiano, V. Albino, P. Delrio, C. Romano, P. Giordano, S. Lastoria, C. Caraco, E. de Lutio di Castelguidone, R. Palaia, G. Daniele, L. Aloj, G. Romano, and R. V. Iaffaioli. Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: A phase 2 trial. *British Journal of Cancer*, 108(8):1566–1570, April 2013.
- [407] Kimmie Ng, Daniel J. Sargent, Richard M. Goldberg, Jeffrey A. Meyerhardt, Erin M. Green, Henry C. Pitot, Bruce W. Hollis, Michael N. Pollak, and Charles S. Fuchs. Vitamin D status in patients with stage IV colorectal cancer: Findings from intergroup trial N9741. *Journal of Clinical Oncology*, 29:1599–1606, 2011.
- [408] Kimmie Ng, Josep Taberner, Jimmy Hwang, Emilio Bajetta, Sunil Sharma, Salvatore A. Del Prete, Edward R. Arrowsmith, David P. Ryan, Michaela Sedova, Jin Jin, Kamel Malek, and Charles S. Fuchs. Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens. *Clinical Cancer Research*, 19(14):3987–3995, 2013.
- [409] Donna Niedzwiecki, Monica M. Bertagnolli, Robert S. Warren, Carolyn C. Compton, Nancy E. Kemeny, Al Bowen Benson, S. Gail Eckhardt, Steven Alberts, Gity N. Porjosh, David J.

- Kerr, Anthony Fields, Philippe Rougier, J. Marc Pipas, Joel H. Schwartz, James Atkins, Mark O'Rourke, Michael C. Perry, Richard M. Goldberg, Robert J. Mayer, and Thomas A. Colacchio. Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: Results from CALGB 9581. *Journal of Clinical Oncology*, 29:3146–3152, 2011.
- [410] Bernard Nordlinger, Halfdan Sorbye, Bengt Glimelius, Graeme J Poston, Peter M Schlag, Philippe Rougier, Wolf O Bechstein, John N Primrose, Euan T Walpole, Meg Finch-Jones, Daniel Jaeck, Darius Mirza, Rowan W Parks, Laurence Collette, Michel Praet, Ullrich Bethe, Eric Van Cutsem, Werner Scheithauer, and Thomas Gruenberger. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. *The Lancet*, 371(9617):1007–1016, 2008.
- [411] Bernard Nordlinger, Halfdan Sorbye, Bengt Glimelius, Graeme J Poston, Peter M Schlag, Philippe Rougier, Wolf O Bechstein, John N Primrose, Euan T Walpole, Meg Finch-Jones, Daniel Jaeck, Darius Mirza, Rowan W Parks, Murielle Mauer, Erik Tanis, Eric Van Cutsem, Werner Scheithauer, and Thomas Gruenberger. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. *The Lancet Oncology*, 14(12):1208–1215, 2013.
- [412] Emmanuelle Norguet, Laetitia Dahan, Jean Gaudart, Mohamed Gasmi, L'houcine Ouafik, and Jean-François Seitz. Cetuximab after bevacizumab in metastatic colorectal cancer: Is it the best sequence? *Digestive and Liver Disease*, 43(11):917–919, November 2011.
- [413] Koji Oba, Masaki Matsuoka, Taroh Satoh, Kei Muro, Noboru Oriuchi, Junichi Sakamoto, and Hideyuki Mishima. Multicentre phase II study of XELOX with bevacizumab in late-stage elderly patients with unresectable advanced/recurrent colorectal cancer: An ASCA study. *Japanese Journal of Clinical Oncology*, 41(1):134–138, 2010.
- [414] A. J. Ocean, D. Niedzwiecki, J. N. Atkins, B. Parker, B. H. O'Neil, J. W. Lee, S. Wadler, and R. M. Goldberg. LE-SN38 for metastatic colorectal cancer after progression on oxaliplatin: Results of CALGB 80402. *ASCO Meeting Abstracts*, 26(15S):4109, 2008.
- [415] Allyson J. Ocean, Blase Polite, Paul Christos, Lisa Horvath, Anne Hamilton, Daniel Matulich, Helen X. Chen, Joseph A. Sparano, and Hedy L. Kindler. Cetuximab is associated with excessive toxicity when combined with bevacizumab plus mFOLFOX6 in metastatic colorectal carcinoma. *Clinical Colorectal Cancer*, 9(5):290–296, 2010.
- [416] Michael J. O'Connell, Ian Lavery, Greg Yothers, Soonmyung Paik, Kim M. Clark-Langone, Margarita Lopatin, Drew Watson, Frederick L. Baehner, Steven Shak, Joffre Baker, J. Wayne Cowens, and Norman Wolmark. Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. *Journal of Clinical Oncology*, 28(25):3937–3944, 2010.
- [417] J. Ocvirk, M. Rebersek, and M. Boc. Bevacizumab in first-line therapy of metastatic colorectal cancer: A retrospective comparison of FOLFIRI and XELIRI. *Anticancer Research*, 31(5):1777–1782, 2011.

- [418] Janja Ocvirk, Thomas Brodowicz, Fritz Wrba, Tudor E Ciuleanu, Galina Kurteva, Semir Beslija, Ivan Koza, Zsuzsanna Pápai, Diethelm Messinger, Ugur Yilmaz, Zolt Faluhelyi, Suayib Yalcin, Demetris Papamichael, Mikls Wenczl, Zrinka Mrcic-Krmpotic, Einat Shacham-Shmueli, Damir Vrbanec, Regina Esser, Werner Scheithauer, and Christoph C Zielinski. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. *World Journal of Gastroenterology*, 16(25):3133–3143, April 2010.
- [419] Dawn Odom, Beth Barber, Lee Bennett, Marc Peeters, Zhongyun Zhao, James Kaye, Michael Wolf, and Jeffrey Wiezorek. Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab. *International Journal of Colorectal Disease*, 26(2):173–181, 2011.
- [420] H. Oettle, L. Meyer, W.O. Bechstein, and H. Riess. 5-fluorouracil: Synchronous application of continuous and bolus therapy in heavily pretreated metastatic colorectal cancer: A phase I/II study. *Oncology Research and Treatment*, 23(2):128–132, 2000.
- [421] A Ohtsu, H Baba, Y Sakata, Y Mitachi, N Horikoshi, K Sugimachi, T Taguchi, and for the S-1 Cooperative Colorectal Carcinoma Study Group. Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. *British Journal of Cancer*, 83(2):141–145, July 2000.
- [422] S Ohwada, T Ikeya, T Yokomori, T Kusaba, T Roppongi, T Takahashi, S Nakamura, S Kakimura, S Iwazaki, H Ishikawa, S Kawate, T Nakajima, and Y Morishita. Adjuvant immunochemotherapy with oral tegafur//uracil plus PSK in patients with stage II or III colorectal cancer: A randomised controlled study. *British Journal of Cancer*, 90(5):1003–1010, 2004.
- [423] Eiji Oki, Yasunori Emi, Yoshito Akagi, Shoji Tokunaga, Noriaki Sadanaga, Takaho Tanaka, Yutaka Ogata, Hiroshi Saeki, Yoshihiro Kakeji, Hideo Baba, Tadashi Nishimaki, Shoji Natsugoe, Kazuo Shirouzu, Yoshihiko Maehara, and Kyushu Study Group of Clinical Cancer. Phase II trial of alternating mFOLFOX6 and FOLFIRI regimens in the first-line treatment for unresectable or metastatic colorectal cancer (KSCC0701). *Oncology*, 84(4):233–239, 2013.
- [424] A Okines, O del Puerto, D Cunningham, I Chau, E Van Cutsem, L Saltz, and J Cassidy. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer first BEAT and the randomised phase-III NO16966 trial. *British Journal of Cancer*, 101(7):1033–1038, 2009.
- [425] Se Hoon Park, Soo-Mee Bang, Eun Kyung Cho, Jeong Heum Baek, Jae Hwan Oh, Seock-Ah Im, Young Suk Park, Dong Bok Shin, and Jae Hoon Lee. First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. *Oncology*, 66(5):353–357, 2004.
- [426] Se Hoon Park, Ju Young Sung, Sang-Hoon Han, Jeong Heum Baek, Jae Hwan Oh, Soo-Mee Bang, Eun Kyung Cho, Dong Bok Shin, and Jae Hoon Lee. Oxaliplatin, folinic acid and 5-fluorouracil (FOLFOX-4) combination chemotherapy as second-line treatment in advanced colorectal cancer patients with irinotecan failure: A Korean single-center experience. *Japanese Journal of Clinical Oncology*, 35(9):531–535, 2005.
- [427] Yehuda Z. Patt, Fa-Chyi Lee, James E. Liebmann, Dimitrios Diamandidis, S Gail Eckhardt, Milind Javle, Glen R. Justice, Wayne Keiser, Joseph R. Salvatore, Alice Bexon, and Edward Lin. Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for



- metastatic colorectal cancer: Phase II trial results. *American Journal of Clinical Oncology*, 30(4):350–357, 2007.
- [428] O. A. Pavia, J. Cangiano, R. Crisostomo, W. Caceres, E. Barranco, M. Wright, T. Antonia, S. Antonia, D. Sullivan, and C. Garrett. Phase II study of oxaliplatin, capecitabine, and irinotecan (OCI) in patients (pts) with previously untreated advanced colorectal cancer (crc). *ASCO Meeting Abstracts*, 23(16S):3746, 2005.
- [429] Dimitrios Pectasides, George Papaxoinis, Konstantine Kalogeras, Anastasia Eleftheraki, Ioannis Xanthakis, Thomas Makatsoris, Epaminondas Samantas, Ioannis Varthalitis, Pavlos Papakostas, Nikitas Nikitas, Christos Papandreou, George Pentheroudakis, Eleni Timotheadou, Angelos Koutras, Joseph Sgouros, Dimitrios Bafaloukos, George Klouvas, Theofanis Economopoulos, Konstantinos Syrigos, and George Fountzilias. XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: A Hellenic cooperative oncology group phase III trial with collateral biomarker analysis. *BioMed Central Cancer*, 12(1):271, 2012.
- [430] M. Peeters, T. J. Price, A. Cervantes, A. F. Sobrero, M. Ducreux, Y. Hotko, T. André, E. Chan, F. Lordick, C. J. A. Punt, A. H. Strickland, G. Wilson, T. E. Ciuleanu, L. Roman, E. Van Cutsem, Y. Tian, and R. Sidhu. Final results from a randomized phase 3 study of FOLFIRI panitumumab for second-line treatment of metastatic colorectal cancer. *Annals of Oncology*, 25(1):107–116, 2014.
- [431] M Peeters, A H Strickland, M Lichinitser, A V S Suresh, G Manikhas, J Shapiro, W Rogowski, X Huang, B Wu, D Warner, R Jain, and N C Tebbutt. A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. *British Journal of Cancer*, 108(3):503–511, February 2013.
- [432] Marc Peeters, Timothy Jay Price, Andrés Cervantes, Alberto F. Sobrero, Michel Ducreux, Yevhen Hotko, Thierry André, Emily Chan, Florian Lordick, Cornelis J.A. Punt, Andrew H. Strickland, Gregory Wilson, Tudor-Eliade Ciuleanu, Laslo Roman, Eric Van Cutsem, Valentina Tzekova, Simon Collins, Kelly S. Oliner, Alan Rong, and Jennifer Gansert. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. *Journal of Clinical Oncology*, 28(31):4706–4713, 2010.
- [433] Marc Peeters, Salvatore Siena, Eric Van Cutsem, Alberto Sobrero, Alain Hendlisz, Stefano Cascinu, Haralabos Kalofonos, Giovanna Devercelli, Michael Wolf, and Rafael G. Amado. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. *Cancer*, 115(7):1544–1554, 2009.
- [434] Stefan Peinert, Wilfried Grothe, Alexander Stein, Lutz P. Müller, Joern Ruessel, Wieland Voigt, Hans-Joachim Schmoll, and Dirk Arnold. Safety and efficacy of weekly 5-fluorouracil/ folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer. *Therapeutic Advances in Medical Oncology*, 2(3):161–174, May 2010.
- [435] Stuart Pendlebury, Francesca Duchesne, Katharine A. Reed, Justine L. Smith, and David J. Kerr. A trial of adjuvant therapy in colorectal cancer: The VICTOR trial. *Clinical Colorectal Cancer*, 3(1):58–60, 2003.

- [436] J. Pénichoux, S. Michiels, O. Bouché, P.-L. Etienne, P. Texereau, D. Auby, P. Rougier, M. Ducreux, and J.-P. Pignon. Taking into account successive treatment lines in the analysis of a colorectal cancer randomised trial. *European Journal of Cancer*, 49(8):1882–1888, 2013.
- [437] A. Pessino, S. Artale, S. Sciallero, A. Guglielmi, G. Fornarini, I. C. Andreotti, S. Mammoliti, D. Comandini, F. Caprioni, E. Bennicelli, V. Andretta, S. Siena, and A. Sobrero. First-line single-agent cetuximab in patients with advanced colorectal cancer. *Annals of Oncology*, 19(4):711–716, 2007.
- [438] Roberto Petrioli, Loretta Paoletti, Stefania Marsili, Serenella Civitelli, Edoardo Francini, Tommaso Cioppa, Franco Roviello, Raffaele Nettuno, Chiara Intrivici, Gabriello Tanzini, Marco Lorenzi, and Guido Francini. FOLFOX-4 stop and go and capecitabine maintenance chemotherapy in the treatment of metastatic colorectal cancer. *Oncology*, 70(5):345–350, 2006.
- [439] P. Pfeiffer, J.P. Mortensen, B. Bjerregaard, L. Eckhoff, K. Schønnemann, E. Sandberg, K. Aabo, and A. Jakobsen. Patient preference for oral or intravenous chemotherapy: A randomised cross-over trial comparing capecitabine and Nordic fluorouracil/leucovorin in patients with colorectal cancer. *European Journal of Cancer*, 42(16):2738–2743, 2006.
- [440] P. Pfeiffer, H. Sørbye, H. Ehrsson, T. Fokstuen, J. P. Mortensen, L. Baltesgard, K. M. Tveit, D. Øgreid, H. Starkhammar, I. Wallin, C. Qvortrup, and B. Glimelius. Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. *Annals of Oncology*, 17(2):252–258, 2006.
- [441] Per Pfeiffer, Pernille Hahn, and Helle Anita Jensen. Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer. *Acta Oncologica*, 42(8):832–836, 2003.
- [442] J. Philip Kuebler, Linda Colangelo, Michael J. O’Connell, Roy E. Smith, Greg Yothers, Mirsada Begovic, Bridget Robinson, Thomas E. Seay, and Norman Wolmark. Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin. *Cancer*, 110(9):1945–1950, 2007.
- [443] Filippo Pietrantonio, Claudia Maggi, Maria Di Bartolomeo, Maria Grazia Facciorusso, Federica Perrone, Adele Testi, Roberto Iacovelli, Rosalba Miceli, Ilaria Bossi, Giorgia Leone, Massimo Milione, Giuseppe Pelosi, and Filippo de Braud. Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status. *PLoS ONE*, 9(4):e92147, 2014.
- [444] Bilal Piperdi, Allen Cohn, J. Hecht, Shaker Dakhil, Mansoor Saleh, Mika Cline-Burkhardt, Ying Tian, and William Go. O-0015SPIRITT (study 20060141): A randomized phase 2 study of 2nd-line treatment with FOLFIRI + panitumumab or bevacizumab for wild-type KRAS MCRC. *Annals of Oncology*, 24(suppl 4):iv17, 2013.
- [445] A Pohl, A El-Khoueiry, D Yang, W Zhang, G Lurje, Y Ning, T Winder, S Hu-Lieskoven, S Iqbal, K D Danenberg, M Kahn, J-L Teo, J Shriki, J Stebbing, and H-J Lenz. Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy. *The Pharmacogenomics Journal*, 13(2):173–180, April 2013.

- [446] J. Polikoff, E. P. Mitchell, S. Badarinarath, C. D. Graham, A. Jennis, T.-T. Chen, T. N. Gustafson, and C. Langer. Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): Preliminary efficacy analysis of a randomized phase III trial. *ASCO Meeting Abstracts*, 23(16S):3574, 2005.
- [447] Elizabeth A. Poplin, Jacqueline K. Benedetti, Norman C. Estes, Daniel G. Haller, Robert J. Mayer, Richard M. Goldberg, Geoffrey R. Weiss, Saul E. Rivkin, and John S. Macdonald. Phase III southwest oncology group 9415/intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. *Journal of Clinical Oncology*, 23(9):1819–1825, 2005.
- [448] Rainer Porschen, Hendrik-Tobias Arkenau, Stephan Kubicka, Richard Greil, Thomas Seufferlein, Werner Freier, Albrecht Kretzschmar, Ullrich Graeven, Axel Grothey, Axel Hinke, Wolff Schmiegell, and Hans-Joachim Schmoll. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: A final report of the AIO colorectal study group. *Journal of Clinical Oncology*, 25(27):4217–4223, 2007.
- [449] Guillaume Portier, Dominique Elias, Olivier Bouche, Philippe Rougier, Jean-François Bosset, Jean Saric, Jacques Belghiti, Pascal Piedbois, Rosine Guimbaud, Bernard Nordlinger, Roland Bugat, Franck Lazorthes, and Laurent Bedenne. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. *Journal of Clinical Oncology*, 24(31):4976–4982, 2006.
- [450] C. Pozzo, M. Basso, A. Cassano, M. Quirino, G. Schinzari, N. Trigila, M. Vellone, F. Giuliante, G. Nuzzo, and C. Barone. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. *Annals of Oncology*, 15(6):933–939, 2004.
- [451] T. J. Price, D. Zannino, K. Wilson, R. J. Simes, J. Cassidy, G. A. Van Hazel, B. A. Robinson, A. Broad, V. Ganju, S. P. Ackland, and N. C. Tebbutt. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: A subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of capecitabine, bevacizumab and mitomycin C. *Annals of Oncology*, 23(6):1531–1536, 2012.
- [452] Timothy J. Price, Jennifer E. Hardingham, Chee K. Lee, Andrew Weickhardt, Amanda R. Townsend, Joseph W. Wrin, Ann Chua, Aravind Shivasami, Michelle M. Cummins, Carmel Murone, and Niall C. Tebbutt. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer. *Journal of Clinical Oncology*, 29(19):2675–2682, 2011.
- [453] Timothy J Price, Marc Peeters, Tae Won Kim, Jin Li, Stefano Cascinu, Paul Ruff, Atilli Satya Suresh, Anne Thomas, Sergei Tjulandin, Kathy Zhang, Swaminathan Murugappan, and Roger Sidhu. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type {KRAS} exon 2 metastatic colorectal cancer (ASPECCT): A randomised, multicentre, open-label, non-inferiority phase 3 study. *The Lancet Oncology*, 15(6):569–579, 2014.

- [454] John Primrose, Stephen Falk, Meg Finch-Jones, Juan Valle, Derek O'Reilly, Ajith Siriwardena, Joanne Hornbuckle, Mark Peterson, Myrddin Rees, Tim Iveson, Tamas Hickish, Rachel Butler, Louise Stanton, Elizabeth Dixon, Louisa Little, Megan Bowers, Siân Pugh, O James Garden, David Cunningham, Tim Maughan, and John Bridgewater. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: The new EPOC randomised controlled trial. *The Lancet Oncology*, 15(6):601–611, 2014.
- [455] John Neil Primrose, Stephen Falk, Meg Finch-Jones, Juan W. Valle, David Sherlock, Joanne Hornbuckle, James Gardner-Thorpe, David Smith, Charles Imber, Tamas Hickish, Brian Davidson, David Cunningham, Graeme John Poston, Tim Maughan, Myrddyn Rees, Louise Stanton, Louisa Little, Megan Bowers, Wendy Wood, and John A. Bridgewater. A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in KRAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study. *ASCO Meeting Abstracts*, 31(15S):3504, 2013.
- [456] Ajithkumar Puthillath, Terry Mashtare Jr., Gregory Wilding, Nikhil Khushalani, Lynn Steinbrenner, Mary Ellen Ross, Karen Romano, Michelle Wisniewski, and Marwan G. Fakih. A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer. *Critical Reviews in Oncology/Hematology*, 71(3):242–248, 2009.
- [457] Miguel Quintela-Fandino, Cristina Gravalos, Enrique Gonzalez, Adelaida García-Velasco, and Hernán Cortés-Funes. Irinotecan (CPT-11)-based chemotherapy as induction treatment for advanced colorectal cancer. *Anti-Cancer Drugs*, 16(1):31–38, 2005.
- [458] R. K. Ramanathan, K. Rajasenan, T. Crandall, E. P. Balaban, R. A. Pinkerton, P. Kane, D. M. Potter, S. Dranko, A. Schmotzer, and B. C. Lembersky. Phase II study of the A-ICOX regimen [bevacizumab (Bev), weekly intermittent capecitabine (Cap) and oxaliplatin (Ox)] for untreated advanced colorectal cancer (CRC). *ASCO Meeting Abstracts*, 25(18S):4092, 2007.
- [459] Ramesh K. Ramanathan, Jimmy J. Hwang, William C. Zamboni, Frank A. Sinicrope, Howard Safran, Michael K. Wong, Martin Earle, Adam Brufsky, Terry Evans, Monica Troetschel, Christine Walko, Roger Day, Helen X. Chen, and Sydney Finkelstein. Low overexpression of HER-2/Neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. *Cancer Investigation*, 22(6):858–865, 2004.
- [460] S. Rao, D. Cunningham, A. de Gramont, W. Scheithauer, M. Smakal, Y. Humblet, G. Kourteva, T. Iveson, T. Andre, J. Dostalova, A. Illes, R. Belly, J.J. Perez-Ruixo, Y.C. Park, and P.A. Palmer. Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. *Journal of Clinical Oncology*, 22(19):3950–3957, 2004.
- [461] Jean-Luc Raoul, Jean-Luc Van Laethem, Marc Peeters, Catherine Brezault, Fares Husseini, Laurent Cals, Johannes Nippgen, Anja-Helena Loos, and Philippe Rougier. Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: A multicentre two-part phase I/II study. *BioMed Central Cancer*, 9(1):112, 2009.
- [462] F I Raynaud, F E Boxall, P M Goddard, M Valenti, M Jones, B A Murrer, M Abrams, and L R Kelland. cis-Amminedichloro (2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: In vivo activity, toxicology, and pharmacokinetics in mice. *Clinical Cancer Research*, 3(11):2063–2074, 1997.

- [463] D. W. Rea, J. W. R. Nortier, W. W. Ten Bokkel Huinink, S. Falk, D. J. Richel, T. Maughan, G. Groenewegen, J. M. Smit, N. Steven, J. M. Bakker, D. Semiond, D. J. Kerr, and C. J. A. Punt. A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. *Annals of Oncology*, 16(7):1123–1132, 2005.
- [464] Srinevas K. Reddy, Michael A. Morse, Herbert I. Hurwitz, Johanna C. Bendell, Tong J. Gan, Steven E. Hill, and Bryan M. Clary. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. *Journal of the American College of Surgeons*, 206(1):96–106, 2008.
- [465] Diane Lauren Reidy, Efsevia Vakiani, Marwan G. Fakih, Muhammad Wasif Saif, Joel Randolph Hecht, Noah Goodman-Davis, Ellen Hollywood, Jinru Shia, Jonathan Schwartz, Kumari Chandrawansa, Aruna Dontabhaktuni, Hagop Youssoufian, David B. Solit, and Leonard B. Saltz. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer. *Journal of Clinical Oncology*, 28(27):4240–4246, 2010.
- [466] Anke Reinacher-Schick, Karsten Schulmann, Dominik Modest, Nina Bruns, Ulrich Graeven, Malgorzata Jaworska, Richard Greil, Rainer Porschen, Dirk Arnold, Wolff Schmiegel, and Andrea Tannapfel. Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group. *BioMed Central Cancer*, 12(1):349, 2012.
- [467] Daniel J. Renouf, Stephen Welch, Malcolm J. Moore, Monika K. Krzyzanowska, Jennifer Knox, Ronald Feld, Geoffrey Liu, Helen MacKay, Jennifer Petronis, Lisa Wang, and Eric Chen. A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer. *Cancer Chemotherapy and Pharmacology*, 69(5):1339–1344, 2012.
- [468] J. M. Rhee, F. C. Lee, M. W. Saif, B. Ardalan, R. Wolff, C. Eng, K. R. Bogaard, P. Cheverton, M. Kimura, M. Danna, and P. M. Hoff. Phase II trial of DJ-927 as a second-line treatment for colorectal cancer demonstrates objective responses. *ASCO Meeting Abstracts*, 23(16S):3654, 2005.
- [469] Susan D. Richman, Matthew T. Seymour, Philip Chambers, Faye Elliott, Catherine L. Daly, Angela M. Meade, Graham Taylor, Jennifer H. Barrett, and Philip Quirke. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: Results from the MRC FOCUS trial. *Journal of Clinical Oncology*, 27(35):5931–5937, 2009.
- [470] Lorenza Rimassa, Giuseppe Gullo, Carlo Carnaghi, Giovanni Abbadessa, Monica Zuradelli, Maria Chiara Tronconi, Tiziana Pressiani, and Armando Santoro. Chemotherapy with mitomycin C and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin. *Tumori*, 92(4):285–289, 2006.
- [471] John Rinehart, Alex A. Adjei, Patricia M. LoRusso, David Waterhouse, J. Randolph Hecht, Ronald B. Natale, Oday Hamid, Mary Varterasian, Peggy Asbury, Eric P. Kaldjian, Stephen Gulyas, David Y. Mitchell, Roman Herrera, Judith S. Sebolt-Leopold, and Mark B. Meyer. Multicenter phase II study of the Oral MEK inhibitor, CI-1040, in patients with advanced

- non-small-cell lung, breast, colon, and pancreatic cancer. *Journal of Clinical Oncology*, 22(22):4456–4462, 2004.
- [472] Jane D. Robertson, Nick A. Botwood, Mace L. Rothenberg, and Hans-Joachim Schmoll. Phase III trial of FOLFOX plus bevacizumab or cediranib (AZD2171) as first-line treatment of patients with metastatic colorectal cancer: HORIZON III. *Clinical Colorectal Cancer*, 8(1):59–60, 2009.
- [473] A. P. Rocha-Lima and A. Del Giglio. Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: A one-centre experience. *European Journal of Cancer Care*, 14(2):151–154, 2005.
- [474] Wendy De Roock, Derek J. Jonker, Federica Di Nicolantonio, Andrea Sartore-Bianchi, Dongsheng Tu, Salvatore Siena, Simona Lamba, Sabrina Arena, Milo Frattini, Hubert Piessevaux, Eric Van Cutsem, Chris J. OCallaghan, Shirin Khambata-Ford, John R. Zalberg, John Simes, Christos S. Karapetis, Alberto Bardelli, and Sabine Tejpar. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. *The Journal of the American Medical Association*, 304(16):1812–1820, 2010.
- [475] G. Rosati, S. Cordio, R. Bordonaro, G. Caputo, G. Novello, G. Reggiardo, and L. Manzione. Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: Results of a randomized phase II study. *Annals of Oncology*, 21(4):781–786, 2009.
- [476] Gerardo Rosati, Antonio Avallone, Giuseppe Aprile, Alfredo Butera, Giorgio Reggiardo, and Domenico Bilancia. XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: The boxe study. *Cancer Chemotherapy and Pharmacology*, 71(1):257–264, 2013.
- [477] Gerardo Rosati, Stefano Cordio, Giuseppe Aprile, Alfredo Butera, Antonio Avallone, Giuseppe Di Lucca, Federica De Pauli, HectorSoto Parra, Giorgio Reggiardo, and Roberto Bordonaro. Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: A retrospective Italian study. *Investigational New Drugs*, 30(5):1978–1983, 2012.
- [478] Lee S. Rosen, Ehtesham Abdi, Ian D. Davis, John Gutheil, Frederick M. Schnell, John Zalberg, Alessandra Cesano, Urte Gayko, Mon-Gy Chen, and Stephen Clarke. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. *Journal of Clinical Oncology*, 24(33):5194–5200, 2006.
- [479] M. L. Rothenberg, J. V. Cox, C. Butts, M. Navarro, Y.-J. Bang, R. Goel, S. Gollins, L. L. Siu, S. Laguerre, and D. Cunningham. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: A randomized phase III noninferiority study. *Annals of Oncology*, 19(10):1720–1726, 2008.
- [480] Mace L. Rothenberg, Bonnie LaFleur, Donna E. Levy, Mary Kay Washington, Sherry L. Morgan-Meadows, Ramesh K. Ramanathan, Jordan D. Berlin, Al B. Benson, and Robert J. Coffey. Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma. *Journal of Clinical Oncology*, 23(36):9265–9274, 2005.

- [481] Mace L. Rothenberg, Amit M. Oza, Robert H. Bigelow, Jordan D. Berlin, John L. Marshall, Ramesh K. Ramanathan, Lowell L. Hart, Sunil Gupta, Carlos A. Garay, Brent G. Burger, Nathalie Le Bail, and Daniel G. Haller. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. *Journal of Clinical Oncology*, 21(11):2059–2069, 2003.
- [482] E Rouits, V Charasson, A Petain, M Boisdron-Celle, J-P Delord, M Fonck, A Laurand, A-L Poirier, A Morel, E Chatelut, J Robert, and E Gamelin. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. *British Journal of Cancer*, 99(8):1239–1245, September 2008.
- [483] Frédérique Rousseau, Roland Bugat, Michel Ducreux, Frédérique Cvitkovic, Elisabeth Carola, Mathilde Gisselbrecht, Frédéric Viret, Benjamin Esterni, Jean Genève, and Etienne Brain. Effect of XELOX on functional ability among elderly patients with metastatic colorectal cancer: Results from the FNCLCC/GERICO 02 phase II study. *Journal of Geriatric Oncology*, 2(2):105–111, 2011.
- [484] Muhammad Wasif Saif, James Merritt, Joan Robbins, Jeffrey Stewart, and Joachim Schupp. Phase III multicenter randomized clinical trial to evaluate the safety and efficacy of cofactor /5-fluorouracil/bevacizumab versus leucovorin/5-fluorouracil/bevacizumab as initial treatment for metastatic colorectal carcinoma. *Clinical Colorectal Cancer*, 6(3):229–234, 2006.
- [485] Leonard B. Saltz, Stephen Clarke, Eduardo Díaz-Rubio, Werner Scheithauer, Arie Figer, Ralph Wong, Sheryl Koski, Mikhail Lichinitser, Tsai-Shen Yang, Fernando Rivera, Felix Couture, Florin Sirzén, and Jim Cassidy. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. *Journal of Clinical Oncology*, 26(12):2013–2019, 2008.
- [486] Leonard B. Saltz, John V. Cox, Charles Blanke, Lee S. Rosen, Louis Fehrenbacher, Malcolm J. Moore, Jean A. Maroun, Stephen P. Ackland, Paula K. Locker, Nicoletta Pirotta, Gary L. Elfring, and Langdon L. Miller. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. *New England Journal of Medicine*, 343(13):905–914, 2000.
- [487] Leonard B. Saltz, Heinz-Josef Lenz, Hedy L. Kindler, Howard S. Hochster, Scott Wadler, Paulo M. Hoff, Nancy E. Kemeny, Ellen M. Hollywood, Mithat Gonen, Marcus Quinones, Meroe Morse, and Helen X. Chen. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 study. *Journal of Clinical Oncology*, 25(29):4557–4561, 2007.
- [488] Leonard B. Saltz, Neal J. Meropol, Patrick J. Loehrer, Michael N. Needle, Justin Kopit, and Robert J. Mayer. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. *Journal of Clinical Oncology*, 22(7):1201–1208, 2004.
- [489] Lisa Salvatore, Gianluca Masi, Fotios Loupakis, Chiara Cremolini, Marta Schirripa, Lorenzo Fornaro, Cristina Granetto, Emanuela Miraglio, Francesco Di Costanzo, Lorenzo Antonuzzo, Lorenzo Marcucci, Samanta Cupini, Corrado Boni, Maria Banzi, Silvana Chiara, Daniela Garbarino, Chiara Valsuani, Andrea Bonetti, Luca Boni, and Alfredo Falcone. O-0027 bevacizumab beyond progression in metastatic colorectal cancer patients receiving a first-line

- treatment containing bevacizumab: Update of BEBYP trial by GONO. *Annals of Oncology*, 24(4):22, 2013.
- [490] E Samalin, O Bouche, S Thezenas, E François, A Adenis, J Bennouna, J Taieb, F Desseigne, J F Seitz, T Conroy, M P Galais, E Assenat, E Crapez, S Poujol, F Bibeau, F Boissiere, P Laurent-Puig, M Ychou, and T Mazard. Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: A multicentre phase I/II trial. *British Journal of Cancer*, 110(5):1148–1154, March 2014.
- [491] Hanna K. Sanoff, Daniel J. Sargent, Megan E. Campbell, Roscoe F. Morton, Charles S. Fuchs, Ramesh K. Ramanathan, Stephen K. Williamson, Brian P. Findlay, Henry C. Pitot, and Richard M. Goldberg. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. *Journal of Clinical Oncology*, 26(35):5721–5727, 2008.
- [492] Hanna K. Sanoff, Daniel J. Sargent, Erin M. Green, Howard L. McLeod, and Richard M. Goldberg. Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: A subgroup analysis of a large randomized clinical trial. *Journal of Clinical Oncology*, 27(25):4109–4115, 2009.
- [493] D. Santini, B. Vincenzi, R. Addeo, C. Garufi, G. Masi, M. Scartozzi, A. Mancuso, A. M. Frezza, O. Venditti, M. Imperatori, G. Schiavon, G. Bronte, G. Cicero, F. Recine, E. Maiello, S. Cascinu, A. Russo, A. Falcone, and G. Tonini. Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? *Annals of Oncology*, 23(9):2313–2318, 2012.
- [494] Daniele Santini, Bruno Vincenzi, Annalisa La Cesa, Marco Caricato, Gaia Schiavon, Bruno Spalletta, Marisa Di Seri, Roberto Coppola, Laura Rocci, and Giuseppe Tonini. Continuous infusion of oxaliplatin plus chronomodulated capecitabine in 5-fluorouracil- and irinotecan-resistant advanced colorectal cancer patients. *Oncology*, 69(1):27–34, 2005.
- [495] A. Santoro, A. Comandone, L. Rimassa, C. Granetti, V. Lorusso, C. Oliva, M. Ronzoni, S. Siena, M. Zuradelli, E. Mari, T. Pressiani, and C. Carnaghi. A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer. *Annals of Oncology*, 19(11):1888–1893, 2008.
- [496] Armando Santoro, Lorenza Rimassa, Alberto F. Sobrero, Giovanni Citterio, Francesco Scalfani, Carlo Carnaghi, Anna Pessino, Francesco Caprioni, Valeria Andretta, Maria Chiara Tronconi, Giovanna Finocchiaro, Gloria Rossoni, Angela Zanoni, Chiara Miggiano, Gian-Paolo Rizzardi, Catia Traversari, Federico Caligaris-Cappio, Antonio Lambiase, and Claudio Bordignon. Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy. *European Journal of Cancer*, 46(15):2746–2752, 2010.
- [497] Bernardo Santos-Ramos, Rocío Fernández-Fernández, Roberto Marín-Gil, María Espinosa-Bosch, Salvador Peiró-Moreno, Concepción Pérez-Guerrero, and Javier Bautista-Paloma. Use of monoclonal antibodies for metastatic colorectal cancer in the andalusian public health system. *International Journal of Clinical Pharmacy*, 35(4):550–553, 2013.



- [498] Z Saridaki, N Androulakis, N Vardakis, L Vamvakas, E Kabouraki, K Kalbakis, D Hatzidaki, A Voutsina, D Mavroudis, V Georgoulis, and J Souglakos. A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS WT, metastatic colorectal cancer: A pilot phase II trial. *British Journal of Cancer*, 107(12):1932–1937, December 2012.
- [499] Andrea Sartore-Bianchi, Mauro Moroni, Silvio Veronese, Carlo Carnaghi, Emilio Bajetta, Gabriele Luppi, Alberto Sobrero, Carlo Barone, Stefano Cascinu, Giuseppe Colucci, Enrico Cortesi, Michele Nichelatti, Marcello Gambacorta, and Salvatore Siena. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. *Journal of Clinical Oncology*, 25(22):3238–3245, 2007.
- [500] J. Sastre, E. Aranda, C. Grávalos, B. Massutí, M. Varella-Garcia, F. Rivera, G. Soler, A. Carrato, J.L. Manzano, E. Díaz-Rubio, and M. Hidalgo. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD). *Critical Reviews in Oncology/Hematology*, 77(1):78–84, 2011.
- [501] Javier Sastre, Enrique Aranda, Bartomeu Massutí, Jose Tabernero, Manuel Chaves, Albert Abad, Alfredo Carrato, Juan José Reina, Bernardo Queralt, Auxiliadora Gómez-España, Encarnación González-Flores, Fernando Rivera, Ferrán Losa, Teresa García, Pedro Sanchez-Rovira, Inmaculada Maestu, and Eduardo Díaz-Rubio. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: Comparative outcomes from the 03-TTD-01 phase III study. *Critical Reviews in Oncology/Hematology*, 70(2):134–144, 2009.
- [502] Javier Sastre, Cristina Grávalos, Fernando Rivera, Bartomeu Massuti, Manuel Valladares-Ayerbes, Eugenio Marcuello, José L. Manzano, Manuel Benavides, Manuel Hidalgo, Eduardo Díaz-Rubio, and Enrique Aranda. First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: Clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD group study. *The Oncologist*, 17(3):339–345, 2012.
- [503] Javier Sastre, M. Luisa Maestro, Auxiliadora Gómez-España, Fernando Rivera, Manuel Valladares, Bartomeu Massuti, Manuel Benavides, Manuel Gallén, Eugenio Marcuello, Albert Abad, Antonio Arrivi, Carlos Fernández-Martos, Encarnación González, Josep M. Tabernero, Marta Vidaurreta, Enrique Aranda, and Eduardo Díaz-Rubio. Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: A Spanish cooperative group for the treatment of digestive tumors study. *The Oncologist*, 17(7):947–955, 2012.
- [504] Javier Sastre, Marta Vidaurreta, Auxiliadora Gómez, Fernando Rivera, Bartomeu Massutí, Margarita Reboredo López, Albert Abad, Manuel Gallen, Manuel Benavides, Enrique Aranda, and Eduardo Díaz Rubio. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab. *Clinical Colorectal Cancer*, 12(4):280–286, 2013.
- [505] Taroh Satoh, Hirofumi Yasui, Kei Muro, Yoshito Komatsu, Shinichi Sameshima, Kensei Yamaguchi, and Kenichi Sugihara. Pharmacokinetic assessment of irinotecan, SN-38, and SN-38-Glucuronide: A substudy of the FIRIS study. *Anticancer Research*, 33(9):3845–3853, 2013.

- [506] M. B. Sawyer, S. Iqbal, H. Lenz, C. S. Rocha Lima, D. P. Rossignol, I. Krivelevich, J. Fan, and A. B. El-Khoueiry. Phase II study of E7820 in combination with cetuximab in subjects (pts) with metastatic and refractory colorectal cancer (CRC). *ASCO Meeting Abstracts*, 28(15S):3537, 2010.
- [507] Frank A. Scappaticci, Jamey R. Skillings, Scott N. Holden, Hans-Peter Gerber, Kathy Miller, Fairouz Kabbinavar, Emily Bergsland, James Ngai, Eric Holmgren, Jiuzhou Wang, and Herbert Hurwitz. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. *Journal of the National Cancer Institute*, 99(16):1232–1239, 2007.
- [508] Mario Scartozzi, Alfredo Falcone, Francesca Pucci, Chiara Braconi, Chiara Pierantoni, Luigi Cavanna, Vittorio Franciosi, Rossana Berardi, Giordano Beretta, Gianluca Masi, et al. Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancer. *Tumori*, 92(5):384–388, 2006.
- [509] W. Scheithauer, G. V. Kornek, M. Raderer, B. Schüll, K. Schmid, F. Längle, and H. Huber. Intermittent weekly high-dose capecitabine in combination with oxaliplatin: A phase I/II study in first-line treatment of patients with advanced colorectal cancer. *Annals of Oncology*, 13(10):1583–1589, 2002.
- [510] W. Scheithauer, J. McKendrick, S. Begbie, M. Borner, W. I. Burns, H. A. Burris, J. Cassidy, D. Jodrell, P. Koralewski, E. L. Levine, N. Marschner, J. Maroun, P. Garcia-Alfonso, J. Tujakowski, G. Van Hazel, A. Wong, J. Zaluski, and C. Twelves. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: Safety results of a randomized, phase III trial. *Annals of Oncology*, 14(12):1735–1743, 2003.
- [511] Werner Scheithauer, Gabriela V. Kornek, Markus Raderer, Birgit Schüll, Katharina Schmid, Erwin Kovats, Bruno Schneeweiss, Fritz Lang, Alfred Lenauer, and Dieter Depisch. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. *Journal of Clinical Oncology*, 21(7):1307–1312, 2003.
- [512] Richard L. Schilsky, Jeremy Levin, William H. West, Alfred Wong, Bruce Colwell, Michael P. Thirlwell, Rafat H. Ansari, William N. Bell, Robin L. White, Barbara B. Yates, Paul V. McGuirt, and Richard Pazdur. Randomized, open-label, phase III study of a 28-day oral regimen of eniluracil plus fluorouracil versus intravenous fluorouracil plus leucovorin as first-line therapy in patients with metastatic/advanced colorectal cancer. *Journal of Clinical Oncology*, 20(6):1519–1526, 2002.
- [513] W Schippinger, M Jagoditsch, C Sorre, M Gnant, G Steger, H Hausmaninger, B Mlineritsch, R Schaberl-Moser, H J Mischinger, F Hofbauer, P Holzberger, M Mittlbock, and R Jakesz. A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer. *British Journal of Cancer*, 92(9):1655–1662, April 2005.
- [514] W Schippinger, H Samonigg, R Schaberl-Moser, R Greil, R Thodtmann, J Tschmelitsch, M Jagoditsch, G G Steger, R Jakesz, F Herbst, F Hofbauer, H Rabl, P Wohlmuth, M Gnant, and J Thaler. A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. *British Journal of Cancer*, 97(8):1021–1027, September 2007.

- [515] W. Schmiegel, A. Reinacher-Schick, D. Arnold, S. Kubicka, W. Freier, G. Dietrich, M. Geibler, S. Hegewisch-Becker, A. Tannapfel, M. Pohl, A. Hinke, H.J. Schmoll, and U. Graeven. Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: A randomized phase II study of the AIO colorectal study group. *Annals of Oncology*, 24(6):1580–1587, 2013.
- [516] Hans-Joachim Schmoll, Thomas Cartwright, Josep Tabernero, Marek P. Nowacki, Arie Figer, Jean Maroun, Timothy Price, Robert Lim, Eric Van Cutsem, Young-Suk Park, Joseph McKendrick, Claire Topham, Gemma Soler-Gonzalez, Filipo de Braud, Mark Hill, Florin Sirzén, and Daniel G. Haller. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1,864 patients. *Journal of Clinical Oncology*, 25(1):102–109, 2006.
- [517] Hans-Joachim Schmoll, David Cunningham, Alberto Sobrero, Christos S. Karapetis, Philippe Rougier, Sheryl L. Koski, Ilona Kocakova, Igor Bondarenko, György Bodoky, Paul Mainwaring, Ramon Salazar, Peter Barker, Bijoyesh Mookerjee, Jane Robertson, and Eric Van Cutsem. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: A double-blind, randomized phase III study (HORIZON III). *Journal of Clinical Oncology*, 30(29):3588–3595, 2012.
- [518] Hans-Joachim Schmoll, Burghardt Wittig, Dirk Arnold, Jorge Riera-Knorrenschild, Dieter Nitsche, Hendrik Kroening, Frank Mayer, Johannes Andel, Reinhard Ziebermayr, and Werner Scheithauer. Maintenance treatment with the immunomodulator MGN1703, a toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: A randomised, double-blind, placebo-controlled trial. *Journal of Cancer Research and Clinical Oncology*, 140(9):1615–1624, 2014.
- [519] B. Schultheis, G. Folprecht, J. Kuhlmann, R. Ehrenberg, U. T. Hacker, C. H. Köhne, M. Kornacker, O. Boix, J. Lettieri, J. Krauss, R. Fischer, S. Hamann, D. Strumberg, and K. B. Mross. Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: Results of a multicenter, phase Ib study. *Annals of Oncology*, 24(6):1560–1567, 2013.
- [520] Lee Steven Schwartzberg, Fernando Rivera, Meinolf Karthaus, Gianpiero Fasola, Jean-Luc Canon, Hua Yu, Kelly S. Oliner, and William Y. Go. Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC). *ASCO Meeting Abstracts*, 31(15S):3631, 2013.
- [521] J.-F. Seitz, J. Bennouna, B. Paillot, E. Gamelin, E. François, T. Conroy, J.-L. Raoul, Y. Becouarn, F. Bertheault-Cvitkovic, M. Ychou, S. Nasca, A. Fandi, P. Barthelemy, and J.-Y. Douillard. Multicenter non-randomized phase II study of raltitrexed (Tomudex) and oxaliplatin in non-pretreated metastatic colorectal cancer patients. *Annals of Oncology*, 13(7):1072–1079, 2002.
- [522] Matthew T Seymour, Sarah R Brown, Gary Middleton, Timothy Maughan, Susan Richman, Stephen Gwyther, Catherine Lowe, Jennifer F Seligmann, Jonathan Wadsley, Nick Maisey, Ian Chau, Mark Hill, Lesley Dawson, Stephen Falk, Ann O’Callaghan, Kim Benstead, Philip Chambers, Alfred Oliver, Helen Marshall, Vicky Napp, and Phil Quirke. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant

- advanced colorectal cancer (PICCOLO): A prospectively stratified randomised trial. *The Lancet Oncology*, 14(8):749–759, 2013.
- [523] Matthew T Seymour, Timothy S Maughan, Jonathan A Ledermann, Clare Topham, Roger James, Stephen J Gwyther, David B Smith, Stephen Shepherd, Anthony Maraveyas, David R Ferry, Angela M Meade, Lindsay Thompson, Gareth O Griffiths, Mahesh KB Parmar, and Richard J Stephens. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): A randomised controlled trial. *The Lancet*, 370(9582):143–152, 2007.
- [524] Matthew T Seymour, Lindsay C Thompson, Harpreet S Wasan, Gary Middleton, Alison E Brewster, Stephen F Shepherd, M Sinead O’Mahony, Timothy S Maughan, Mahesh Parmar, and Ruth E Langley. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): An open-label, randomised factorial trial. *The Lancet*, 377(9779):1749–1759, 2011.
- [525] S.Y Sharp, C.F O’Neill, P Rogers, F.E Boxall, and L.R Kelland. Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin. *European Journal of Cancer*, 38(17):2309–2315, 2002.
- [526] H Y Sheikh, J W Valle, T Waddell, K Palmer, G Wilson, A Sjursen, O Craven, R Swindell, and M P Saunders. Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer. *British Journal of Cancer*, 99(4):577–583, August 2008.
- [527] L Shen, MJ Xu, M Lu, Y Wang, W Liu, and MC Bai. A multicenter feasibility study with S-1, oxaliplatin and oral leucovorin (SOL) for the patients with untreated metastatic colorectal cancer : The result of interim analysis. *Annals of Oncology*, 21(8S):215, 2010.
- [528] Perry Shen, Christopher R. Thomas, Joyce Fenstermaker, Mebea Aklilu, Thomas P. McCoy, and Edward A. Levine. Phase II trial of adjuvant oral thalidomide following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface disease from colorectal/appendiceal cancer. *Journal of Gastrointestinal Cancer*, 45(3):268–275, 2014.
- [529] Anthony F. Shields, Lisa M. Lange, and Mark M. Zalupski. Phase II study of liposomal doxorubicin in patients with advanced colorectal cancer. *American Journal of Clinical Oncology*, 24(1):96–98, 2001.
- [530] Anthony F. Shields, Mark M. Zalupski, John L. Marshall, and Neal J. Meropol. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine. *Cancer*, 100(3):531–537, 2004.
- [531] Kuniaki Shirao, Atsushi Ohtsu, Hideho Takada, Yasushi Mitachi, Kosei Hirakawa, Noboru Horikoshi, Takeshi Okamura, Koichi Hirata, Soh Saitoh, Hiroharu Isomoto, and Atsushi Satoh. Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. *Cancer*, 100(11):2355–2361, 2004.
- [532] Salvatore Siena, Eric Van Cutsem, Mingyu Li, Ulf Jungnelius, Alfredo Romano, Robert Beck, Katia Bencardino, Maria Elena Elez, Hans Prenen, Mireia Sanchis, Andrea Sartore-Bianchi, Sabine Tejpar, Anita Gandhi, Tao Shi, and Josep Tabernero. Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer. *PLoS ONE*, 8(11):e62264, 11 2013.

- [533] Lieke H.J. Simkens, Miriam Koopman, Linda Mol, Gerrit Jan Veldhuis, Daan Ten Bokkel Huinink, Erik W. Muller, Veerle A. Derleyn, Steven Teerenstra, and Cornelis J.A. Punt. Influence of body mass index on outcome in advanced colorectal cancer patients receiving chemotherapy with or without targeted therapy. *European Journal of Cancer*, 47(17):2560–2567, 2011.
- [534] Lillian L. Siu, Jeremy D. Shapiro, Derek J. Jonker, Chris S. Karapetis, John R. Zalberg, John Simes, Felix Couture, Malcolm J. Moore, Timothy J. Price, Jehan Siddiqui, Louise M. Nott, Danielle Charpentier, Winston Liauw, Michael B. Sawyer, Michael Jefford, Nadine M. Magoski, Andrew Haydon, Ian Walters, Jolie Ringash, Dongsheng Tu, and Chris J. O’Callaghan. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type KRAS colorectal carcinoma: The NCIC clinical trials group and AGITG CO.20 trial. *Journal of Clinical Oncology*, 31(19):2477–2484, 2013.
- [535] Erik Skof, Martina Rebersek, Zvezdana Hlebanja, and Janja Ocvirk. Capecitabine plus irinotecan (XELIRI regimen) compared to 5-FU/LV plus irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: A randomised prospective phase II trial. *BioMed Central Cancer*, 9(1):120, 2009.
- [536] N Snoeren. *Colorectal liver metastases: factors affecting outcome after surgery*. PhD thesis, Utrecht University, 2013.
- [537] Nikol Snoeren, Emile Voest, Andre Bergman, Otilia Dalesio, Henk Verheul, Rob Tollenaar, Joost van der Sijp, Sander Schouten, Inne Rinkes, and R van Hillegersberg. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment. *BioMed Central Cancer*, 10(1):545, 2010.
- [538] Alberto Sobrero, Stephen Ackland, Stephen Clarke, Ramón Perez-Carrión, Silvia Chiara, John Gapski, Paul Mainwaring, Bernd Langer, Scott Young, AVIRI Trial investigators, et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. *Oncology*, 77(2):113–119, August 2009.
- [539] Alberto F. Sobrero, Joan Maurel, Louis Fehrenbacher, Werner Scheithauer, Yousif A. Abubakr, Manfred P. Lutz, M. Eugenia Vega-Villegas, Cathy Eng, Ernst U. Steinhauer, Jana Prausova, Heinz-Josef Lenz, Christophe Borg, Gary Middleton, Hendrik Krning, Gabriele Luppi, Oliver Kisker, Angela Zubel, Christiane Langer, Justin Kopit, and Howard A. Burris. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. *Journal of Clinical Oncology*, 26(14):2311–2319, 2008.
- [540] Byeong Seok Sohn, Tae Won Kim, Jae-Lyun Lee, Min-Hee Ryu, Heung Moon Chang, Yoon-Koo Kang, Hyo Suk Park, Young-Soon Na, Se Jin Jang, Jin Cheon Kim, and Jung Shin Lee. The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients. *Oncology*, 77(3-4):224–230, 2009.
- [541] A Soran, L Nesbitt, E P Mamounas, B Lembersky, J Bryant, S Anderson, A Brown, and M Passarelo. Centralized medical monitoring in phase III clinical trials: the national surgical adjuvant breast and bowel project (NSABP) experience. *Clinical Trials*, 3(5):478–485, 2006.

- [542] Halfdan Sørbye, Bengt Glimelius, Åke Berglund, Tone Fokstuen, Kjell Magne Tveit, Morten Brændengen, Dagfinn Øgreid, and Olav Dahl. Multicenter phase II study of nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. *Journal of Clinical Oncology*, 22(1):31–38, 2004.
- [543] Halfdan Sørbye, Murielle Mauer, Thomas Gruenberger, Bengt Glimelius, Graeme J. Poston, Peter M. Schlag, Philippe Rougier, Wolf O. Bechstein, John N. Primrose, Euan T. Walpole, Meg Finch-Jones, Daniel Jaeck, Darius Mirza, Rowan W. Parks, Laurence Collette, Eric Van Cutsem, Werner Scheithauer, Manfred P. Lutz, Bernard Nordlinger, and for the EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK (CRUK), Arbeitsgruppe Lebermetastasen und Tumoren in der Chirurgischen Arbeitsge. Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). *Annals of Surgery*, 255(3):534–539, 2012.
- [544] J Souglakos, N Androulakis, K Syrigos, A Polyzos, N Ziras, A Athanasiadis, S Kakolyris, S Tsousis, Ch Kouroussis, L Vamvakas, A Kalykaki, G Samonis, D Mavroudis, and V Georgoulas. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): A multicentre randomised phase III trial from the hellenic oncology research group (HORG). *British Journal of Cancer*, 94(6):798–805, February 2006.
- [545] J Souglakos, A Kalykaki, L Vamvakas, N Androulakis, K Kalbakis, S Agelaki, N Vardakis, M Tzardi, AP Kotsakis, J Gioulbasanis, D Tsetis, G Sfakiotaki, D Chatzidaki, D Mavroudis, and V Georgoulas. Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy. *Annals of Oncology*, 18(2):305–310, 2007.
- [546] J. Souglakos, D. Mavroudis, S. Kakolyris, Ch. Kouroussis, N. Vardakis, N. Androulakis, S. Agelaki, K. Kalbakis, D. Tsetis, N. Athanasiadis, G. Samonis, and V. Georgoulas. Triplet combination with irinotecan plus oxaliplatin plus continuous-infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: A multicenter phase II trial. *Journal of Clinical Oncology*, 20(11):2651–2657, 2002.
- [547] J Souglakos, N Ziras, S Kakolyris, I Boukovinas, N Kentepozidis, P Makrantonakis, S Xynogalos, Ch Christophyllakis, Ch Kouroussis, L Vamvakas, V Georgoulas, and A Polyzos. Randomised phase-II trial of CAPIRI (capecitabine, irinotecan) plus bevacizumab vs FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer (mCRC). *British Journal of Cancer*, 106(3):453–459, January 2012.
- [548] David R. Spigel, F. Anthony Greco, David Waterhouse, Dianna Shipley, C. Lane, E. Vazquez, Bobby L. Clark, Jeffrey R. Infante, Johanna C. Bendell, Howard A. Burris III, and John D. Hainsworth. Phase II trial of FOLFOX6, bevacizumab and cetuximab in the first-line treatment of metastatic colorectal cancer. *Clinical Advances in Hematology & Oncology*, 8(7):480–486, 2010.
- [549] Karen-Lise G. Spindler, Niels Pallisgaard, Rikke F. Andersen, John Ploen, and Anders Jakobsen. Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients A phase II and translational research study. *Anticancer Research*, 34(2):845–850, 2014.

- [550] Karen-Lise G. Spindler, Morten M. Sorensen, Niels Pallisgaard, Rikke F. Andersen, Birgitte M. Havelund, John Ploen, Ulrik Lassen, and Anders K. M. Jakobsen. Phase II trial of temsirolimus alone and in combination with irinotecan for KRAS mutant metastatic colorectal cancer: Outcome and results of KRAS mutational analysis in plasma. *Acta Oncologica*, 52(5):963–970, 2013.
- [551] Karen-Lise Garm Spindler, Niels Pallisgaard, Rikke Fredslund Andersen, John Ploen, and Anders Jakobsen. Pemetrexed and gemcitabine for chemotherapy refractory colorectal cancer—results of a phase II and translational research study. *Journal of Cancer Therapy*, 4(6B):44–50, July 2013.
- [552] Ludger Staib, KarlHeinz Link, and Hans Günther Beger. Toxicity and effects of adjuvant therapy in colon cancer: Results of the German prospective, controlled randomized multicenter trial FOGT-1. *Journal of Gastrointestinal Surgery*, 5(3):275–281, 2001.
- [553] GP Stathopoulos, C Batziou, D Trafalis, J Koutantos, S Batzios, J Stathopoulos, J Legakis, and A Armakolas. Treatment of colorectal cancer with and without bevacizumab: A phase III study. *Oncology*, 78(5-6):376–381, 2010.
- [554] Alexander Stein, Djordje Atanackovic, Bert Hildebrandt, Patrick Stuebs, Claus-Christoph Steffens, Wolfram Brugger, Gunnar Hapke, Gerald Illerhaus, Ernst Bluemner, and Carsten Bokemeyer. FOLFOXIRI plus bevacizumab (BEV) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC): Preliminary safety results from the OPAL study. *ASCO Meeting Abstracts*, 31(4S):515, 2013.
- [555] Alexander Stein, Gabriel Glockzin, Andreas Wienke, Dirk Arnold, Thomas Edelmann, Bert Hildebrandt, Stephan Hollerbach, Gerald Illerhaus, Alfred Konigsrainer, Michael Richter, Hans Schlitt, and Hans-Joachim Schmoll. Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: Presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. *BioMed Central Cancer*, 12(1):356, 2012.
- [556] Alexander Stein, Albrecht Kretschmar, Dirk Behringer, Thomas Wolff, Joachim Zimmer, Susanna Hegewisch-Becker, Erika Kettner, Karl-Heinz Pflüger, Andreas Kirsch, and Dirk Arnold. Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: Final results from phase II AIO KRK 0105 trial. *BioMed Central Cancer*, 13(1):454, 2013.
- [557] S. Stintzing, L. Fischer von Weikersthal, T. Decker, U. Vehling-Kaiser, E. Jäger, T. Heintges, C. Stoll, C. Giessen, D. P. Modest, J. Neumann, A. Jung, T. Kirchner, W. Scheithauer, and V. Heinemann. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancersubgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. *Annals of Oncology*, 23(7):1693–1699, 2012.
- [558] S Stintzing, L Fischer von Weikersthal, U Vehling-Kaiser, M Stauch, H G Hass, H Dietzfelbinger, D Oruzio, S Klein, K Zellmann, T Decker, M Schulze, W Abenhardt, G Puchtler, H Kappauf, J Mittermuller, C Haberl, C Giessen, N Moosmann, and V Heinemann. Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: Results from the German AIO KRK-0104 trial. *British Journal of Cancer*, 105(2):206–211, July 2011.

- [559] Sebastian Stintzing, Christine Kapaun, Rüdiger Pödig, Paul Laubender, Andreas Jung, Jens Neumann, Dominik Paul Modest, Clemens Giessen, Nicolas Moosmann, Andreas Wollenberg, Thomas Kirchner, and Volker Heinemann. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the German AIO CRC study group. *International Journal of Cancer*, 132(1):236–245, 2013.
- [560] Jonathan R. Strosberg, Timothy Yeatman, Jill Weber, Domenico Coppola, Michael J. Schell, Gang Han, Khaldoun Almhanna, Richard Kim, Tiffany Valone, Helen Jump, and Dan Sullivan. A phase II study of RO4929097 in metastatic colorectal cancer. *European Journal of Cancer*, 48(7):997–1003, 2012.
- [561] Mitsukuni Suenaga, Nobuyuki Mizunuma, Daigo Shouji, Eiji Shinozaki, Satoshi Matsusaka, Keisho Chin, Masatoshi Oya, Toshiharu Yamaguchi, Tetsuichiro Muto, and Kiyohiko Hatake. Modified irinotecan plus bolus 5-fluorouracil/1-leucovorin for metastatic colorectal cancer at a single institution in Japan. *Journal of Gastroenterology*, 43(11):842–848, 2008.
- [562] Sun Jin Sym, Junshik Hong, Hee Kyung Ahn, Jinny Park, Eun Kyung Cho, Jae Hoon Lee, Won-Suk Lee, Jeong-Heum Baek, Yeon Ho Park, and Dong Bok Shin. A phase II trial of salvage treatment with gemcitabine and S-1 combination in heavily pretreated patients with metastatic colorectal cancer. *ASCO Meeting Abstracts*, 31(15S):3595, 2013.
- [563] Josep Tabernero, Rocio Garcia-Carbonero, James Cassidy, Alberto Sobrero, Eric Van Cutsem, Claus-Henning Köhne, Sabine Tejpar, Oleg Gladkov, Irina Davidenko, Ramon Salazar, Liubov Vladimirova, Sergey Cheporov, Olga Burdaeva, Fernando Rivera, Leslie Samuel, Irina Bulavina, Vanessa Potter, Yu-Lin Chang, Nathalie A. Lokker, and Peter J. O’Dwyer. Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: The RESPECT trial. *Clinical Cancer Research*, 19(9):2541–2550, 2013.
- [564] Josep Tabernero, Eric Van Cutsem, Eduardo Díaz-Rubio, Andrés Cervantes, Yves Humblet, Thierry André, Jean-Luc Van Laethem, Patrick Soulié, Esther Casado, Chris Verslype, Javier Sastre Valera, Giampaolo Tortora, Fortunato Ciardiello, Oliver Kisker, and Aimery de Gramont. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. *Journal of Clinical Oncology*, 25(33):5225–5232, 2007.
- [565] Julien Taïeb, Pascal Artru, François Paye, Christophe Louvet, Nathalie Perez, Thierry André, Brice Gayet, Mohamed Hebbar, Frédérique Maindrault Goebel, Christophe Tournigand, Rolland Parc, and Aimery de Gramont. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: Results of a phase II study. *Journal of Clinical Oncology*, 23(3):502–509, 2005.
- [566] Julien Taïeb, Pierre Laurent Puig, and Laurent Bedenne. Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: Scientific background and the ongoing PETACC-8 trial. *Expert Review of Anticancer Therapy*, 8(2):183–189, 2008.
- [567] Julien Taïeb, Josep Tabernero, Enrico Mini, Fabien Subtil, Gunnar Folprecht, Jean-Luc Van Laethem, Josef Thaler, John Bridgewater, Lone Nørgård Petersen, Hélène Blons, Laurence Collette, Eric Van Cutsem, Philippe Rougier, Ramon Salazar, Laurent Bedenne, Jean-François Emile, Pierre Laurent-Puig, and Come Lepage. Oxaliplatin, fluorouracil, and leucovorin with



- or without cetuximab in patients with resected stage III colon cancer (PETACC-8): An open-label, randomised phase 3 trial. *The Lancet Oncology*, 15(8):862–873, 2014.
- [568] M. B. Tamayo, G. H. Cornelio, J. B. Bautista, M. L. Flores, P. S. Tioleco, M. R. Kurman, L. M. Marsh, M. A. Gargano, and M. L. Patchen. A phase Ib/II, dose-escalating, safety, and efficacy study of imprime PGG and cetuximab in patients with advanced colorectal cancer (CRC). *ASCO Meeting Abstracts*, 28(15S):e14103, 2010.
- [569] Patricia A. Tang, Steven J. Cohen, Christian Kollmannsberger, Georg Bjarnason, Kiran Virik, Mary J. MacKenzie, Lillian Lourenco, Lisa Wang, Alice Chen, and Malcolm J. Moore. Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. *Clinical Cancer Research*, 18(21):6023–6031, 2012.
- [570] Niall C. Tebbutt, Kate Wilson, Val J. Gebski, Michelle M. Cummins, Diana Zannino, Guy A. van Hazel, Bridget Robinson, Adam Broad, Vinod Ganju, Stephen P. Ackland, Garry Forgeson, David Cunningham, Mark P. Saunders, Martin R. Stockler, YuJo Chua, John R. Zalberg, R. John Simes, and Timothy J. Price. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: Results of the australasian gastrointestinal trials group randomized phase III MAX study. *Journal of Clinical Oncology*, 28(19):3191–3198, 2010.
- [571] Josef Thaler, Meinolf Karthaus, Laurent Mineur, Richard Greil, Henry Letocha, Ralf Hofheinz, Eva Fernebro, Erick Gamelin, Ana Banos, and Claus-Henning Kohne. Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study. *BioMed Central Cancer*, 12(1):438, 2012.
- [572] J. Tol, M. Koopman, C. J. Rodenburg, A. Cats, G. J. Creemers, J. G. Schrama, F. L. G. Erdkamp, A. H. Vos, L. Mol, N. F. Antonini, and C. J. A. Punt. A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch colorectal cancer group (DCCG). an interim analysis of toxicity. *Annals of Oncology*, 19(4):734–738, 2008.
- [573] Jolien Tol, Miriam Koopman, Annemieke Cats, Cees J. Rodenburg, Geert J.M. Creemers, Jolanda G. Schrama, Frans L.G. Erdkamp, Allert H. Vos, Cees J. van Groeningen, Harm A.M. Sinnige, Dirk J. Richel, Emile E. Voest, Jeroen R. Dijkstra, Marianne E. Vink-Börger, Ninja F. Antonini, Linda Mol, Johan H.J.M. van Krieken, Otilia Dalesio, and Cornelis J.A. Punt. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. *New England Journal of Medicine*, 360(6):563–572, 2009.
- [574] D. Tougeron, T. Lecomte, J. C. Pagès, C. Villalva, C. Collin, A. Ferru, J. M. Tourani, C. Silvain, P. Levillain, and L. Karayan-Tapon. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. *Annals of Oncology*, 24(5):1267–1273, 2013.
- [575] David Tougeron, Ulrich Cortes, Aurélie Ferru, Claire Villalva, Christine Silvain, JeanMarc Tourani, Pierre Levillain, and Lucie Karayan-Tapon. Epidermal growth factor receptor (EGFR) and KRAS mutations during chemotherapy plus anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer. *Cancer Chemotherapy and Pharmacology*, 72(2):397–403, 2013.
- [576] Christophe Tournigand, Thierry André, Emmanuel Achille, Gérard Lledo, Michel Flesh, Dominique Mery-Mignard, Emmanuel Quinaux, Corinne Couteau, Marc Buyse, Gérard

- Ganem, Bruno Landi, Philippe Colin, Christophe Louvet, and Aimery de Gramont. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. *Journal of Clinical Oncology*, 22(2):229–237, 2004.
- [577] Christophe Tournigand, Thierry André, Franck Bonnetain, Benoist Chibaudel, Gérard Lledo, Tamas Hickish, Josep Tabernero, Corrado Boni, Jean-Baptiste Bachet, Luis Teixeira, and Aimery de Gramont. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: Subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant treatment of colon cancer trial. *Journal of Clinical Oncology*, 30(27):3353–3360, 2012.
- [578] Christophe Tournigand, Andres Cervantes, Arie Figer, Gérard Lledo, Michel Flesch, Marc Buyse, Laurent Mineur, Elisabeth Carola, Pierre-Luc Etienne, Fernando Rivera, Isabel Chirivella, Nathalie Perez-Staub, Christophe Louvet, Thierry André, Isabelle Tabah-Fisch, and Aimery de Gramont. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer A GERCOR study. *Journal of Clinical Oncology*, 24(3):394–400, 2006.
- [579] C A Townsley, P Major, L L Siu, J Dancey, E Chen, G R Pond, T Nicklee, J Ho, D Hedley, M Tsao, M J Moore, and A M Oza. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. *British Journal of Cancer*, 94(8):1136–1143, March 2006.
- [580] Yasushi Tsuji, Taroh Satoh, Akihito Tsuji, Kei Muro, Motoki Yoshida, Tomohiro Nishina, Michitaka Nagase, Yoshito Komatsu, Takeshi Kato, Yoshinori Miyata, Naoko Mizutani, Satoshi Hashigaki, Maria Jose Lechuga, and Tadamichi Denda. First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: A phase II study. *Cancer Science*, 103(8):1502–1507, 2012.
- [581] Soichi Tsutsumi, Keiichiro Ishibashi, Nobuyuki Uchida, Hitoshi Ojima, Yasuo Hosouchi, Naokuni Yashuda, Wakako Kigure, Satoru Yamauchi, Takayuki Asao, Hideyuki Ishida, and Hiroyuki Kuwano. Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: The gunma clinical oncology group (GCOG) trial 001 SILK study. *Oncology*, 83(3):151–157, 2012.
- [582] Kjell Magne Tveit, Tormod Guren, Bengt Glimelius, Per Pfeiffer, Halfdan Sorbye, Seppo Pyrhonen, Fridbjorn Sigurdsson, Elin Kure, Tone Ikdahl, Eva Skovlund, Tone Fokstuen, Flemming Hansen, Eva Hofslis, Elke Birkemeyer, Anders Johnsson, Hans Starkhammar, Mette Karen Yilmaz, Nina Keldsen, Anne Berit Erdal, Olav Dajani, Olav Dahl, and Thoralf Christoffersen. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: The NORDIC-VII study. *Journal of Clinical Oncology*, 30:1755–1762, 2012.
- [583] C Twelves. Capecitabine as first-line treatment in colorectal cancer: Pooled data from two large, phase III trials. *European Journal of Cancer*, 38, Supplement 2(0):15–20, 2002.
- [584] C Twelves, M Boyer, M Findlay, J Cassidy, C Weitzel, C Barker, B Osterwalder, C Jamieson, and K Hieke. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma. *European Journal of Cancer*, 37(5):597–604, 2001.

- [585] C. Twelves, W. Scheithauer, J. McKendrick, J.-F. Seitz, G. Van Hazel, A. Wong, E. Díaz-Rubio, F. Gilberg, and J. Cassidy. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. *Annals of Oncology*, 23(5):1190–1197, 2011.
- [586] Chris Twelves, Alfred Wong, Marek P. Nowacki, Markus Abt, Howard Burris, Alfredo Carrato, Jim Cassidy, Andrés Cervantes, Jan Fagerberg, Vassilis Georgoulas, Fares Hussein, Duncan Jodrell, Piotr Koralewski, Hendrik Kröning, Jean Maroun, Norbert Marschner, Joseph McKendrick, Marek Pawlicki, Riccardo Rosso, Johannes Schüller, Jean-François Seitz, Borut Stabuc, Jerzy Tujakowski, Guy Van Hazel, Jerzy Zaluski, and Werner Scheithauer. Capecitabine as adjuvant treatment for stage III colon cancer. *New England Journal of Medicine*, 352(26):2696–2704, 2005.
- [587] Preeta Tyagi and Axel Grothey. Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: The NO16966 trial. *Clinical Colorectal Cancer*, 6(4):261–264, 2006.
- [588] Craig Underhill, David Goldstein, Vera A Gorbounova, Mikhail Y Biakhov, Igor S Bazin, Dmitry A Granov, Anwar M Hossain, Johannes Blatter, Christopher Kaiser, and Doreen Ma. A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer. *Oncology*, 73(1-2):9–20, 2007.
- [589] Gayatri Vaidyanathan, Adrienne Groman, Gregory Wilding, and Marwan G Fakih. Stop and go FOLFOX plus bevacizumab chemotherapy in the first-line treatment of metastatic colorectal cancer. *Oncology*, 79(1-2):67–71, 2010.
- [590] Daniel Vallböhmer, Wu Zhang, Michael Gordon, Dong Yun Yang, Jim Yun, Oliver A. Press, Katrin E. Rhodes, Andy E. Sherrod, Syma Iqbal, Kathleen D. Danenberg, Susan Groshen, and Heinz-Josef Lenz. Molecular determinants of cetuximab efficacy. *Journal of Clinical Oncology*, 23(15):3536–3544, 2005.
- [591] L. Vamvakas, A. Athanasiadis, A. Karampeazis, S. Kakolyris, A. Polyzos, Ch. Kouroussis, N. Ziras, K. Kalbakis, V. Georgoulas, and J. Souglakos. Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the hellenic oncology research group (HORG). *Critical Reviews in Oncology/Hematology*, 76(1):61–70, 2010.
- [592] Lambros Vamvakas, Alexios Matikas, Athanasios Karampeazis, Dora Hatzidaki, Stelios Kakolyris, Charalampos Christophylakis, Ioannis Boukovinas, Aris Polyzos, Vassilis Georgoulas, and John Souglakos. Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged > 70years) with metastatic colorectal cancer (mCRC): A multicenter phase II study of the hellenic oncology research group (HORG). *BioMed Central Cancer*, 14(1):277, 2014.
- [593] E. Van Cutsem, F. Rivera, S. Berry, A. Kretzschmar, M. Michael, M. Dibartolomeo, M.-A. Mazier, J.-L. Canon, V. Georgoulas, M. Peeters, J. Bridgewater, D. Cunningham, and on behalf of the First BEAT investigators. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: The BEAT study. *Annals of Oncology*, 20(11):1842–1847, 2009.

- [594] E. Van Cutsem, S. Siena, Y. Humblet, J.-L. Canon, J. Maurel, E. Bajetta, B. Neyns, D. Kotasek, A. Santoro, W. Scheithauer, S. Spadafora, R.G. Amado, N. Hogan, and M. Peeters. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. *Annals of Oncology*, 19(1):92–98, 2007.
- [595] Eric Van Cutsem, Emilio Bajetta, Juan Valle, Claus-Henning Köhne, J. Randolph Hecht, Malcolm Moore, Colin Germond, William Berg, Bee-Lian Chen, Tarja Jalava, David Lebwohl, Gerold Meinhardt, Dirk Laurent, and Edward Lin. Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma. *Journal of Clinical Oncology*, 29(15):2004–2010, 2011.
- [596] Eric Van Cutsem, Michael Findlay, Bruno Osterwalder, Walter Kocha, David Dalley, Richard Pazdur, Jim Cassidy, Luc Dirix, Chris Twelves, David Allman, Jean-François Seitz, Jürgen Schölmerich, Hans Ulrich Burger, and Jaap Verweij. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: Results of a randomized phase II study. *Journal of Clinical Oncology*, 18(6):1337–1345, 2000.
- [597] Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, Jerzy Zaluski, Chung-Rong Chang Chien, Anatoly Makhson, Geert D’Haens, Tamás Pintér, Robert Lim, György Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Johannes Nippgen, and Philippe Rougier. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *New England Journal of Medicine*, 360(14):1408–1417, 2009.
- [598] Eric Van Cutsem, Claus-Henning Köhne, István Láng, Gunnar Folprecht, Marek P. Nowacki, Stefano Cascinu, Igor Shchepotin, Joan Maurel, David Cunningham, Sabine Tejpar, Michael Schlichting, Angela Zubel, Ilhan Celik, Philippe Rougier, and Fortunato Ciardiello. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. *Journal of Clinical Oncology*, 29(15):2011–2019, 2011.
- [599] Eric Van Cutsem, Roberto Labianca, György Bodoky, Carlo Barone, Enrique Aranda, Bernard Nordlinger, Claire Topham, Josep Tabernero, Thierry André, Alberto F. Sobrero, Enrico Mini, Richard Greil, Francesco Di Costanzo, Laurence Collette, Laura Cisar, Xiaoxi Zhang, David Khayat, Carsten Bokemeyer, Arnaud D. Roth, and David Cunningham. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. *Journal of Clinical Oncology*, 27(19):3117–3125, 2009.
- [600] Eric Van Cutsem, Marc Peeters, Salvatore Siena, Yves Humblet, Alain Hendlisz, Bart Neyns, Jean-Luc Canon, Jean-Luc Van Laethem, Joan Maurel, Gary Richardson, Michael Wolf, and Rafael G. Amado. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. *Journal of Clinical Oncology*, 25(13):1658–1664, 2007.
- [601] Eric Van Cutsem, Josep Tabernero, Radek Lakomy, Hans Prenen, Jana Prausová, Teresa Macarulla, Paul Ruff, Guy A. van Hazel, Vladimir Moiseyenko, David Ferry, Joe McKendrick, Jonathan Polikoff, Alexia Tellier, Rmi Castan, and Carmen Allegra. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. *Journal of Clinical Oncology*, 30(28):3499–3506, 2012.

- [602] Eric Van Cutsem, Sabine Tejpar, Dirk Vanbeckevoort, Marc Peeters, Yves Humblet, Hans Gelderblom, Jan B. Vermorken, Frederic Viret, Bengt Glimelius, Elisa Gallerani, Alain Hendlisz, Annemieke Cats, Markus Moehler, Xavier Sagaert, Soetkin Vlassak, Michael Schlichting, and Fortunato Ciardiello. Inpatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: The randomized EVEREST study. *Journal of Clinical Oncology*, 30(23):2861–2868, 2012.
- [603] Eric Van Cutsem, Chris Twelves, Jim Cassidy, David Allman, Emilio Bajetta, Michael Boyer, Roland Bugat, Mike Findlay, Stefan Frings, Michaela Jahn, Joe McKendrick, Bruno Osterwalder, Gumersindo Perez-Manga, Riccardo Rosso, Philippe Rougier, Wolff H. Schmiegel, Jean-François Seitz, Paul Thompson, Jose Maria Vieitez, Christof Weitzel, Peter Harper, and for the Xeloda Colorectal Cancer Study Group. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. *Journal of Clinical Oncology*, 19(21):4097–4106, 2001.
- [604] Johan Vansteenkiste, Eric Van Cutsem, Herlinde Dumez, Cong Chen, Justin L. Ricker, Sophia S. Randolph, and Patrick Schöffski. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. *Investigational New Drugs*, 26(5):483–488, 2008.
- [605] E Vasile, G Masi, L Fornaro, S Cupini, F Loupakis, S Bursi, I Petrini, S Di Donato, I M Brunetti, S Ricci, A Antonuzzo, S Chiara, D Amoroso, M Andreuccetti, and A Falcone. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer. *British Journal of Cancer*, 100(11):1720–1724, May 2009.
- [606] A. Venook, D. Niedzwiecki, D. Hollis, S. Sutherland, R. Goldberg, S. Alberts, A. Benson, J. Wade, R. Schilsky, and R. Mayer. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) +/- cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. *ASCO Meeting Abstracts*, 24(18S):3509, 2006.
- [607] Alan P. Venook, Charles D. Blanke, Donna Niedzwiecki, Heinz-Josef Lenz, John R. Taylor, Donna R. Hollis, Susan Sutherland, and Richard M. Goldberg. Cancer and leukemia group b/southwest oncology group trial 80405: A phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma. *Clinical Colorectal Cancer*, 5(4):292–294, 2005.
- [608] Alan P. Venook, Charles D. Blanke, Donna Niedzwiecki, Heinz-Josef Lenz, John R. Taylor, Donna R. Hollis, Susan Sutherland, and Richard M. Goldberg. Revisiting the cancer and leukemia group B/southwest oncology group 80405 trial: A phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma. *Clinical Colorectal Cancer*, 6(7):536–538, 2007.
- [609] M L Veronese, W Sun, B Giantonio, J Berlin, J Shults, L Davis, D G Haller, and P J O'Dwyer. A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. *British Journal of Cancer*, 92(10):1846–1849, May 2005.
- [610] Jose Maria Vieitez, Paula J. Fonseca, Berros Jose P., Miguel Fernandez de Sanmamed, Eduardo Gutierrez Restrepo, Marta Izquierdo, Pablo Pardo, and Angel J. Lacave. Irinotecan

and capecitabine (CAPIRI) plus bevacizumab in first-line treatment of metastatic colorectal cancer. *Cancer and Clinical Oncology*, 1(2):25–35, 2012.

- [611] Erika Viel, Martin Frederico Demarchi, Loic Chaigneau, Thierry Nguyen, Christine Legat, Ulrich Stein, Antoine Thiery-Vuillemin, Samuel Limat, Xavier Pivot, and Christophe Borg. A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies. *American Journal of Clinical Oncology*, 31(1):89–94, 2008.
- [612] B Vincenzi, D Santini, C Rabitti, R Coppola, B Beomonte Zobel, L Trodella, and G Tonini. Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: A single centre phase II trial. *British Journal of Cancer*, 94(6):792–797, February 2006.
- [613] E. E. Voest, N. Snoeren, S. B. Schouten, A. M. Bergman, E. van Werkhoven, O. J. L. Loosveld, T. M. van Gulik, J. M. Smit, A. Cats, E. Boven, E. Hesselink, A. Rijken, M. Tol, O. Dalesio, H. M. Verheul, R. A. Tollenaar, J. van der Sijp, I. Borel Rinkes, and R. van Hillegersberg. A randomized two-arm phase III study to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) versus CAPOX alone in post radical resection of patients with liver metastases of colorectal cancer. *ASCO Meeting Abstracts*, 29(15S):3565, 2011.
- [614] J.C. Von Einem, V. Heinemann, L. Fischer von Weikersthal, U. Vehling-Kaiser, M. Stauch, H.G. Hass, T. Decker, S. Klein, S. Held, A. Jung, T. Kirchner, M. Haas, J. Holch, M. Michl, P. Aubele, S. Boeck, C. Schulz, C. Giessen, S. Stintzing, and D.P. Modest. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: An analysis of the AIO KRK-0104 trial. *Journal of Cancer Research and Clinical Oncology*, 140(9):1607–1614, 2014.
- [615] R. Von Moos, A. Roth, T. Ruhstaller, L. Widmer, C. Uhlmann, R. Cathomas, D. Köberle, M. Simcock, D. Lanz, and R. Popescu. Oxaliplatin, irinotecan and capecitabine (OCX) for first-line treatment of advanced/metastatic colorectal cancer: A phase I trial (SAKK 41/03). *Oncology Research and Treatment*, 33(6):295–299, 2010.
- [616] T. Waddell, S. Gollins, W. Soe, J. Valle, J. Allen, D. Bentley, J. Morris, A. Lloyd, R. Swindell, M.B. Taylor, and M.P. Saunders. Phase II study of short-course capecitabine plus oxaliplatin (XELOX) followed by maintenance capecitabine in advanced colorectal cancer: XelQuali study. *Cancer Chemotherapy and Pharmacology*, 67(5):1111–1117, 2011.
- [617] Raymond C. Wadlow, Aram F. Hezel, Thomas A. Abrams, Lawrence S. Blazzkowsky, Charles S. Fuchs, Matthew H. Kulke, Eunice L. Kwak, Jeffrey A. Meyerhardt, David P. Ryan, Jackie Szymonifka, Brian M. Wolpin, Andrew X. Zhu, and Jeffrey W. Clark. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab. *The Oncologist*, 17(1):14–34, 2012.
- [618] Yan Wang, Lin Shen, Nong Xu, Jin-Wan Wang, Shun-Chang Jiao, Ze-Yuan Liu, and Jian-Ming Xu. UGT1A1 predicts outcome in colorectal cancer treated with irinotecan and fluorouracil. *World Journal of Gastroenterology*, 18(45):6635–6644, October 2012.
- [619] Harpreet Wasan, Angela M Meade, Richard Adams, Richard Wilson, Cheryl Pugh, David Fisher, Benjamin Sydes, Ayman Madi, Bruce Sizer, Charles Lowdell, Gary Middleton, Rachel

- Butler, Richard Kaplan, and Tim Maughan. Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): A randomised phase 2 trial. *The Lancet Oncology*, 15(6):631–639, 2014.
- [620] Dohan Weeraratne, Alin Chen, Jason Pennucci, Chi-Yuan Wu, Kathy Zhang, Jacqueline Wright, Juan Perez-Ruixo, Bing-Bing Yang, Arunan Kaliyaperumal, Shalini Gupta, Steven Swanson, Narendra Chirmule, and Marta Starcevic. Immunogenicity of panitumumab in combination chemotherapy clinical trials. *BioMed Central Cancer Clinical Pharmacology*, 11(1):17, 2011.
- [621] A. J. Weickhardt, T. J. Price, N. Pavlakis, E. Skrinos, A. Dobrovic, R. Salemi, A. M. Scott, J. Mariadason, G. Chong, and N. C. Tebbutt. DUX study: A phase II study of evaluating dual targeting of the EGFR using the combination of cetuximab and erlotinib in patients with chemotherapy refractory metastatic colorectal cancer. *ASCO Meeting Abstracts*, 28(15S):3533, 2010.
- [622] Andrew J. Weickhardt, Tim J. Price, Geoff Chong, Val GebSKI, Nick Pavlakis, Terrance G. Johns, Arun Azad, Effie Skrinos, Kate Fluck, Alexander Dobrovic, Renato Salemi, Andrew M. Scott, John M. Mariadason, and Niall C. Tebbutt. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: Preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. *Journal of Clinical Oncology*, 30(13):1505–1512, 2012.
- [623] RobertP. Whitehead, Sheryl McCoy, JohnS. Macdonald, SaulE. Rivkin, MarcusA. Neubauer, ShakerR. Dakhil, Heinz-Josef Lenz, MichaelS. Tanaka, and JamesL. Abbruzzese. Phase II trial of R115777 in patients with advanced colorectal cancer: A southwest oncology group study. *Investigational New Drugs*, 24(4):335–341, 2006.
- [624] RobertP. Whitehead, Cathryn Rankin, PauloM.G. Hoff, PhilipJ. Gold, KevinG. Billingsley, RobertA. Chapman, Lucas Wong, JohnH. Ward, JamesL. Abbruzzese, and CharlesD. Blanke. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: A southwest oncology group study (S0336). *Investigational New Drugs*, 27(5):469–475, 2009.
- [625] Rafal Wierzbicki, DerekJ. Jonker, MalcolmJ. Moore, ScottR. Berry, PatrickJ. Loehrer, Hagop Youssoufian, and EricK. Rowinsky. A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining. *Investigational New Drugs*, 29(1):167–174, 2011.
- [626] Hansjochen Wilke, Robert Glynne-Jones, Josef Thaler, Antoine Adenis, Peter Preusser, Enrique Aranda Aguilar, Matti S. Aapro, Regina Esser, Anja H. Loos, and Salvatore Siena. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL study. *Journal of Clinical Oncology*, 26(33):5335–5343, 2008.
- [627] NealW. Wilkinson, Greg Yothers, Samia Lopa, JosephP. Costantino, NicholasJ. Petrelli, and Norman Wolmark. Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: Pooled analysis of NSABP C-01 through C-05. a baseline from which to compare modern adjuvant trials. *Annals of Surgical Oncology*, 17(4):959–966, 2010.

- [628] Robert A. Wolff, Martin Fuchs, Maria Di Bartolomeo, Anwar M. Hossain, Clemens Stoffregen, Steven Nicol, and Volker Heinemann. A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer. *Cancer*, 118(17):4132–4138, 2012.
- [629] Brian M. Wolpin, Kimmie Ng, Andrew X. Zhu, Thomas Abrams, Peter C. Enzinger, Nadine J. McCleary, Deborah Schrag, Eunice L. Kwak, Jill N. Allen, Pankaj Bhargava, Jennifer A. Chan, Wolfram Goessling, Lawrence S. Blaszkowsky, Jeffrey G. Supko, Meaghan Elliot, Kaori Sato, Eileen Regan, Jeffrey A. Meyerhardt, and Charles S. Fuchs. Multicenter phase II study of Tivozanib (AV-951) and Everolimus (RAD001) for patients with refractory, metastatic colorectal cancer. *The Oncologist*, 18(4):377–378, 2013.
- [630] Young-Woong Won, Young-Hyo Lim, Ho-Yong Park, Ho-Suk Oh, Jung-Hye Choi, Young-Yeul Lee, In-Soon Kim, Il-Young Choi, and Myung-Ju Ahn. Phase II study of irinotecan, 5-fluorouracil, and leucovorin in relapsed or metastatic colorectal cancer as first-line therapy. *Cancer Research and Treatment*, 36(4):235–239, August 2004.
- [631] Nan Soon Wong, Nishan H. Fernando, Johanna C. Bendell, Michael A. Morse, Gerard C. Blobe, Wanda Honeycutt, Herbert Pang, and Herbert I. Hurwitz. A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. *Clinical Colorectal Cancer*, 10(3):210–216, 2011.
- [632] Nan Soon Wong, Nishan H. Fernando, Andrew B. Nixon, Stephanie Cushman, Mebea Aklilu, Johanna C. Bendell, Michael A. Morse, Gerard C. Blobe, Jill Ashton, Herbert Pang, and Herbert I. Hurwitz. A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. *Anticancer Research*, 31(1):255–261, 2011.
- [633] R. Wong, D. Cunningham, Y. Barbachano, C. Saffery, J. Valle, T. Hickish, S. Mudan, G. Brown, A. Khan, A. Wotherspoon, A. S. Strimpakos, J. Thomas, S. Compton, Y. J. Chua, and I. Chau. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. *Annals of Oncology*, 22(9):2042–2048, 2011.
- [634] R.P. Wong, T. Baetz, M.J. Krahn, J. Biagi, N. Wainman, and E. Eisenhauer. SarCNU in recurrent or metastatic colorectal cancer: A phase II study of the national cancer institute of Canada clinical trials group. *Investigational New Drugs*, 24(4):347–351, 2006.
- [635] Fuguo Xu, Qingyong Ma, and Huanchen Sha. Optimizing drug delivery for enhancing therapeutic efficacy of recombinant human endostatin in cancer treatment. *Critical Reviews<sup>®</sup> in Therapeutic Drug Carrier Systems*, 24(5):445–492, 2007.
- [636] Hong-Xia Xu, Xin-En Huang, Zhi-Ying Qian, Xia Xu, Ying Li, and Cheng-Guang Li. Clinical observation of endostar<sup>®</sup> combined with chemotherapy in advanced colorectal cancer patients. *Asian Pacific Journal of Cancer Prevention*, 12(11):3087–3090, 2011.
- [637] Jian-Ming Xu, Yan Wang, Fei-Jiao Ge, Li Lin, Ze-Yuan Liu, and Manish R Sharma. Severe irinotecan-induced toxicity in a patient with UGT1A1\*28 and UGT1A1\*6 polymorphisms. *World Journal of Gastroenterology*, 19(24):3899–3903, May 2013.
- [638] Suayib Yalcin, Ruchan Uslu, Faysal Dane, Ugur Yilmaz, Nurullah Zengin, Evin Buyukunal, Suleyman Buyukberber, Celalettin Camci, Orhan Sencan, Sadettin Kilickap, Fatih Ozdener, and



- Duygu Cevik. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: Phase III 'stop and go' study results—a Turkish oncology group trial. *Oncology*, 85(6):328–335, 2013.
- [639] Yasuhide Yamada, Daisuke Takahari, Hiroshi Matsumoto, Hideo Baba, Masato Nakamura, Kazuhiro Yoshida, Motoki Yoshida, Shigeyoshi Iwamoto, Ken Shimada, Yoshito Komatsu, Yasutsuna Sasaki, Taroh Satoh, Keiichi Takahashi, Hideyuki Mishima, Kei Muro, Masahiko Watanabe, Yuh Sakata, Satoshi Morita, Yasuhiro Shimada, and Kenichi Sugihara. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): An open-label, non-inferiority, randomised phase 3 trial. *The Lancet Oncology*, 14(13):1278–1286, 2013.
- [640] Yasuhide Yamada, Tatsuro Yamaguchi, Hiroshi Matsumoto, Yasushi Ichikawa, Ayumu Goto, Ken Kato, Tetsuya Hamaguchi, and Yasuhiro Shimada. Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer. *Investigational New Drugs*, 30(4):1690–1696, 2012.
- [641] K. Yamazaki, T. Yoshino, N. Boku, T. Kojima, Y. Onozawa, S. Hironaka, A. Fukutomi, H. Yasui, and K. Taku. Phase I/II study of S-1/LV plus oxaliplatin (SOL) for untreated metastatic colorectal cancer: Preliminary report of the phase I part. *ASCO Meeting Abstracts*, 26(15S):15101, 2008.
- [642] M. Ychou, W. Hohenberger, S. Thezenas, M. Navarro, J. Maurel, C. Bokemeyer, E. Shacham-Shmueli, F. Rivera, C. Kwok-Keung Choi, and A. Santoro. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. *Annals of Oncology*, 20(12):1964–1970, 2009.
- [643] M. Ychou, J.-L. Raoul, J.-Y. Douillard, S. Gourgou-Bourgade, R. Bugat, L. Mineur, F. Viret, Y. Becouarn, O. Bouché, E. Gamelin, M. Ducreux, T. Conroy, J.-F. Seitz, L. Bedenne, and A. Kramar. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). *Annals of Oncology*, 20(4):674–680, 2009.
- [644] M. Ychou, F. Viret, A. Kramar, F. Desseigne, E. Mitry, R. Guimbaud, J.R. Delpero, M. Rivoire, F. Quénet, G. Portier, and B. Nordlinger. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): A phase II study in colorectal cancer patients with non-resectable liver metastases. *Cancer Chemotherapy and Pharmacology*, 62(2):195–201, 2008.
- [645] Marc Ychou, Jacqueline Duffour, Andrew Kramar, Charles Debrigode, Sophie Gourgou, Françoise Bressolle, and Frédéric Pinguet. Individual 5-FU dose adaptation in metastatic colorectal cancer: Results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. *Cancer Chemotherapy and Pharmacology*, 52(4):282–290, 2003.
- [646] Marc Ychou, Michel Rivoire, Simon Thezenas, François Quenet, Jean-Robert Delpero, Christine Rebischung, Christian Letoublon, Rosine Guimbaud, Eric Francois, Michel Ducreux, Françoise Desseigne, Jean-Michel Fabre, and Eric Assenat. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. the METHEP trial. *Annals of Surgical Oncology*, 20(13):4289–4297, 2013.

- [647] Le-Chi Ye, Tian-Shu Liu, Li Ren, Ye Wei, De-Xiang Zhu, Sheng-Yong Zai, Qing-Hai Ye, Yiyi Yu, Bo Xu, Xin-Yu Qin, and Jianmin Xu. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. *Journal of Clinical Oncology*, 31:1931–1938, 2013.
- [648] Yung-Sung Yeh, Cheng-Ying Chiang, Chin-Fan Chen, Cheng-Jen Ma, Fang-Ming Chen, Hon-Man Chan, Che-Jen Huang, Jan-Sing Hsieh, and Jaw-Yuan Wang. Efficacy and safety of weekly and biweekly cetuximab-combined FOLFIRI regimen as first-line setting in patients with metastatic colorectal cancer: Experience in a southern Taiwan medical center. *Journal of Society of Colon and Rectal Surgeon (Taiwan)*, 21(2):59–68, June 2010.
- [649] Li-Chen Yen, Yih-Huei Uen, Deng-Chyang Wu, Chien-Yu Lu, Fang-Jung Yu, I-Chen Wu, Shiu-Ru Lin, and Jaw-Yuan Wang. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. *Annals of Surgery*, 251(2):254–260, 2010.
- [650] Ramazan Yildiz, Mustafa Benekli, Metin Ozkan, Necati Alkis, Veli Berk, MehmetAli Kaplan, Aydin Ciltas, Halit Karaca, AyseGok Durnali, Ugur Coskun, Mustafa Dikilitas, Alper Sevinc, Faysal Dane, Tarkan Yetisyigit, GamzeGokoz Dogu, and Suleyman Buyukberber. Bevacizumab every 4 weeks is as effective as every 2 weeks in combination with biweekly FOLFIRI in metastatic colorectal cancer. *Journal of Cancer Research and Clinical Oncology*, 138(11):1845–1852, 2012.
- [651] Takayuki Yoshino, Nobuyuki Mizunuma, Kentaro Yamazaki, Tomohiro Nishina, Yoshito Komatsu, Hideo Baba, Akihito Tsuji, Kensei Yamaguchi, Kei Muro, Naotoshi Sugimoto, Yasushi Tsuji, Toshikazu Moriwaki, Taito Esaki, Chikuma Hamada, Takanori Tanase, and Atsushi Ohtsu. TAS-102 monotherapy for pretreated metastatic colorectal cancer: A double-blind, randomised, placebo-controlled phase 2 trial. *The Lancet Oncology*, 13(10):993–1001, 2012.
- [652] T Yoshioka, S Kato, M Gamoh, N Chiba, T Suzuki, N Sakayori, S Kato, H Shibata, H Shimodaira, K Otsuka, Y Kakudo, S Takahashi, and C Ishioka. Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer. *British Journal of Cancer*, 101(12):1972–1977, November 2009.
- [653] Greg Yothers, Michael J. O’Connell, Carmen J. Allegra, J. Philip Kuebler, Linda H. Colangelo, Nicholas J. Petrelli, and Norman Wolmark. Oxaliplatin as adjuvant therapy for colon cancer: Updated results of NSABP C-07 trial, including survival and subset analyses. *Journal of Clinical Oncology*, 29(28):3768–3774, 2011.
- [654] Greg Yothers, Daniel J. Sargent, Norman Wolmark, Richard M. Goldberg, Michael J. O’Connell, Jacqueline K. Benedetti, Leonard B. Saltz, James J. Dignam, A. William Blackstock, and on behalf of the ACCENT Collaborative Group. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: An analysis of ACCENT adjuvant trials. *Journal of the National Cancer Institute*, 103(20):1498–1506, 2011.
- [655] Maria Giulia Zampino, Elena Magni, Cristian Massacesi, Alberto Zaniboni, Angelo Martignetti, Laura Zorzino, Katia Lorizzo, Luigi Santoro, Sabrina Boselli, and Filippo de Braud. First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. *Cancer*, 110(4):752–758, 2007.

- [656] D. Y. Zang, B. H. Lee, H.-C. Park, H. H. Song, H. J. Kim, J. Y. Jung, J. H. Kim, H. Y. Kim, J. H. Kwon, S. W. Hwang, S. R. Park, C. H. Park, K. O. Kim, M.-J. Kim, and K. M. Jang. Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer. *Annals of Oncology*, 20(5):892–896, 2009.
- [657] W. Zhang, T. Winder, Y. Ning, A. Pohl, D. Yang, M. Kahn, G. Lurje, M. J. LaBonte, P. M. Wilson, M. A Gordon, S. Hu-Lieskovan, D. J. Mauro, C. Langer, E. K. Rowinsky, and H.-J. Lenz. A let-7 microRNA-binding site polymorphism in 3-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. *Annals of Oncology*, 22(1):104–109, 2011.
- [658] Wu Zhang, Michael Gordon, Anne M. Schultheis, Dong Yun Yang, Fumio Nagashima, Mizutomo Azuma, Heung-Moon Chang, Eva Borucka, Georg Lurje, Andy E. Sherrod, Syma Iqbal, Susan Groshen, and Heinz-Josef Lenz. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptorexpressing metastatic colorectal cancer patients treated with single-agent cetuximab. *Journal of Clinical Oncology*, 25(24):3712–3718, 2007.
- [659] Ren Zhao, Jianwei Zhu, Xiaopin Ji, Jianhua Cai, Fangjun Wan, Qing Li, Baoliang Zhong, Steven Tucker, and Daoyuan Wang. A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer. *Japanese Journal of Clinical Oncology*, 40(1):10–16, 2009.
- [660] Jian-Feng Zhou, Chun-Mei Bai, Yu-Zhou Wang, Xiao-Yuan Li, Yue-Juan Cheng, and Shu-Chang Chen. Endostar combined with chemotherapy for treatment of metastatic colorectal and gastric cancer: A pilot study. *Chinese medical journal*, 124(24):4299–4303, December 2011.
- [661] N Ziras, A Potamianou, I Varthalitis, K Syrigos, S Tsousis, I Boukovinas, E Tselepatiotis, C Christofillakis, and V Georgoulas. Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan. *Oncology*, 70(2):106–114, 2006.
- [662] Jeffrey A. Zonder, Anthony F. Shields, Mark Zalupski, Ruth Chaplen, Lance K. Heilbrun, Patricia Arlauskas, and Philip A. Philip. A phase II trial of bryostatatin 1 in the treatment of metastatic colorectal cancer. *Clinical Cancer Research*, 7(1):38–42, 2001.